

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/078283 A1

(43) International Publication Date

30 May 2013 (30.05.2013)

(51) International Patent Classification:

C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/US2012/066221

(22) International Filing Date:

21 November 2012 (21.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/562,770 22 November 2011 (22.11.2011) US
61/648,548 17 May 2012 (17.05.2012) US

(71) Applicant: INTERMUNE, INC. [US/US]; 3280 Bayshore Boulevard, Brisbane, CA 94005-1021 (US).

(72) Inventors: KOSSEN, Karl; 301 Pacific View Drive, Pacifica, CA 94044 (US). LIM, Sharlene; 2201 Bridgepointe Parkway, #207, San Mateo, CA 94404 (US). QIN, Xiaoli; 426 Sonora Drive, San Mateo, CA 94402 (US). BRADFORD, Williamson, Ziegler; PO Box 566, Ross, CA 94957 (US). SEIWERT, Scott, D.; 828 Rockaway Beach Avenue, Pacifica, CA 94044 (US).

(74) Agents: BRASHEAR, Jeanne M. et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2013/078283 A1

(54) Title: METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS

(57) Abstract: Described herein are materials and methods for the diagnosis of idiopathic pulmonary fibrosis.

METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of priority to U.S. Provisional Application No. 61/562,770, filed November 22, 2011, and U.S. Provisional Application No. 61/648,548, filed May 17, 2012. The disclosure of each priority application is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] The present application is directed to methods of diagnosing and treating idiopathic pulmonary fibrosis.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0003] Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: ASCII (text) file named “46562B_SeqListing.txt,” 37,589 bytes, created on November 20, 2012.

BACKGROUND

[0004] Idiopathic pulmonary fibrosis (IPF), a chronic interstitial lung disease characterized by the unregulated deposition of extracellular matrix leading to unremitting destruction of normal lung. Patients diagnosed with IPF typically experience progressive pulmonary insufficiency, and most die of respiratory failure. The estimated median survival upon diagnosis is approximately 3 years (ATS/ERS.Am J Respir Crit Care Med 2002: 165(2): 277-304) . The ratio of the estimated prevalence (90,000 individuals) and incidence (30,000 individuals) of IPF in the United States reflects this poor prognosis (Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006: 174(7): 810-816).

[0005] Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia and is characterized by the UIP pattern on histology. IPF has an insidious onset, but once symptoms appear, there is a relentless deterioration of pulmonary function and death within 3-5 years after diagnosis.

[0006] miRNAs are a class of small non-coding RNAs of about 19-25 nucleotides that function as post-transcriptional gene regulators; and can regulate the entire set of genes (Lim, et al. Nature 2005. 433:769-73). miRNAs provide important regulatory functions in a variety of biological processes, including development, cell proliferation, differentiation, and apoptosis.

SUMMARY OF THE INVENTION

[0007] In one aspect, described herein is a method of diagnosing idiopathic pulmonary fibrosis (IPF) in a human subject comprising detecting in a blood sample from the subject the level of one, two, three, four, five, six, seven or more microRNAs, wherein a differential expression level (increased or decreased) of the one or more microRNA relative to a predetermined criterion or range is indicative of a diagnosis of IPF. For example, the level of the microRNA may be increased or decreased relative to the level in samples of patients without IPF. The method optionally further comprises the step of comparing the level of the microRNA (preferably a normalized level of microRNA) to a predetermined criterion or range. In related aspects, described herein is a method of diagnosing IPF in a human subject comprising detecting in a blood sample from the subject the level of one, two, three, four, five, six, seven or more microRNAs, wherein detection of a level within a predetermined range correlated to IPF is indicative of a diagnosis of IPF. Alternatively, the detection of a level outside of a predetermined range, correlated to patients without IPF, is indicative of a diagnosis of IPF.

[0008] In another aspect, described herein is a method of treating a human subject diagnosed with idiopathic pulmonary fibrosis (IPF) according to any of the diagnostic methods described herein comprising administering a therapeutic agent to the subject to treat IPF.

[0009] In yet another aspect, described herein is a method of treating a human subject identified as having idiopathic pulmonary fibrosis (IPF) or at risk of IPF based on an abnormal level of one or more IPF-associated microRNAs in a blood sample of the subject, comprising administering a therapeutic agent to the subject to treat IPF.

[0010] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375

(SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-

194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1249 (SEQ ID NO: 200), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1298 (SEQ ID NO: 204), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-186 (SEQ ID NO: 210), miR-18a# (SEQ ID NO: 211), miR-193a-3p (SEQ ID NO: 212), miR-199b-5p (SEQ ID NO: 213), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214

(SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-23b (SEQ ID NO: 222), miR-30a-3p (SEQ ID NO: 223), miR-30e-3p (SEQ ID NO: 224), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-431 (SEQ ID NO: 227), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-501-5p (SEQ ID NO: 234), miR-505# (SEQ ID NO: 235), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), miR-885-5p (SEQ ID NO: 247), miR-892b (SEQ ID NO: 248), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250) and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0011] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-32 (SEQ ID NO:60), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID

NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0012] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-26b (SEQ ID NO:40), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-148b (SEQ ID NO:53), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), let-7e (SEQ ID NO:93), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-590-5p (SEQ ID NO:104), miR-598 (SEQ ID NO:110), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140).

NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0013] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), let-7d (SEQ ID NO: 45), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72),miR-128 (SEQ ID NO:158), miR-103(SEQ ID NO:105), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO:175), miR-132 (SEQ ID NO: 159), miR-1244(SEQ ID NO:20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO:195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-142-3p (SEQ ID NO: 38), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-150 (SEQ ID NO: 27), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO:162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO:163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74),

miR-19b-1# (SEQ ID NO: 178), miR-21 (SEQ ID NO: 51), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-26a (SEQ ID NO: 70), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-324-3p (SEQ ID NO: 107), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-29b (SEQ ID NO: 125), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-30b (SEQ ID NO: 42), miR-362-3p (SEQ ID NO: 96), miR-30c (SEQ ID NO: 52), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0014] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO: 195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO: 162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO: 163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID

NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0015] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), miR-132 (SEQ ID NO: 159), let-7d (SEQ ID NO: 45), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-103 (SEQ ID NO: 105), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-21 (SEQ ID NO: 51), miR-142-3p (SEQ ID NO: 38), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO: 18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations

thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0016] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO:173), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO:18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0017] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-

190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0018] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0019] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:

NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0020] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-1256 (SEQ ID NO: 195), miR-127-3p (SEQ ID NO: 101), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-301a (SEQ ID NO: 67), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0021] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7d (SEQ ID NO: 45), miR-103 (SEQ ID NO: 105), miR-125a-5p (SEQ ID NO: 176), miR-142-3p (SEQ ID NO: 38), miR-26a (SEQ ID NO: 70), miR-29b (SEQ ID NO: 125), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-379 (SEQ ID NO: 186), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0022] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-18a (SEQ ID NO: 39), miR-26b (SEQ ID NO: 40), miR-106b (SEQ ID NO: 41), miR-29c (SEQ ID NO: 44), miR-144 (SEQ ID NO: 46), miR-1260 (SEQ ID NO: 47), miR-361-5p (SEQ ID NO: 48),

miR-520e (SEQ ID NO: 49), miR-660 (SEQ ID NO: 50), miR-148b (SEQ ID NO: 53), miR-27b (SEQ ID NO: 54), miR-15b# (SEQ ID NO: 55), miR-16-1# (SEQ ID NO: 57), miR-17# (SEQ ID NO: 58), miR-22 (SEQ ID NO: 59), miR-32 (SEQ ID NO: 60), miR-532-5p (SEQ ID NO: 61), miR-101 (SEQ ID NO: 62), miR-27a (SEQ ID NO: 65), miR-181a (SEQ ID NO: 66), miR-320B (SEQ ID NO: 71), miR-324-5p (SEQ ID NO: 73), let-7b (SEQ ID NO: 76), miR-422a (SEQ ID NO: 77), let-7f-2# (SEQ ID NO: 78), let-7g# (SEQ ID NO: 79), miR-128a (SEQ ID NO: 80), miR-199a-5p (SEQ ID NO: 81), miR-29a# (SEQ ID NO: 83), miR-329 (SEQ ID NO: 84), miR-337-5p (SEQ ID NO: 85), miR-369-3p (SEQ ID NO: 86), miR-376a# (SEQ ID NO: 87), miR-486-3p (SEQ ID NO: 88), miR-20a (SEQ ID NO: 89), miR-106b# (SEQ ID NO: 92), miR-25 (SEQ ID NO: 94), miR-656 (SEQ ID NO: 95), miR-340 (SEQ ID NO: 97), miR-451 (SEQ ID NO: 98), miR-423-5p (SEQ ID NO: 99), miR-652 (SEQ ID NO: 100), miR-495 (SEQ ID NO: 102), miR-328 (SEQ ID NO: 103), miR-19b (SEQ ID NO: 106), miR-145# (SEQ ID NO: 108), miR-199a-3p (SEQ ID NO: 109), miR-151-5P (SEQ ID NO: 111), miR-502-3p (SEQ ID NO: 113), miR-136# (SEQ ID NO: 114), miR-194 (SEQ ID NO: 115), miR-221 (SEQ ID NO: 116), miR-22# (SEQ ID NO: 117), miR-93 (SEQ ID NO: 118), miR-130b (SEQ ID NO: 121), miR-195 (SEQ ID NO: 123), miR-576-3p (SEQ ID NO: 126), miR-212 (SEQ ID NO: 129), miR-143 (SEQ ID NO: 131), dme-miR-7 (SEQ ID NO: 132), miR-30d# (SEQ ID NO: 134), miR-213 (SEQ ID NO: 135), miR-126# (SEQ ID NO: 136), miR-1197 (SEQ ID NO: 137), miR-1255B (SEQ ID NO: 138), miR-335# (SEQ ID NO: 142), miR-33a# (SEQ ID NO: 143), miR-374a# (SEQ ID NO: 144), miR-381 (SEQ ID NO: 145), miR-409-5p (SEQ ID NO: 146), miR-551b (SEQ ID NO: 149), miR-616 (SEQ ID NO: 150), miR-638 (SEQ ID NO: 151), miR-889 (SEQ ID NO: 153), rno-miR-29c# (SEQ ID NO: 154), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0023] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103 (SEQ ID NO: 105), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO:

186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-758 (SEQ ID NO: 190), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-668 (SEQ ID NO: 194), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0024] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-339-5p (SEQ ID NO: 182), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0025] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103 (SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ

ID NO: 122); miR-668 (SEQ ID NO: 194), miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b, (SEQ ID NO: 248) and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0026] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103(SEQ ID NO:105), miR-107 (SEQ ID NO:175), miR-1244(SEQ ID NO:20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO:124), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-26a-2# (SEQ ID NO: 82), miR-34a (SEQ ID NO: 166), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b (SEQ ID NO: 248), and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0027] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7b (SEQ ID NO: 76), miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-151-5P (SEQ ID NO: 111), miR-154# (SEQ ID NO: 139), miR-15a (SEQ ID NO: 208), miR-181a (SEQ ID NO: 66), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-194 (SEQ ID NO: 115), miR-199a-5p (SEQ ID NO: 81), miR-199b-5p (SEQ ID NO: 213), miR-20a (SEQ ID NO: 89), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID

NO: 224), miR-324-5p (SEQ ID NO: 73), miR-411# (SEQ ID NO: 147), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-505# (SEQ ID NO: 235), miR-520a-3p (SEQ ID NO: 188), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), let-7a# (SEQ ID NO: 155), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-128 (SEQ ID NO: 158), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-130a (SEQ ID NO: 112), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-142-5p (SEQ ID NO: 43), miR-146b-5p (SEQ ID NO: 24), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-185 (SEQ ID NO: 163), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-19a (SEQ ID NO: 74), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-20b (SEQ ID NO: 216), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-320 (SEQ ID NO: 37), miR-324-3p (SEQ ID NO: 107), miR-326 (SEQ ID NO: 225), miR-335 (SEQ ID NO: 119), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-362-3p (SEQ ID NO: 96), miR-375 (SEQ ID NO: 8), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234) miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-574-3p (SEQ ID NO: 4), miR-577 (SEQ ID NO: 243), miR-579 (SEQ ID NO: 170), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103(SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244(SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-

19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b, (SEQ ID NO: 248) and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0028] In any of the embodiments described herein, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-199a-5p (SEQ ID NO: 81), miR-23b (SEQ ID NO: 222), miR-29b (SEQ ID NO: 125), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-744# (SEQ ID NO: 245), miR-154# (SEQ ID NO: 139), miR-27b# (SEQ ID NO: 180), miR-374a (SEQ ID NO: 68), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-548J (SEQ ID NO: 148), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-214# (SEQ ID NO: 218), miR-214 (SEQ ID NO: 217), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-338-5P (SEQ ID NO: 15), miR-

346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-375 (SEQ ID NO: 8), miR-429 (SEQ ID NO: 169), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-95 (SEQ ID NO: 250), let-7a# (SEQ ID NO: 155), miR-130a (SEQ ID NO: 112), miR-132 (SEQ ID NO: 159), miR-141 (SEQ ID NO: 161), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-345 (SEQ ID NO: 18), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-579 (SEQ ID NO: 170), miR-598 (SEQ ID NO: 110), let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103 (SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b, (SEQ ID NO: 248) and combinations thereof, and the levels relative to a predetermined criterion or range are increased or decreased as disclosed herein.

[0029] In any of the embodiments described herein, the levels of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40 or more different microRNAs is detected. When levels of multiple different microRNAs are detected, some of which may be increased or decreased relative to a predetermined criterion or range, the various increased or decreased levels form an expression pattern.

[0030] In one variation, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), and combinations thereof.

[0031] In one variation, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined

criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-222 (SEQ ID NO:16), miR-345 (SEQ ID NO:18), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-150 (SEQ ID NO:27), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96, miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), and combinations thereof.

[0032] In another variation, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7b (SEQ ID NO: 76), miR-106a (SEQ ID NO: 156), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-132 (SEQ ID NO: 159), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-222 (SEQ ID NO: 16), miR-223 (SEQ ID NO: 221), miR-26a-2# (SEQ ID NO: 82), miR-30a-3p (SEQ ID NO: 223), miR-320 (SEQ ID NO: 37), miR-326 (SEQ ID NO: 225), miR-338-5P (SEQ ID NO: 15), miR-345 (SEQ ID NO: 18), miR-346 (SEQ ID NO: 226), miR-34a (SEQ ID NO: 166), miR-34a# (SEQ ID NO: 13), miR-375 (SEQ ID NO: 8), miR-429 (SEQ ID NO: 169), miR-450a (SEQ ID NO: 228), miR-

450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-574-3p (SEQ ID NO: 4), miR-577 (SEQ ID NO: 243), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), miR-26a-2# (SEQ ID NO: 82), miR-551b# (SEQ ID NO: 172), let-7a# (SEQ ID NO: 155), miR-1260 (SEQ ID NO: 47), miR-128 (SEQ ID NO: 158), miR-130a (SEQ ID NO: 112), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-142-5p (SEQ ID NO: 43), miR-146b-5p (SEQ ID NO: 24), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-185 (SEQ ID NO: 163), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-579 (SEQ ID NO: 170), and combinations thereof.

[0033] In some embodiments, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-26a-2# (SEQ ID NO: 82), miR-34a (SEQ ID NO: 166), miR-551b# (SEQ ID NO: 172), and combinations thereof.

[0034] In some embodiments, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), and combinations thereof.

[0035] In some embodiments, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined

criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-214# (SEQ ID NO: 218), miR-214 (SEQ ID NO: 217), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-375 (SEQ ID NO: 8), miR-429 (SEQ ID NO: 169), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-95 (SEQ ID NO: 250), let-7a# (SEQ ID NO: 155), miR-130a (SEQ ID NO: 112), miR-132 (SEQ ID NO: 159), miR-141 (SEQ ID NO: 161), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-345 (SEQ ID NO: 18), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-579 (SEQ ID NO: 170), miR-598 (SEQ ID NO: 110), and combinations thereof.

[0036] In some embodiments, the expression pattern or increased level or presence of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7a# (SEQ ID NO: 155), let-7b (SEQ ID NO: 76), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-128 (SEQ ID NO: 158), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-130a (SEQ ID NO: 112), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-142-5p (SEQ ID NO: 43), miR-146b-5p (SEQ ID NO: 24), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-185 (SEQ ID NO: 163), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ

ID NO: 10), miR-19a (SEQ ID NO: 74), miR-200a (SEQ ID NO:214), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-20b (SEQ ID NO:216), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-214 (SEQ ID NO:217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO:220), miR-223 (SEQ ID NO:221), miR-30a-3p (SEQ ID NO: 223), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-320 (SEQ ID NO: 37), miR-324-3p (SEQ ID NO: 107), miR-326 (SEQ ID NO:225), miR-335 (SEQ ID NO: 119), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-362-3p (SEQ ID NO: 96), miR-375 (SEQ ID NO: 8), miR-378 (SEQ ID NO:167), miR-425 (SEQ ID NO: 168), miR-450a (SEQ ID NO:228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234) miR-511 (SEQ ID NO:236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO:239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-574-3p (SEQ ID NO: 4), miR-577 (SEQ ID NO: 243), miR-579 (SEQ ID NO: 170), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250) and combinations thereof.

[0037] In some embodiments, the one, two, three, four, five, six, seven or more microRNAs is selected from the group miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), and combinations thereof.

[0038] In some embodiments, the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13) and miR-548a-3p (SEQ ID NO:14) and combinations thereof.

[0039] In some embodiments, the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), and combinations thereof.

[0040] In another variation, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-

130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

[0041] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-1244 (SEQ ID NO:20), miR-142-3p (SEQ ID NO:38), miR-30b (SEQ ID NO:42), let-7d (SEQ ID NO:45), miR-30c (SEQ ID NO:52), miR-15b (SEQ ID NO:56), miR-190 (SEQ ID NO:63), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), let-7g (SEQ ID NO:72), miR-20a# (SEQ ID NO:75), miR-28-5p (SEQ ID NO:90), let-7e (SEQ ID NO:93), miR-127-3p (SEQ ID NO:101), miR-103 (SEQ ID NO:105), miR-24-2# (SEQ ID NO:120), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID

NO:125), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-543 (SEQ ID NO:133), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-664 (SEQ ID NO:152), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

[0042] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-1256 (SEQ ID NO: 195), miR-127-3p (SEQ ID NO: 101), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-301a (SEQ ID NO: 67), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[0043] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a

diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7d (SEQ ID NO: 45), miR-103 (SEQ ID NO: 105), miR-125a-5p (SEQ ID NO: 176), miR-142-3p (SEQ ID NO: 38), miR-26a (SEQ ID NO: 70), miR-29b (SEQ ID NO: 125), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-379 (SEQ ID NO: 186), and combinations thereof

[0044] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-18a (SEQ ID NO: 39), miR-26b (SEQ ID NO: 40), miR-106b (SEQ ID NO: 41), miR-29c (SEQ ID NO: 44), miR-144 (SEQ ID NO: 46), miR-1260 (SEQ ID NO: 47), miR-361-5p (SEQ ID NO: 48), miR-520e (SEQ ID NO: 49), miR-660 (SEQ ID NO: 50), miR-148b (SEQ ID NO: 53), miR-27b (SEQ ID NO: 54), miR-15b# (SEQ ID NO: 55), miR-16-1# (SEQ ID NO: 57), miR-17# (SEQ ID NO: 58), miR-22 (SEQ ID NO: 59), miR-32 (SEQ ID NO: 60), miR-532-5p (SEQ ID NO: 61), miR-101 (SEQ ID NO: 62), miR-27a (SEQ ID NO: 65), miR-181a (SEQ ID NO: 66), miR-320B (SEQ ID NO: 71), miR-324-5p (SEQ ID NO: 73), let-7b (SEQ ID NO: 76), miR-422a (SEQ ID NO: 77), let-7f-2# (SEQ ID NO: 78), let-7g# (SEQ ID NO: 79), miR-128a (SEQ ID NO: 80), miR-199a-5p (SEQ ID NO: 81), miR-29a# (SEQ ID NO: 83), miR-329 (SEQ ID NO: 84), miR-337-5p (SEQ ID NO: 85), miR-369-3p (SEQ ID NO: 86), miR-376a# (SEQ ID NO: 87), miR-486-3p (SEQ ID NO: 88), miR-20a (SEQ ID NO: 89), miR-106b# (SEQ ID NO: 92), miR-25 (SEQ ID NO: 94), miR-656 (SEQ ID NO: 95), miR-340 (SEQ ID NO: 97), miR-451 (SEQ ID NO: 98), miR-423-5p (SEQ ID NO: 99), miR-652 (SEQ ID NO: 100), miR-495 (SEQ ID NO: 102), miR-328 (SEQ ID NO: 103), miR-19b (SEQ ID NO: 106), miR-145# (SEQ ID NO: 108), miR-199a-3p (SEQ ID NO: 109), miR-151-5P (SEQ ID NO: 111), miR-502-3p (SEQ ID NO: 113), miR-136# (SEQ ID NO: 114), miR-194 (SEQ ID NO: 115), miR-221 (SEQ ID NO: 116), miR-22# (SEQ ID NO: 117), miR-93 (SEQ ID NO: 118), miR-130b (SEQ ID NO: 121), miR-195 (SEQ ID NO: 123), miR-576-3p (SEQ ID NO: 126), miR-212 (SEQ ID NO: 129), miR-143 (SEQ ID NO: 131), dme-miR-7 (SEQ ID NO: 132), miR-30d# (SEQ ID NO: 134), miR-213 (SEQ ID NO: 135), miR-126# (SEQ ID NO: 136), miR-1197 (SEQ ID NO: 137), miR-1255B (SEQ ID NO: 138), miR-335# (SEQ ID NO: 142), miR-33a# (SEQ ID NO: 143), miR-374a# (SEQ ID NO: 144), miR-381 (SEQ ID NO: 145), miR-409-5p (SEQ ID NO: 146), miR-551b (SEQ ID NO: 149), miR-616 (SEQ ID NO: 150), miR-638

(SEQ ID NO: 151), miR-889 (SEQ ID NO: 153), rno-miR-29c# (SEQ ID NO: 154), and combinations thereof.

[0045] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103 (SEQ ID NO: 105), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-758 (SEQ ID NO: 190), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-668 (SEQ ID NO: 194), and combinations thereof.

[0046] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-339-5p (SEQ ID NO: 182), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[0047] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of progressive IPF, and the one or more microRNAs is selected from the group consisting of miR-1183 (SEQ ID NO: 197) and miR-892b (SEQ ID NO: 248). In some embodiments, subjects identified as having progressive IPF are administered an anti-fibrotic agent described herein.

[0048] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72), miR-103 (SEQ ID NO: 105), miR-106b# (SEQ ID NO: 92), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-1249 (SEQ ID NO: 200), miR-125a-5p (SEQ ID NO: 176), miR-1260 (SEQ ID NO: 47), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-145 (SEQ ID NO: 207), miR-148b# (SEQ ID NO: 128), miR-151-5P (SEQ ID NO: 111), miR-15a (SEQ ID NO: 208), miR-15b (SEQ ID NO: 56), miR-181a (SEQ ID NO: 66), miR-181a-2# (SEQ ID NO: 177), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-190 (SEQ ID NO: 63), miR-194 (SEQ ID NO: 115), miR-196b (SEQ ID NO: 140), miR-199a-5p (SEQ ID NO: 81), miR-199b-5p (SEQ ID NO: 213), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a (SEQ ID NO: 89), miR-20a# (SEQ ID NO: 75), miR-23b (SEQ ID NO: 222), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-30e-3p (SEQ ID NO: 224), miR-324-5p (SEQ ID NO: 73), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-431 (SEQ ID NO: 227), miR-454 (SEQ ID NO: 187), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-505# (SEQ ID NO: 235), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-744# (SEQ ID NO: 245), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-769-5p (SEQ ID NO: 246), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), miR-148b# (SEQ ID NO: 128), miR-668 (SEQ ID NO: 194), and combinations thereof.

[0049] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103(SEQ ID NO:105), miR-107 (SEQ

ID NO:175), miR-1244(SEQ ID NO:20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO:124), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), and combinations thereof.

[0050] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103(SEQ ID NO:105), miR-107 (SEQ ID NO:175), miR-1244(SEQ ID NO:20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO:124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), and combinations thereof.

[0051] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a

diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-199a-5p (SEQ ID NO: 81), miR-23b (SEQ ID NO: 222), miR-29b (SEQ ID NO: 125), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-744# (SEQ ID NO: 245), miR-154# (SEQ ID NO: 139), miR-27b# (SEQ ID NO: 180), miR-374a (SEQ ID NO: 68), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-548J (SEQ ID NO: 148), and combinations thereof.

[0052] In some embodiments, the expression pattern, or decreased level or absence of one or more microRNA is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-151-5P (SEQ ID NO: 111), miR-154# (SEQ ID NO: 139), miR-15a (SEQ ID NO: 208), miR-181a (SEQ ID NO: 66), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-194 (SEQ ID NO: 115), miR-199a-5p (SEQ ID NO: 81), miR-199b-5p (SEQ ID NO: 213), miR-20a (SEQ ID NO: 89), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-324-5p (SEQ ID NO: 73), miR-411# (SEQ ID NO: 147), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-505# (SEQ ID NO: 235), miR-520a-3p (SEQ ID NO: 188), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), and combinations thereof.

[0053] In some embodiments, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO: 2), miR-1303 (SEQ ID NO: 3), miR-574-3p (SEQ ID NO: 4), miR-10b# (SEQ ID NO: 5), miR-875-5p (SEQ ID NO: 6), miR-29a (SEQ ID NO: 7), miR-197 (SEQ ID NO: 10), miR-663B (SEQ ID NO: 11), miR-34a# (SEQ ID NO: 13), miR-548a-3p (SEQ ID NO: 14), miR-338-5P (SEQ ID NO: 15), miR-222 (SEQ ID NO: 16), miR-520D-3P (SEQ ID NO: 17), miR-345 (SEQ ID NO: 18), miR-99b# (SEQ ID NO: 19), miR-1244 (SEQ ID NO: 20), miR-146a (SEQ ID NO: 21), miR-122 (SEQ ID NO: 22), miR-206 (SEQ ID NO: 23), miR-146b-5p (SEQ ID NO: 24), miR-1300 (SEQ ID NO: 25), miR-28-3p (SEQ ID NO: 26), miR-202 (SEQ ID NO: 28), miR-636 (SEQ ID NO: 29), miR-27a# (SEQ ID NO: 30), miR-323-3p (SEQ ID NO: 31), miR-520c-3p (SEQ ID NO: 32), miR-191 (SEQ ID NO: 33), miR-572 (SEQ ID NO: 35), miR-886-3p (SEQ ID NO: 36), and combinations thereof.

NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-32 (SEQ ID NO:60), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), let-7e (SEQ ID NO:93), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-324-3p (SEQ ID NO:107), miR-598 (SEQ ID NO:110), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO:

168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), and combinations thereof.

[0054] In some embodiments, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-26b (SEQ ID NO:40), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-148b (SEQ ID NO:53), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), let-7e (SEQ ID NO:93), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID

NO:102), miR-590-5p (SEQ ID NO:104), miR-598 (SEQ ID NO:110), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

[0055] In some embodiments, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), let-7d (SEQ ID NO: 45), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72), miR-128 (SEQ ID NO:158), miR-103(SEQ ID NO:105), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO:175), miR-132 (SEQ ID NO: 159), miR-1244(SEQ ID NO:20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO:195), miR-141 (SEQ ID

NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-142-3p (SEQ ID NO: 38), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-150 (SEQ ID NO: 27), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO: 162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO: 163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-21 (SEQ ID NO: 51), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-26a (SEQ ID NO: 70), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-324-3p (SEQ ID NO: 107), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-29b (SEQ ID NO: 125), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-30b (SEQ ID NO: 42), miR-362-3p (SEQ ID NO: 96), miR-30c (SEQ ID NO: 52), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[0056] In some embodiments, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO: 195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-

148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO: 162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO: 163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[0057] In some embodiments, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), miR-132 (SEQ ID NO: 159), let-7d (SEQ ID NO: 45), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-103 (SEQ ID NO: 105), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-21 (SEQ ID NO: 51), miR-142-3p (SEQ ID NO: 38), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO: 18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183),

miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof.

[0058] In some embodiments, the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO:173), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO:18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof.

[0059] In some embodiments, the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84).

NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), and combinations thereof.

[0060] In some embodiments, the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), and combinations thereof.

[0061] In some embodiments, the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

[0062] In some embodiments, an “expression pattern” based on (a) the presence or increased levels of selected microRNAs, relative to a predetermined criterion or range, combined with (b) the absence or decreased levels of additional selected microRNAs, relative to a predetermined criterion or range (e.g. increased or decreased relative to levels in samples of patients without IPF), is indicative of a diagnosis of IPF.

[0063] In any of the embodiments disclosed herein, the method optionally comprises administering a therapeutic agent to the subject. Exemplary therapeutic agents include, but are not limited to, the agents selected from the group consisting of steroids (including but not limited to prednisolone), cytotoxic agents (including but not limited to azathioprine and cyclophosphamide), bardoxolone, LPA agonists (including but not limited to AM152); Torisel (temsirolimus); PI3K inhibitors; pentraxin or serum amyloid P (including but not limited to Pentraxin-2 (PTX-2 or PRM-151)); MEK inhibitors (including but not limited to ARRY-162 and ARRY-300); p38 inhibitors; PAI-1 inhibitors (including but not limited to Tiplaxtinin); agents that reduce the activity of transforming growth factor-beta (TGF- β) (including but not limited to GC-1008 (Genzyme/MedImmune); lerdelimumab (CAT-152;

Trabio, Cambridge Antibody); metelimumab(CAT-192,Cambridge Antibody,); LY-2157299 (Eli Lilly); ACU-HTR-028 (Opko Health)) including antibodies that target one or more TGF- β isoforms, inhibitors of TGF- β receptor kinases TGFBR1 (ALK5) and TGFBR2, and modulators of post-receptor signaling pathways; chemokine receptor signaling; endothelin receptor antagonists including inhibitors that target both endothelin receptor A and B and those that selectively target endothelin receptor A (including but not limited to ambrisentan; avosentan; bosentan; clazosentan; darusentan; BQ-153; FR-139317, L-744453; macitentan; PD-145065; PD-156252; PD163610;PS-433540; S-0139; sitaxentan sodium; TBC-3711; zibotentan); agents that reduce the activity of connective tissue growth factor (CTGF) (including but not limited to FG-3019, FibroGen), and including other CTGF-neutralizing antibodies; matrix metalloproteinase (MMP) inhibitors (including but not limited to MMPI-12, PUP-1 and tigapotide trifluate); agents that reduce the activity of epidermal growth factor receptor (EGFR) including but not limited to erlotinib, gefitinib, BMS-690514, cetuximab, antibodies targeting EGF receptor, inhibitors of EGF receptor kinase, and modulators of post-receptor signaling pathways; agents that reduce the activity of platelet derived growth factor (PDGF) (including but not limited to Imatinib mesylate (Novartis)) and also including PDGF neutralizing antibodies, antibodies targeting PDGF receptor (PDGFR), inhibitors of PDGFR kinase activity, and post-receptor signaling pathways; agents that reduce the activity of vascular endothelial growth factor (VEGF) (including but not limited to axitinib, bevacizumab, BIBF-1120, CDP-791, CT-322, IMC-18F1, PTC-299, and ramucirumab) and also including VEGF-neutralizing antibodies, antibodies targeting the VEGF receptor 1 (VEGFR1, Flt-1) and VEGF receptor 2 (VEGFR2, KDR), the soluble form of VEGFR1 (sFlt) and derivatives thereof which neutralize VEGF, and inhibitors of VEGF receptor kinase activity; inhibitors of multiple receptor kinases such as BIBF-1120 which inhibits receptor kinases for vascular endothelial growth factor, fibroblast growth factor, and platelet derived growth factor; agents that interfere with integrin function (including but not limited to STX-100 and IMGN-388) and also including integrin targeted antibodies; agents that interfere with the pro-fibrotic activities of IL-4 (including but not limited to AER-001, AMG-317, APG-201, and sIL-4R α) and IL-13 (including but not limited to AER-001, AMG-317, anrukizumab, CAT-354, cintredekin besudotox, MK-6105, QAX-576, SB-313, SL-102, and TNX-650) and also including neutralizing anti-bodies to either cytokine, antibodies that target IL-4 receptor or IL-13 receptor, the soluble form of IL-4 receptor or derivatives thereof that is reported to bind and neutralize both IL-4 and IL-13, chimeric proteins including all or part of IL-13 and a toxin particularly pseudomonas endotoxin, signaling through the JAK-

STAT kinase pathway; agents that interfere with epithelial mesenchymal transition including inhibitors of mTor (including but not limited to AP-23573 or rapamycin); agents that reduce levels of copper such as tetrathiomolybdate; agents that reduce oxidative stress including N-acetyl cysteine and tetrathiomolybdate; and interferon gamma, inhibitors of phosphodiesterase 4 (PDE4) (including but not limited to Roflumilast); inhibitors of phosphodiesterase 5 (PDE5) (including but not limited to mirodenafil, PF-4480682, sildenafil citrate, SLx-2101, tadalafil, udenafil, UK-369003, vardenafil, and zaprinast); or modifiers of the arachidonic acid pathway including cyclooxygenase and 5-lipoxygenase inhibitors (including but not limited to Zileuton), compounds that reduce tissue remodeling or fibrosis including prolyl hydrolase inhibitors (including but not limited to 1016548, CG-0089, FG-2216, FG-4497, FG-5615, FG-6513, fibrostatin A (Takeda), lufironil,P-1894B, and safironil) and peroxisome proliferator-activated receptor (PPAR)-gamma agonists (including but not limited to pioglitazone and rosiglitazone), and combinations thereof.

[0064] In any of the embodiments described herein, the therapeutic agent can be an oligonucleotide that decreases the activity or level of expression of one or more of the microRNA in the subject. Alternatively, the therapeutic agent can be an oligonucleotide that increases the activity or level of expression of one or more of the microRNA in the subject.

[0065] In any of the embodiments described herein, the blood sample can be selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles. In one exemplary embodiment, the blood sample is plasma.

[0066] The therapeutic agent can also be an anti-fibrotic agent, such as pirfenidone.

[0067] Kits, diagnostic test systems and computer program products are also contemplated.

[0068] A kit to be used in the diagnosis of subjects having idiopathic pulmonary fibrosis as described herein (IPF) preferably comprises one or more probes that specifically hybridize to, or primers that specifically amplify, one, two, three, four, five, six, seven or more microRNAs selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a

(SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128)

NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1249 (SEQ ID NO: 200), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1298 (SEQ ID NO: 204), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-186 (SEQ ID NO: 210), miR-18a# (SEQ ID NO: 211), miR-193a-3p (SEQ ID NO: 212), miR-199b-5p (SEQ ID NO: 213), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-23b (SEQ ID NO: 222), miR-30a-3p (SEQ ID NO: 223), miR-30e-3p (SEQ ID NO: 224), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-431 (SEQ ID NO: 227), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p

(SEQ ID NO: 230), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-501-5p (SEQ ID NO: 234), miR-505# (SEQ ID NO: 235), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), miR-885-5p (SEQ ID NO: 247), miR-892b (SEQ ID NO: 248), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), and combinations thereof.

[0069] Also provided is a diagnostic test system adapted for performing any of the diagnostic methods described herein. Such a diagnostic test system can comprise means for obtaining test results comprising the activity or level of one or more microRNA correlated with a diagnosis of idiopathic pulmonary fibrosis (IPF) in a blood sample of the subject; means for collecting and tracking test results for one or more individual blood sample; means for comparing the activity or level of one or more microRNA to a predetermined criterion; and means for reporting whether the activity or level of the one or more microRNA meets or exceeds the predetermined criterion.

[0070] A computer program product comprising computer-executable instructions embodied in a computer-readable medium for performing the steps of any of the diagnostic methods described herein is also provided.

[0071] The foregoing summary is not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the Detailed Description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. With respect to aspects of the invention described or claimed with “a” or “an,” it should be understood that these terms mean “one or more” unless context unambiguously requires a more restricted meaning. The term “or” should be understood to encompass items in the alternative or together, unless context unambiguously requires otherwise. If aspects of the invention are described as “comprising” a feature, embodiments also are contemplated “consisting of” or “consisting essentially of” the feature.

BRIEF DESCRIPTION OF THE FIGURES

[0072] Figure 1 is a Principle Component Analysis (PCA) of IPF and healthy control subjects based on the data provided in Example 1. A principle component analysis is based on a group of differentially regulated miRNAs shows a clear separation of IPF and healthy control subjects. The analysis is based on normalized values (ΔCt) and includes the ten most statistically significantly upregulated (relatively increased) and ten most statistically significantly downregulated (relatively decreased) sequences, as identified by ANOVA.

[0073] Figure 2 is another PCA of IPF and healthy control subjects based on the data provided in Example 2. The analysis is based on 86 differentially expressed miRNAs, as identified by ANOVA with $FDR \leq 0.05$.

DETAILED DESCRIPTION OF THE INVENTION

[0074] The present application is based on the discovery that the level of one or more microRNAs (including an increased level of, presence of, decreased level of, or absence of such microRNAs) or an alteration in the expression pattern of one or more microRNAs in a blood sample of a human subject is a useful tool for diagnosing the subject with idiopathic pulmonary fibrosis (IPF). The diagnostic methods described herein may permit earlier diagnosis and therapeutic intervention than regimens that rely on conventional clinical diagnosis. The methods described herein also provide a less invasive method of diagnosis compared to conventional methods that utilize a lung tissue sample for diagnosis.

[0075] Described herein are methods of diagnosis comprising detecting/measuring a level and/or expression pattern of a disease-associated microRNA (“miRNA”) in a blood sample of a human subject. Detection of a differential blood level or expression pattern of one or more disease-associated miRNAs compared to a control may be used to diagnose a patient suffering from the disease or at risk of suffering from the disease (e.g., idiopathic pulmonary fibrosis), to determine when to begin administering a therapeutic agent, or to select an increased or decreased amount of the therapeutic agent. Expression levels and/or expression patterns of one or more disease-associated miRNAs may also be used to monitor the treatment and disease state of a patient. Such methods include administering a therapeutic agent to a patient, and detecting levels and/or expression patterns of one or more disease-associated miRNAs at periodic intervals, e.g. about one week, one month, two months, three months, or six months. Furthermore, levels of one or more disease-associated miRNAs may allow the screening of drug candidates for altering a particular miRNA profile associated with disease.

[0076] In any of the diagnostic methods, diagnostic devices/apparatus, or treatment methods described herein, the selection of miRNAs screened may include, or exclude, one, two, three, four, five, six, more, or all of miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-150 (SEQ ID NO: 27), miR-21 (SEQ ID NO: 51), miR-324-3p (SEQ ID NO: 107), let-7d (SEQ ID NO: 45), miR-103 (SEQ ID NO: 105), miR-125a-5p (SEQ ID NO: 176), miR-142-3p (SEQ ID NO: 38), miR-26a (SEQ ID NO: 70), miR-29b (SEQ ID NO: 125), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52) and miR-362 (SEQ ID NO: 96).

[0077] In any of the diagnostic methods, diagnostic devices/apparatus, or treatment methods herein, the selection of miRNAs screened may exclude one, two, three, four, five, six, more, or all of miR-21 (SEQ ID NO: 51), miR-17 (SEQ ID NO: 162), let-7a (SEQ ID NO: 173), miR-106a (SEQ ID NO: 156), miR-222 (SEQ ID NO: 16), miR-146a (SEQ ID NO: 21), miR-132 (SEQ ID NO: 159), miR-142-3p (SEQ ID NO: 38), let-7f (SEQ ID NO: 174), miR-128 (SEQ ID NO: 158), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-103 (SEQ ID NO: 105), miR-26a (SEQ ID NO: 70), miR-99b (SEQ ID NO: 122), miR-107 (SEQ ID NO: 175), miR-122 ((SEQ ID NO: 22), miR-141 (SEQ ID NO: 161), miR-200c (SEQ ID NO: 179) and miR-130a (SEQ ID NO: 112).

[0078] In one aspect, described herein are methods of diagnosing idiopathic pulmonary fibrosis (IPF) in a human subject comprising detecting or measuring in a blood sample from the subject the level or expression pattern of one or more microRNAs, wherein an alteration in the level or expression pattern of the one or more microRNA relative to a predetermined criterion is indicative of idiopathic pulmonary fibrosis in the subject. For some microRNAs, a higher level relative to a predetermined criterion is indicative of IPF, while for other microRNAs, a lower level relative to a predetermined criterion is indicative of IPF. Such microRNAs which exhibit differential expression in IPF patients, compared to the expression pattern of the same microRNAs in control patients without IPF, are termed “disease-associated miRNAs or IPF-associated miRNAs.” The methods may further comprise the step of comparing the level or expression pattern of the one or more microRNAs to the predetermined criterion. In related embodiments, the method of diagnosing comprises detecting a level of one or more microRNAs that falls within a predetermined range indicative of IPF. This predetermined range of levels is typically different from (higher or lower than) the levels of the respective microRNAs seen in patients without IPF.

[0079] The term “differential expression” as used herein refers to both quantitative as well as qualitative differences in the expression patterns of one or more microRNAs in a blood

sample versus the expression patterns of the one or more microRNAs in a blood sample from a healthy subject. For example, a differentially expressed microRNA may either be present or absent in normal versus disease conditions, or may be increased or decreased in a disease condition versus a normal condition. Such a qualitatively regulated microRNA may exhibit an expression pattern within a blood sample that is detectable in either control or disease conditions, but is not detectable in both. In other words, a microRNA is differentially expressed when expression of the microRNA occurs at a different level (higher or lower, presence or absence) in the blood sample of a subject with IPF relative to the level of its expression in the blood sample from a disease-free subject without IPF. The level of a differentially expressed microRNA may refer to either the uncorrected (raw) or normalized abundance of a microRNA in a sample. Comparisons of microRNA levels may consider the uncorrected quantified abundance of a given microRNA relative to an uncorrected reference value. Alternatively, the abundance of a given microRNA may be expressed as a ratio relative to one or more additional microRNAs (or other internal controls) in that sample. In such a case, this “normalized” ratio would be compared relative to a similar “normalized” reference value from a sample of healthy patients (or patients without IPF).

[0080] As used herein the terms “microRNA,” “miR,” “mir,” and “miRNA” are used to refer to a class of small RNA molecules that are capable of modulating RNA levels (see, Zeng and Cullen, RNA, 9(1):112-123, 2003; Kidner and Martienssen Trends Genet, 19(1):13-6, 2003; Dennis C, Nature, 420(6917):732, 2002; Couzin J, Science 298(5602):2296-7, 2002, each of which is incorporated by reference herein). microRNAs are a class of small non-coding RNAs that generally function as post-transcriptional gene regulators. In some cases, microRNAs can hybridize to the 3' untranslated region (UTR) of RNAs, often mRNAs, and can mediate translational repression or RNA cleavage/destruction. Recent studies have shown that microRNAs provide important regulatory functions in a variety of biological processes including cell proliferation, differentiation, development, and apoptosis.

[0081] Without being bound to theory, a gene coding for a miRNA may be transcribed leading to production of an miRNA precursor known as the “pri-miRNA”. The pri-miRNA may be part of a polycistronic RNA comprising multiple pri-miRNAs. The pri-miRNA may form a hairpin with a stem and loop, and the stem may comprise mismatched bases.

[0082] The hairpin structure of the pri-miRNA may be recognized by Drosha, which is an RNase III endonuclease. Processing by Drosha may yield a pre-miRNA stem loop having a 5'

phosphate and about a 2 nucleotide 3' overhang. The details of pri-miRNA processing are well known in the art, and may be found, e.g., in U.S. Pat. Publication No. 20070050146, which is incorporated herein by reference in its entirety.

[0083] A subject having or at risk for developing IPF will exhibit altered levels or expression pattern of certain miRNAs (increased or decreased relative to a predetermined criterion specific to the miRNA, or falling within a predetermined range that is correlated with IPF or falling outside of a predetermined range that is correlated with patients that do not have IPF, e.g. healthy patients). In any of the embodiments described herein, the expression pattern, presence or an increased level of one or more microRNAs is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and such one, two, three, four, five, six, seven or more microRNAs comprises a nucleotide sequence selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), let-7b (SEQ ID NO: 76), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-20a (SEQ ID NO: 89), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO:

168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), or fully complementary nucleotide sequences thereto and combinations thereof, microRNAs that comprise at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more consecutive bases of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that are at least 80% or 85% or 90% or 95% or more identical to the nucleotide sequence of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; or a nucleotide sequence that hybridizes to any of these SEQ ID NOs or the full complement thereof, or combinations thereof. In some embodiments, the one, two, three, four, five, six, seven or more microRNAs comprises a nucleotide sequence selected from the group consisting of miR-222 (SEQ ID NO:16), miR-345 (SEQ ID NO:18), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-150 (SEQ ID NO:27), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579

(SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that comprise at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more consecutive bases of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that are at least 80% or 85% or 90% or 95% or more identical to the nucleotide sequence of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; or a nucleotide sequence that hybridizes to any of these SEQ ID NOs or the full complement thereof, or combinations thereof.

[0084] Alternatively, the level of one, two, three, four, five, six, seven or more microRNAs is detected as falling within a predetermined range that is correlated with IPF. This predetermined range of levels is typically higher than the levels seen in patients without IPF.

[0085] In any of the embodiments described herein, the absence or a decreased level of one, two, three, four, five, six, seven or more microRNAs is detected, relative to a predetermined criterion, and is indicative of a diagnosis of IPF, and such one or more microRNAs comprises a nucleotide sequence selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-

15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-20a# (SEQ ID NO:75), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-28-5p (SEQ ID NO:90), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), -151-5P (SEQ ID NO:111), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758

(SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-199b-5p (SEQ ID NO: 213), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-505# (SEQ ID NO: 235), or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that comprise at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more consecutive bases of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that are at least 80% or 85% or 90% or 95% or more identical to the nucleotide sequence of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; or a nucleotide sequence that hybridizes to any of these SEQ ID NOs or the full complement thereof, or combinations thereof. In some embodiments, the one, two, three, four, five, six, seven or more microRNAs comprises a nucleotide sequence selected from the group consisting of miR-1244 (SEQ ID NO: 20), miR-142-3p (SEQ ID NO: 38), miR-30b (SEQ ID NO: 42), let-7d (SEQ ID NO: 45), miR-30c (SEQ ID NO: 52), miR-15b (SEQ ID NO: 56), miR-190 (SEQ ID NO: 63), miR-301a (SEQ ID NO: 67), miR-374a (SEQ ID NO: 68), miR-144# (SEQ ID NO: 69), miR-26a (SEQ ID NO: 70), let-7g (SEQ ID NO: 72), miR-20a# (SEQ ID NO: 75), miR-28-5p (SEQ ID NO: 90), let-7e (SEQ ID NO: 93), miR-127-3p (SEQ ID NO: 101), miR-103 (SEQ ID NO: 105), miR-24-2# (SEQ ID NO: 120), miR-99b (SEQ ID NO: 122), miR-411 (SEQ ID NO: 124), miR-29b (SEQ ID NO: 125), miR-340# (SEQ ID NO: 127), miR-148b# (SEQ ID NO: 128), miR-543 (SEQ ID NO: 133), miR-154# (SEQ ID NO: 139), miR-196b (SEQ ID NO: 140), miR-411# (SEQ ID NO: 147), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID

NO: 211), miR-199b-5p (SEQ ID NO: 213), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-505# (SEQ ID NO: 235), or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that comprise at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more consecutive bases of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that are at least 80% or 85% or 90% or 95% or more identical to the nucleotide sequence of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; or a nucleotide sequence that hybridizes to any of these SEQ ID NOs or the full complement thereof, or combinations thereof.

[0086] In embodiments where samples are collected as described in Example 1, the expression pattern, absence or a decreased level of one or more microRNAs is detected, relative to the control, is indicative of a diagnosis of IPF, and such one, two, three, four, five, six, seven or more microRNAs comprises a nucleotide sequence selected from the group consisting of let-7b (SEQ ID NO: 76), miR-148a (SEQ ID NO: 91), miR-130a (SEQ ID NO: 112), miR-152 (SEQ ID NO: 130), miR-142-5p (SEQ ID NO: 43), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-20a (SEQ ID NO: 89), miR-598 (SEQ ID NO: 110), or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that comprise at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more consecutive bases of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; microRNAs that are at least 80% or 85% or 90% or 95% or more identical to the nucleotide sequence of any of these SEQ ID NOs or fully complementary nucleotide sequences thereto, or combinations thereof; or a nucleotide sequence that hybridizes to any of these SEQ ID NOs or the full complement thereof, or combinations thereof.

[0087] Any of these preceding nucleotide sequences that are differentially expressed (i.e. increased or decreased levels are observed in samples from patients with IPF, compared to levels in samples from patients without IPF) are encompassed by the term “disease-associated miRNA” or “IPF-associated miRNA.”

[0088] The terms “identical” or “percent identity,” in the context of two or more polynucleotide or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides that are the same, when

compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.

[0089] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0090] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection.

[0091] Alternatively, the level of such one or more microRNAs is detected as falling within a predetermined range that is correlated with IPF. This predetermined range of levels is typically lower than the levels seen in patients without IPF.

[0092] In any of the embodiments described herein, the level of multiple different microRNAs is detected or measured. Thus, for example, the preceding methods of diagnosing idiopathic pulmonary fibrosis (IPF) in a human subject may comprise (a) detecting or measuring in a blood sample from the subject the level of a first microRNA, wherein an alteration in the level of the first microRNA relative to a first predetermined criterion is indicative of IPF (or wherein detection of a level falling within a first predetermined range is indicative of IPF), and (b) detecting or measuring in a blood sample from the subject the level of a second microRNA, wherein an alteration in the level of the second microRNA relative to a second predetermined criterion is indicative of IPF (or wherein detection of a level falling within a second predetermined range is indicative of IPF); and optionally further comprising the steps of (c) comparing the level of the first microRNA to the first predetermined criterion or range and (d) comparing the level of the second microRNA to the second predetermined criterion or range. Similarly, the methods may further comprise detecting or measuring the level of a third microRNA and optionally

comparing the level of the third microRNA to a third predetermined criterion or range. Steps may be repeated for fourth, fifth, sixth or more microRNAs. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40 or more different microRNAs can be detected and can be compared to the respective predetermined criterion or range for the microRNA. It is understood that combinations of one or more of the microRNAs herein include any possible combination of any of the nucleotide sequences described herein, without having to list every combination.

[0093] The term “predetermined criterion” as used herein refers to a number indicative of the level of microRNA obtained from prior measurements of the microRNA in blood samples from a plurality of subjects without IPF. In some variations, the predetermined criterion is the level of microRNA in healthy human controls (i.e., subjects with no clinical manifestation of any respiratory disorder), in which case the level of one, two, three, four, five, six, seven or more microRNAs in idiopathic pulmonary fibrosis is either increased (e.g., miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), let-7b (SEQ ID NO: 76), miR-21 (SEQ ID NO: 51), miR-20a (SEQ ID NO: 89), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO:

164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172, miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250)) or decreased (e.g., miR-1244 (SEQ ID NO: 20), miR-142-3p (SEQ ID NO: 38), miR-18a (SEQ ID NO: 39), miR-26b (SEQ ID NO: 40), miR-106b (SEQ ID NO: 41), miR-30b (SEQ ID NO: 42), miR-29c (SEQ ID NO: 44), let-7d (SEQ ID NO: 45), miR-144 (SEQ ID NO: 46), miR-1260 (SEQ ID NO: 47), miR-361-5p (SEQ ID NO: 48), miR-520e (SEQ ID NO: 49), miR-660 (SEQ ID NO: 50), miR-30c (SEQ ID NO: 52), miR-148b (SEQ ID NO: 53), miR-27b (SEQ ID NO: 54), miR-15b# (SEQ ID NO: 55), miR-15b (SEQ ID NO: 56), miR-16-1# (SEQ ID NO: 57), miR-17# (SEQ ID NO: 58), miR-22 (SEQ ID NO: 59), miR-32 (SEQ ID NO: 60), miR-532-5p (SEQ ID NO: 61), miR-101 (SEQ ID NO: 62), miR-190 (SEQ ID NO: 63), miR-27a (SEQ ID NO: 65), miR-181a (SEQ ID NO: 66), miR-301a (SEQ ID NO: 67), miR-374a (SEQ ID NO: 68), miR-144# (SEQ ID NO: 69), miR-26a (SEQ ID NO: 70), miR-320B (SEQ ID NO: 71), let-7g (SEQ ID NO: 72), miR-324-5p (SEQ ID NO: 73), miR-20a# (SEQ ID NO: 75), miR-422a (SEQ ID NO: 77), let-7f-2# (SEQ ID NO: 78), let-7g# (SEQ ID NO: 79), miR-128a (SEQ ID NO: 80), miR-199a-5p (SEQ ID NO: 81), miR-26a-2# (SEQ ID NO: 82), miR-29a# (SEQ ID NO: 83), miR-329 (SEQ ID NO: 84), miR-337-5p (SEQ ID NO: 85), miR-369-3p (SEQ ID NO: 86), miR-376a# (SEQ ID NO: 87), miR-486-3p (SEQ ID NO: 88), miR-28-5p (SEQ ID NO: 90), miR-106b# (SEQ ID NO: 92), let-7e (SEQ ID NO: 93), miR-25 (SEQ ID NO: 94), miR-656 (SEQ ID NO: 95), miR-340 (SEQ ID NO: 97), miR-451 (SEQ ID NO: 98), miR-423-5p (SEQ ID NO: 99), miR-652 (SEQ ID NO: 100), miR-127-3p (SEQ ID NO: 101), miR-495 (SEQ ID NO: 102), miR-328 (SEQ ID NO: 103), miR-103 (SEQ ID

NO:105), miR-19b (SEQ ID NO:106), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-151-5P (SEQ ID NO:111), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196, miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-199b-5p (SEQ ID NO: 213), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-505# (SEQ ID NO: 235), compared to the level or expression pattern of microRNA in a blood sample obtained from the healthy controls.

[0094] The term “predetermined range” as used herein refers to a range of levels or measurements of microRNA typically observed in human IPF subjects, in which case the level of the microRNA is indicative of IPF if it falls within the predetermined range.

[0095] In other variations, the predetermined criterion or range might include information such as mean, standard deviation, quartile measurements, confidence intervals, or other information about the distribution or range of microRNA concentration in IPF subjects or subjects without IPF. In still other variations, the predetermined criterion is a receiver operating characteristic curve based on data of microRNA measurements in subjects with IPF and subjects that do not have IPF. In still other variations, the predetermined criterion is a cutoff value of microRNA measurements, wherein the cutoff value is determined, based on previous measurements to discriminate IPF with a sensitivity and specificity calculated from measurements of microRNA in human subjects with IPF and non-IPF human subjects. Optionally, the predetermined criterion is based on subjects further stratified by other characteristics that can be determined for a subject, to further refine the diagnostic precision. Such additional characteristics include, for example, sex, age, weight, smoking habits, race or ethnicity, blood pressure, other diseases, and medications.

[0096] The “level” of a nucleic acid (i.e., microRNA) in the methods described herein is the amount of the nucleic acid or its activity as measured by standard laboratory methods. The term includes the amount of nucleic acid (e.g., concentration or total amount) detected in a sample, e.g., by northern blot or microarray analysis or quantitative RT-PCR methods, as well as detection of the presence or absence of the nucleic acid. In one embodiment, the level of a disease-associated miRNA is measured using an amplification method such as quantitative real-time PCR (Q-PCR). Such amplification methods will use primers complementary to at least 12 bases of (a) the miRNAs of any of SEQ ID NOS: 1-250 or (b) the full complement thereof. In another embodiment, the level is measured by contacting a biological sample with a probe or biochip and measuring the amount of hybridization. The level of a differentially expressed microRNA may refer to either the uncorrected (raw) or normalized abundance of a microRNA in a sample. Comparisons of microRNA levels may consider the uncorrected quantified abundance of a given microRNA relative to an uncorrected reference value. Alternatively, the abundance of a given microRNA may be expressed as a ratio relative to one or more additional microRNAs (or other internal controls) in that sample. In such a case, this “normalized” ratio would be compared relative to a similar “normalized” reference value from a sample of healthy patients (or patients without IPF).

[0097] In a related embodiment, the nucleic acid may be detected by contacting a sample comprising the nucleic acid with a biochip comprising an attached oligonucleotide probe

sufficiently complementary to the nucleic acid and detecting hybridization to the probe above control levels. Hybridization of the specific oligonucleotide probes may be detected using Northern Blot analysis, slot-blot analysis or *in situ* hybridization analysis and any other methods known in the art, such as those techniques described in Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratories (New York, 1989)). Hybridization means contacting two or more nucleic acids under conditions suitable for base pairing. Hybridization includes interaction between partially or perfectly complementary nucleic acids. Suitable hybridization conditions are well known to those of skill in the art. In certain applications, it is appreciated that lower stringency conditions may be required. Under these conditions, hybridization may occur even though the sequences of the interacting strands are not perfectly complementary, being mismatched at one or more positions. Conditions may be rendered less stringent by adjusting conditions in accordance with the knowledge in the art, e.g., increasing salt concentration and/or decreasing temperature. Suitable hybridization conditions are those conditions that allow the detection of gene expression from identifiable expression units such as genes. Preferred hybridization conditions are stringent hybridization conditions, such as hybridization at 42°C in a solution (i.e., a hybridization solution) comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate, and washing for 30 minutes at 65°C in a wash solution comprising 1 X SSC and 0.1% SDS. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration, as described in Ausubel, et al. (Eds.), *Protocols in Molecular Biology*, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, et al., (Eds.), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (2d. Ed.; 1989), pp. 9.47 to 9.51.

[0098] The oligonucleotide probes may be labeled for detection of hybridization with the RNA extracted from the biological sample, or the RNA may be labeled for detection. Labels include a radioactive label such as ³H, ¹⁴C, ³²P, ³⁵S, or ¹²⁵I. In addition, the labels may be a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, phycoerythrin, rhodamine, or luciferin. The labels may be enzymes such as alkaline phosphatase, β-galactosidase, biotin and avidin or horseradish peroxidase (Bayer et al., *Meth. Enz.*, 184:138-163 (1990)). The oligonucleotide probes may be attached to solid substrates

such as membranes, beads, filters, glass, silicon, metal, metal-alloy, anopore, polymeric, nylon or plastic. The substrates may be chemically treated with chemical prior to attaching probes to enhance binding or to inhibit nonspecific binding during use. Exemplary treatments include coating glass slides with coating of aminoalkyl silanes or polymeric materials such as acrylamide or proteins. The probes may be covalently or non-covalently attached to the substrate. Probes or primers may be, e.g., 8-20, 8-30, 8-40, 12-20, 12-30 or 12-40 bases in length.

[0099] As used herein, the term “target” as used in the context of an miRNA target refers to the RNA which contains a binding site for the miRNA and which is presumably regulated by the miRNA.

[00100] In some embodiments, target gene sequences for an miRNA sequence are determined by comparing the sequence of potential target gene sequences with the miRNA sequence for complementary matches (e.g., for Watson-Crick complementarity pairing and/or G:U pairing). For example, the UTR of potential target gene sequences can be compared with the miRNA sequence for complementary matches, and used to identify those gene sequences with higher degrees of complementarity as being target gene sequences. The determination may be performed manually, or with the aid of a machine such as a computer system.

[00101] The expression of or activity of an miRNA described herein can be modulated (increased or decreased) by administering (a) a nucleotide sequence of any of SEQ ID NOS: 1-250, or the full complement thereof, (b) a nucleotide sequence comprising (i) at least 8, 9, 10, 11, 12, 13, 14, or 15 consecutive bases of any of SEQ ID NOS: 1-250, or (ii) the full complement of the at least 8, 9, 10, 11, 12, 13, 14, or 15 consecutive bases; or (c) a nucleotide sequence that is at least 80%, 90% or 95% or more identical to any of SEQ ID NOS: 1-250, or the full complement thereof, or (d) a nucleotide sequence that hybridizes under stringent conditions to any of SEQ ID NOS: 1-250, or the full complement thereof.

[00102] One of ordinary skill in the art will appreciate that a complementary sequence need not be an exact complement, and that it is within the scope of the present invention to employ miRNA fragments, fragments of complement sequences, or sequences which are similar to the miRNA or its complement. As one example, the level or activity of an miRNA that is increased in IPF patients, e.g. miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-

875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO: 37), let-7b (SEQ ID NO: 76), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-20a (SEQ ID NO: 89), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), may be decreased using a sequence

which is complementary to the microRNA, a fragment that is complementary to at least 8, 9, 10, 11, 12, 13, 14, or 15 consecutive bases, or, e.g., a sequence which is 80%, 85%, 90%, or 95% or more identical to the complementary sequence (or fragment thereof). In another example, the level or activity of an miRNA that is decreased in IPF patients, e.g., miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-20a# (SEQ ID NO:75), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-28-5p (SEQ ID NO:90), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-151-5P (SEQ ID NO:111), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146)

NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-199b-5p (SEQ ID NO: 213), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-505# (SEQ ID NO: 235)), may be increased using the nucleotide sequence comprising the nucleotide sequence of that SEQ ID, a fragment of the nucleotide sequence comprising the sequence of that SEQ ID, or a sequence which is 80%, 85%, 90%, or 95% or more identical to the either the sequence or a fragment thereof.

[00103] The potential target gene sequences and miRNA sequences are preferably human.

[00104] As noted above, the miRNA may be detected by immobilizing RNA from the blood sample on a solid support such as nylon membranes and hybridizing a labeled probe with the sample. Similarly, the miRNA may also be detected by immobilizing the labeled probe to the solid support and hybridizing the blood sample comprising the miRNA to the probe. Following washing to remove the non-specific hybridization, the label may be detected.

[00105] These assays can be direct hybridization assays or can include the use of multiple probes, as is generally outlined in U.S. Pat. Nos. 5,681,702; 5,597,909; 5,545,730; 5,594,117; 5,591,584; 5,571,670; 5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352; 5,594,118; 5,359,100; 5,124,246; and 5,681,697, each of which is hereby incorporated by reference.

[00106] In addition, other methods known in the art for detecting miRNA may be employed. For example, the methods described in U.S. Pat. Pub. Nos. US 2006/0292616 A1,

US 2006/0228729, and US 2007/0050146 (the disclosures of which are all incorporated herein by reference in their entirety) may be used.

[00107] One method of detection is microarray analysis. In this method, multiple target sequences may be assayed within a single sample volume. Microarrays may be used to identify both precursor and mature miRNAs.

[00108] A preferred method of detection is quantitative RT-PCR. In this method, reverse transcription (RT) is used to convert the target RNA into cDNA, cDNA is then amplified and quantified using standard PCR methods. Primers used for reverse transcription or PCR amplification may include both conventional or modified primers, such as stem-loop RT primers, and LNA-containing primers. Quantitative PCR may be used in a single or multiplex format.

[00109] Additional methods for detection may use micro or nanotechnologies to increase measurement sensitivity, precision, dynamic range, and/or to increase throughput. These methods may include chemical, electrical, and/or optical detection methods. These may also be used in combination with the above mentioned conventional molecular detection methods (i.e. hybridization or RT-PCR).

[00110] To carry out the diagnostic methods described herein, the miRNA may be harvested from a biological fluid sample. Biological fluids include, but are not limited to, blood, serum and plasma. In some embodiments, the biological sample comprises exosomes or isolated microvesicles. The biological sample can be used (i) directly as obtained from the source or (ii) following a pre-treatment to modify the character of the sample. Thus, the sample can be pre-treated prior to use by, for example, preparing plasma from blood, isolating nucleic acid, concentrating liquids, inactivating interfering components, removing heparin from the sample, adding reagents, and the like. Samples also can be pretreated to digest, restrict or render double stranded nucleic acid sequences single stranded. Moreover, samples may be pretreated to accumulate, purify, amplify or otherwise concentrate sequences that may be contained therein.

[00111] Therapeutic Uses

[00112] Also described herein are methods of treating a human subject diagnosed with idiopathic pulmonary fibrosis (IPF) according to any of the diagnostic methods described herein, wherein the method comprises administering a therapeutic agent to the patient to treat IPF. Optionally, the method further includes one or more additional steps of detecting the

level or expression pattern of one or more microRNA post-treatment, to monitor therapeutic efficacy of the treatment and (if warranted) adjust the dose, dosing schedule, or treatment agents.


[00113] In another aspect, a method of treating a human subject identified as having an abnormal level of one or more IPF-associated microRNAs in a blood sample of the subject, comprising administering a therapeutic agent to the subject to treat IPF is provided. The term “abnormal level” as used herein refers to a level of one or more microRNAs present in a blood sample of a subject suffering from IPF that is either increased or decreased when compared to a predetermined criterion as that term is defined herein; or falls within a predetermined range indicative of IPF as that term is defined herein. Alternatively, the abnormal level falls outside of a predetermined range indicative of healthy patients, or patients without IPF. The level of a differentially expressed microRNA may refer to either the uncorrected (raw) or normalized abundance of a microRNA in a sample. Comparisons of microRNA levels may consider the uncorrected quantified abundance of a given microRNA relative to an uncorrected reference value. Alternatively, the abundance of a given microRNA may be expressed as a ratio relative to one or more additional microRNAs (or other internal controls) in that sample. In such a case, this “normalized” ratio would be compared relative to a similar “normalized” reference value from a sample of healthy patients (or patients without IPF).

[00114] In some embodiments, the therapeutic agent is selected from the group consisting steroids (including but not limited to prednisolone), cytotoxic agents (including but not limited to azathioprine and cyclophosphamide), bardoxolone, LPA antagonists (including but not limited to AM152); Torisel (temsirolimus); PI3K inhibitors; pentraxin (including but not limited to Pentraxin-2 (PTX-2 or PRM-151)); MEK inhibitors (including but not limited to ARRY-162 and ARRY-300); p38 inhibitors; PAI-1 inhibitors (including but not limited to Tiplaxtinin); agents that reduce the activity of transforming growth factor-beta (TGF- β) (including but not limited to pan TGF- β neutralizing antibodies, such as GC-1008 (Genzyme/MedImmune); anti-TGF- β 2 mAbs, such as lerdelimumab (CAT-152; Trabio, Cambridge Antibody); anti-TGF- β 1 antibodies, such as metelimumab (CAT-192, Cambridge Antibody); small molecule TGF- β R1 inhibitors, such as LY-2157299 (Eli Lilly); ACU-HTR-028 (Opko Health)) including antibodies that target one or more TGF- β isoforms, inhibitors of TGF- β receptor kinases TGFBR1 (ALK5) and TGFBR2, and modulators of post-receptor signaling pathways; modulators of chemokine receptor signaling; endothelin receptor

antagonists including inhibitors that target both endothelin receptor A and B and those that selectively target endothelin receptor A (including but not limited to ambrisentan; avosentan; bosentan; clazosentan; darusentan; BQ-153; FR-139317, L-744453; macitentan; PD-145065; PD-156252; PD163610;PS-433540; S-0139; sitaxentan sodium; TBC-3711; zibotentan); agents that reduce the activity of connective tissue growth factor (CTGF) (including but not limited to FG-3019, FibroGen), and also including other CTGF-neutralizing antibodies, such as FG-3019; matrix metalloproteinase (MMP) inhibitors (including but not limited to MMPI-12, PUP-1 and tigapotide trifluate, and doxycycline, marimastat, and cipemastat); agents that reduce the activity of epidermal growth factor receptor (EGFR) including but not limited to erlotinib, gefitinib, BMS-690514, cetuximab, antibodies targeting EGF receptor, inhibitors of EGF receptor kinase, and modulators of post-receptor signaling pathways; agents that reduce the activity of platelet derived growth factor (PDGF) (including but not limited to Imatinib mesylate (Novartis)) and also including PDGF neutralizing antibodies, antibodies targeting PDGF receptor (PDGFR), inhibitors of PDGFR kinase activity, and post-receptor signaling pathways; agents that reduce the activity of vascular endothelial growth factor (VEGF) (including but not limited to axitinib, bevacizumab, BIBF-1120, CDP-791, CT-322, IMC-18F1, PTC-299, and ramucirumab) and also including VEGF-neutralizing antibodies, antibodies targeting the VEGF receptor 1 (VEGFR1, Flt-1) and VEGF receptor 2 (VEGFR2, KDR), the soluble form of VEGFR1 (sFlt) and derivatives thereof which neutralize VEGF, and inhibitors of VEGF receptor kinase activity; inhibitors of multiple receptor kinases such as BIBF-1120 which inhibits receptor kinases for vascular endothelial growth factor, fibroblast growth factor, and platelet derived growth factor; agents that interfere with integrin function (including but not limited to STX-100 and IMGN-388) and also including integrin targeted antibodies; agents that interfere with the pro-fibrotic activities of IL-4 (including but not limited to AER-001, AMG-317, APG-201, and sIL-4Ra) and IL-13 (including but not limited to AER-001, AMG-317, anrukizumab, CAT-354, cintredekin besudotox, MK-6105, QAX-576, SB-313, SL-102, and TNX-650) and also including neutralizing anti-bodies to either cytokine, antibodies that target IL-4 receptor or IL-13 receptor, the soluble form of IL-4 receptor or derivatives thereof that is reported to bind and neutralize both IL-4 and IL-13, chimeric proteins including all or part of IL-13 and a toxin particularly pseudomonas endotoxin, signaling through the JAK-STAT kinase pathway; agents that interfere with epithelial mesenchymal transition including inhibitors of mTor (including but not limited to AP-23573 or rapamycin); agents that reduce levels of copper such as tetrathiomolybdate; agents that reduce oxidative stress including N-acetyl cysteine and tetrathiomolybdate; and

interferon gamma. Also contemplated are agents that are inhibitors of phosphodiesterase 4 (PDE4) (including but not limited to Roflumilast); inhibitors of phosphodiesterase 5 (PDE5) (including but not limited to mirodenafil, PF-4480682, sildenafil citrate, SLx-2101, tadalafil, udenafil, UK-369003, vardenafil, and zaprinast); or modifiers of the arachidonic acid pathway including cyclooxygenase and 5-lipoxygenase inhibitors (including but not limited to Zileuton). Further contemplated are compounds that reduce tissue remodeling or fibrosis including prolyl hydrolase inhibitors (including but not limited to 1016548, CG-0089, FG-2216, FG-4497, FG-5615, FG-6513, fibrostatin A (Takeda), lufironil, P-1894B, and safironil) and peroxisome proliferator-activated receptor (PPAR)-gamma agonists (including but not limited to pioglitazone and rosiglitazone). The method disclosed can comprise administering an agent as disclosed directly above and/or an agent selected from BG-12, chemokine activity modulators (including but not limited to CNTO 888, an antibody targeting CCL2), Lys1 oxidase inhibitors (including but not limited to AB0024/GS-6624, an antibody targeting human lysyl oxidase-like 2), NOX4 inhibitors (including but not limited to GKT137831, a selective NOX 1/4 inhibitor), angiotensin II receptor antagonists (including but not limited to losartan), inhibitors of Wnt-beta catenin signaling agents (including but not limited to ICG-001); JNK inhibitors (including but not limited to CC930); IL-4/IL-13 antibody/soluble receptors (including but not limited to SAR156597), and a deuterated pirfenidone (as described e.g., in WO 09/035598 and having one to fourteen deuterium atoms replacing a hydrogen atom in pirfenidone).

[00115] For example for LPA1 receptor antagonists, the agent can be



or one or more of

(4'-{3-Methyl-4-[1-(2-trifluoromethyl-phenyl)-ethoxycarbonylamino]-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1); (4'-{3-Methyl-4-[1-(3-trifluoromethyl-phenyl)-ethoxycarbonylamino]-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 2); (4'-{4-[1-(2,4-Dichloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 3); (4'-{4-[1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 4); (4'-{4-[1-(3-Bromo-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 5); (4'-{4-[1-(2-Methoxy-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 6); (4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-6-methoxy-biphenyl-3-yl)-acetic acid (Compound 7); 4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-carboxylic acid (Compound 8); 4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-2-carboxylic acid (Compound 9); (4'-{4-[1-(2-Chloro-phenyl)-

ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-2-yl)-acetic acid (Compound 10); (4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 11); (4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-3-yl)-acetic acid (Compound 12); 3-(4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 13); (4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-6-fluorobiphenyl-3-yl)-acetic acid (Compound 14); (4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-4-fluoro-biphenyl-3-yl)-acetic acid (Compound 15); (4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid methyl ester (Compound 16); 2-(4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid ethyl ester (Compound 17); 2-(4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 18); 2-(4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-2-methyl-propionic acid (Compound 19); 2-(4'-{4-[1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 20); 4-(4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-butyric acid (Compound 21); 4'-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-3-carboxylic acid (Compound 22); (4'-{4-[1-(4-Chloro-2-fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 23); (4'-{4-[(R)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 24); (4'-{4-[(R)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-2'-methyl-biphenyl-4-yl)-acetic acid (Compound 25); 2-(4'-{4-[1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-2-methyl-propionic acid (Compound 26); (4'-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 27); 2-(4'-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-2-methyl-propionic acid (Compound 28); 2-(4'-{4-[(R)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-2-methyl-propionic acid (Compound 29); 2-(4'-{4-[(R)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic


acid (Compound 30); 2-(4'-{4-[{(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 31); {4'-{4-[1-(2,6-Dichlorophenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 32); 2-(4'-{4-[{(R)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 33); {4'-{4-[{(S)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 34); {4'-{4-[{(S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 35); {4'-{4-[2-Chlorobenzyl-oxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 36); {4'-{3-Methyl-4-{(R)-1-phenyl-ethoxycarbonylamino}-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 37); {4'-{4-[1-(2,3-Difluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 38); {4'-{4-[1-(2,4-Difluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 39); {4'-{4-[1-(2-Fluoro-4-methoxy-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 40); {4'-{4-[1-(2,5-Difluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 41); {4'-{4-[1-(2,6-Difluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 42); {4'-{3-Methyl-4-{(R)-1-phenyl-ethoxycarbonylamino}-isoxazol-5-yl}-biphenyl-3-yl)-acetic acid (Compound 43); {4'-{3-Methyl-4-{(R)-1-phenyl-ethoxycarbonylamino}-isoxazol-5-yl}-biphenyl-4-carboxylic acid (Compound 44); {4'-{3-Methyl-4-{(R)-1-phenyl-ethoxycarbonylamino}-isoxazol-5-yl}-biphenyl-2-yl)-acetic acid (Compound 45); {4'-{3-Methyl-4-{(R)-1-o-tolyl-ethoxycarbonylamino}-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 46); 2-(4'-{4-{(R,R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 47); 2-(4'-{4-{(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 48); {3'-Chloro-4'-{4-{(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 49); 2-(4'-{4-{(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-butyric acid (Compound 50); {2'-Chloro-4'-{4-{(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 51);

(4'-{4-[*(R*)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-2'-fluoro-biphenyl-4-yl)-acetic acid (Compound 52); 4'-{4-[*(R*)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-carboxylic acid (Compound 53); (4'-{4-[*(R*)-1-(3,5-Dibromo-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 56); {4'-[3-Methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid (Compound 57); (4'-[*(R*)-1-(3-Hydroxy-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl)-biphenyl-4-yl)-acetic acid (Compound 58); (4'-[3-Methyl-4-(1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl)-acetic acid (Compound 59); [5-(4'-Cyanomethyl-biphenyl-4-yl)-3-methyl-isoxazol-4-yl]-carbamic acid (*R*)-1-(2-chloro-phenyl)-ethyl ester (Compound 61); [5-(4'-Cyanomethyl-biphenyl-4-yl)-3-methyl-isoxazol-4-yl]-carbamic acid (*R*)-1-(2-fluoro-phenyl)-ethyl ester (Compound 62); {3-Methyl-5-[4'-(*2H*-tetrazol-5-ylmethyl)-biphenyl-4-yl]-isoxazol-4-yl}-carbamic acid (*R*)-1-(2-chloro-phenyl)-ethyl ester (Compound 64); [5-(4'-Carbamimidoylmethyl-biphenyl-4-yl)-3-methyl-isoxazol-4-yl]-carbamic acid (*R*)-1-(2-fluoro-phenyl)-ethyl ester (Compound 65); {5-[4'-{(2-Acetylamino-2-imino-ethyl)-biphenyl-4-yl}-3-methyl-isoxazol-4-yl]-carbamic acid (*R*)-1-(2-fluoro-phenyl)-ethyl ester (Compound 66); and 2-(2-{4'-[3-Methyl-4-((*R*)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl})-acetylamino)-ethanesulfonic acid

[00116] In particular, the LPA1 receptor antagonist can have a structure of any one of formulae (I), (Ia), (II), (IIa), (III), (IIIa), (IV), and (V) as disclosed in WO 2011/041462; a structure of any one of formulae (I), (II), and (III) as disclosed in WO 2010/68775; a structure of formula (I) as disclosed in US 2010/311799; a structure of formula (I) as disclosed in WO 2010/141761; a structure of any one of formulae (I), (II), (III), (IV) and (IV) as disclosed in WO 2010/141768; a structure of formula (I) as disclosed in US 2010/152257; a structure of any one of formulae (I), (II) and (III) as disclosed in WO 10/77882; a structure of formula (I) as disclosed in WO 10/77883; a structure of formula (I) as disclosed in US 2011/0082164; a structure of any one of formulae (I) and (II), as disclosed in WO 11/041461; a structure of any one of compounds 1-79 or formula (I) as disclosed in US 2011/0082181; a structure of any one of formulae (I), (II), (III), (IV), (V), (VI), and (VI) as disclosed in WO 2011/041694; a structure of formula (I) as disclosed in WO 11/041729; structure of any one of formulae (I), (II), (III), (IV), and (V) as disclosed in WO 11/017350, each of which is incorporated by reference in its entirety. These and related LPA1 receptor antagonists, and methods of synthesizing them, are disclosed generally in the following patent publications: WO 2010/68775; US 2010/311799; WO 2010/141761; WO 2010/141768; US 2010/152257; WO

2010/77883; WO 2010/77882, US 2011/82164; WO 2011/41461; WO 2011/41462; US 2011/82181; WO 2011/41694; WO 2011/41729; WO 2011/17350, each of which is incorporated by reference in its entirety.

[00117] Additional LPA1 receptor antagonists contemplated include compounds of formulae (1), (2) and (5), and in particular compounds 101-169, as disclosed in US Patent No. 6,964,975 and US Patent Publication No. 2003/114505, each of which is incorporated by reference in its entirety. A specific compound from this family is



[00118] Still other LPA receptor antagonists contemplated include compounds disclosed in US Patent No. 7,517,996, and in particular a compound having a structure of formula (I), which is incorporated by reference in its entirety.

[00119] Still other LPA receptor antagonists contemplated include compounds disclosed in US Patent No. 7,288,558, and in particular compounds having a structure of formula (I) , which is incorporated by reference in its entirety.


[00120] Also contemplated are agents that are PG D₂ modulators, such as compounds having a structure of any one of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII), and (IX), as disclosed in US 2011/0098302 or structure of formula (I), as disclosed in US 2011/0098352, each of which is incorporated by reference in its entirety.

[00121] Also contemplated are the following agents or classes of agents: one or more of nitric oxide (e.g., inhaled nitric oxide), a vitamin E and pentoxifylline combination (e.g., PTL-202 from Pacific Therapeutics), PXS25, desatinib (a multiple kinase inhibitor), PI3K/mTor dual inhibitor (e.g., BAY806946, XL765, GDC0980, GSK2126458, BEZ235, BGT226, PF04691502, PK1587, and/or SF1126), PI3K inhibitor (e.g., XL147, GDC0941, BKM120, PX866, ZSTK474, BYL719 (PI3K alpha), AMG319 (PI3K delta), CAL101 (PI3K delta), and/or GDC0032), 5-HT2A/B receptor antagonists (e.g., terguride), telomerase activator (e.g., TAT153), modulators (e.g., reducers) of chemokine activity (e.g., CNTO 888, an antibody that targets CCL2), Lys1 oxidase inhibitors (e.g., AB0024 / GS-6624, a

humanized mAb targeting human lysyl oxidase-like 2), NOX4 inhibitor (e.g., GKT137831, a selective Nox 1/4 inhibitor), angiotensin II receptor antagonist (e.g., lortsartan), an anti $\alpha_v\beta_6$ integrin agent, and pentraxin (e.g., serum amyloid P, PTX-2, or PRM-151).

[00122] Also contemplated are agents that are pirfenidone analogs, such as compounds having a structure of any one of formulae (I), (II), (III), (IV), and (V), as disclosed in WO 10/085805, the disclosure of which is incorporated by reference in its entirety. The synthesis of the pirfenidone analog compounds disclosed in WO 10/085805 are further described in U.S. Patent Publication No. 2007/0049624 (US national stage of WO 05/0047256), International Publication No. WO 03/068230, WO 08/003141, WO 08/157786, or in U.S. Patent Nos. 5,962,478; 6,300,349; 6,090,822; 6,114,353; Re. 40,155; 6,956,044; or 5,310,562, each of which is incorporated by reference in its entirety.

[00123] The pirfenidone analogs disclosed in WO 10/085805, have structures of formulae (I), (II), (III), (IV), or (V):



wherein A is N or CR²; B is N or CR⁴; E is N or CX⁴; G is N or CX³; J is N or CX²; K is N or CX¹; a dashed line is a single or double bond, R¹, R², R³, R⁴, X¹, X², X³, X⁴, X⁵, Y¹, Y², Y³, and Y⁴ are independently selected from the group consisting of H, deuterium, C₁-C₁₀ alkyl, C₁-C₁₀ deuterated alkyl, substituted C₁-C₁₀ alkyl, C₁-C₁₀ alkenyl, substituted C₁-C₁₀ alkenyl, C₁-C₁₀ thioalkyl, C₁-C₁₀ alkoxy, substituted C₁-C₁₀ alkoxy, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroalkyl, substituted heteroalkyl, aryl,

substituted aryl, heteroaryl, substituted heteroaryl, halogen, hydroxyl, C₁-C₁₀ alkoxyalkyl, substituted C₁-C₁₀ alkoxyalkyl, C₁-C₁₀ carboxy, substituted C₁-C₁₀ carboxy, C₁-C₁₀ alkoxy carbonyl, substituted C₁-C₁₀ alkoxy carbonyl, CO-uronide, CO-monosaccharide, CO-oligosaccharide, and CO-polysaccharide; X⁶ and X⁷ are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkylenylaryl, alkylenylheteroaryl, alkylenylheterocycloalkyl, alkylenylcycloalkyl, or X⁶ and X⁷ together form an optionally substituted 5 or 6 membered heterocyclic ring; Ar is pyridinyl or phenyl; and Z is O or S. In some embodiments, A is N or CR²; B is N or CR⁴; E is N, N⁺X⁴ or CX⁴; G is N, N⁺X³ or CX³; J is N, N⁺X² or CX²; K is N, N⁺X¹ or CX¹; a dashed line is a single or double bond, R¹, R², R³, R⁴, X¹, X², X³, X⁴, X⁵, Y¹, Y², Y³, and Y⁴ are independently selected from the group consisting of H, deuterium, optionally substituted C₁-C₁₀ alkyl, optionally substituted C₁-C₁₀ deuterated alkyl, optionally substituted C₁-C₁₀ alkenyl, optionally substituted C₁-C₁₀ thioalkyl, optionally substituted C₁-C₁₀ alkoxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted amido, optionally substituted sulfonyl, optionally substituted amino, optionally substituted sulfonamido, optionally substituted sulfoxyl, cyano, nitro, halogen, hydroxyl, SO₂H₂, optionally substituted C₁-C₁₀ alkoxyalkyl, optionally substituted C₁-C₁₀ carboxy, optionally substituted C₁-C₁₀ alkoxy carbonyl, CO-uronide, CO-monosaccharide, CO-oligosaccharide, and CO-polysaccharide; X⁶ and X⁷ are independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkylenylaryl, optionally substituted alkylenylheteroaryl, optionally substituted alkylenylheterocycloalkyl, optionally substituted alkylenylcycloalkyl, or X⁶ and X⁷ together form an optionally substituted 5 or 6 membered heterocyclic ring; and Ar is optionally substituted pyridinyl or optionally substituted phenyl; and Z is O or S.

[00124] The pirfenidone administered in the methods disclosed herein can be deuterated. The pirfenidone can be a mixture of deuterated forms of pirfenidone, a single deuterated form, or a mixture of deuterated form (or forms) and non-deuterated pirfenidone. Contemplated deuterated pirfenidone includes pirfenidone with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 deuterium atoms. The phenyl ring of pirfenidone can be deuterated with 1, 2, 3, 4, or 5 deuterium atoms. Additionally or alternatively, the methyl of pirfenidone can be

deuterated with 1, 2, or 3 deuterium atoms. Additionally or alternatively, the pyridone ring hydrogens can be substituted with 1, 2, 3, or 4 deuterium atoms. Multiple different deuterated pirfenidone forms and methods of synthesizing the various deuterated pirfenidone forms are disclosed in WO 09/035598, the disclosure of which is incorporated by reference in its entirety.

[00125] Combinations of one or more of the foregoing agents are also contemplated.

[00126] In one embodiment the invention provides methods of treating a subject having IPF, for example, by administering to the subject an effective amount of an agent which modulates the level of at least one miRNA in a target cell. In some embodiments, the agent increases or stimulates the expression or activity of a miRNA in a mammalian subject (i.e., a miRNA enhancer). In other embodiments, the agent decreases or inhibits the expression or activity of a miRNA in a mammalian subject (i.e., an miRNA or miRNA inhibitor).

[00127] As used herein, “an agent which modulates the level of miRNA” indicates that the agent, when administered to a sample or subject increases or a decreases in the measured value of at least one miRNA. In some embodiments the miRNA is increased or decreased by an amount between 1-fold and 20-fold, or more than 20-fold. In some particular embodiments the miRNA is increased or decreased by 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 7-fold, 9-fold, 10-fold, 12-fold, or 15-fold, or more. In other embodiments the miRNA is increased or decreased by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, or more.

[00128] miRNA enhancers are molecules, e.g., nucleic acid molecules, which act to increase the level of a miRNA gene product in a cell. In one variation, a miRNA enhancer comprises a sequence of a miRNA, or a variant thereof. In another variation, the miRNA molecule is a synthetic molecule. In another variation, the miRNA molecule comprises one or more stabilizing mutations. The miRNA sequence may be 12-100 nucleotides in length. For example, the miRNA sequence may comprise 20-80, 20-70, 20-60, 20-50, 20-40, 21-23, 21-25 12-33, 18-24, 18-26, or 21-23 nucleotides. In some embodiments, the miRNA sequence may comprise 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. The sequence of the miRNA may be the first 13-33, or 21-25 nucleotides of the pre-miRNA. In some embodiments, the sequence of the miRNA may be the last 13-33 or 21-25 nucleotides of the pre-miRNA.

[00129] In another variation, the miRNA enhancer comprises a sequence of a pri-miRNA or a variant thereof. The pri-miRNA sequence may comprise from 30-300, 35-375, 45-250, 55-200, 70-150 or 80-100 nucleotides. The pri-miRNA may also comprise a miRNA and the complement thereof, and variants thereof. The pri-miRNA may form a hairpin structure. The hairpin may comprise a first and second nucleic acid sequence that are substantially complimentary. The first and second nucleic acid sequence may be from 37-50 nucleotides. The first and second nucleic acid sequence may be separated by a third sequence of from 8-12 nucleotides. The hairpin structure may have a free energy less than -25 Kcal/mole as calculated by the Vienna algorithm with default parameters, as described in Hofacker et al., Monatshefte f. Chemie 125: 167-188 (1994), the contents of which are incorporated herein. The hairpin may comprise a terminal loop of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides.

[00130] In contrast, miRNA inhibitors decrease or inhibit the expression or activity of a miRNA in a mammalian subject. In some embodiments, the miRNA inhibitor is antagomir. As used herein, the term “antagomir” is an anti-miRNA molecule that is capable of blocking the activity of a miRNA. The antagomir may comprise a total of 12-50 or 8-50, or 8-40, or 5-40 nucleotides in length. In some embodiments, the antagomir comprises a total of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55 or 60 nucleotides. The sequence of an antagomir may comprise the complement of a sequence of a miRNA such that, e.g., the anti-miRNA binds to the miRNA to block its activity.

[00131] In some embodiments, the antagomirs comprise one or more non-naturally occurring or modified nucleotides. The one or more modified nucleotide analog may be located for example at the 5'-end and/or the 3'-end of the nucleic acid molecule or within the nucleic acid molecule. Representative examples of nucleotide analogs may be selected from sugar- or backbone-modified ribonucleotides. It should be noted, however, that nucleobase-modified ribonucleotides, i.e. ribonucleotides, containing a non-naturally occurring nucleobase instead of a naturally occurring nucleobase such as uridines or cytidines modified at the 5-position, e.g. 5-(2-amino)propyl uridine, 5-bromo uridine; adenosines and guanosines modified at the 8-position, e.g. 8-bromo guanosine; deaza nucleotides, e.g. 7-deaza-adenosine; O- and N-alkylated nucleotides, e.g. N6-methyl adenosine are suitable. The 2'-OH-group may be replaced by a group selected from H, OR, R, halo, SH, SR, NH₂, NHR, NR₂ or CN, wherein R is C₁-C₆ alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I. In a

preferred embodiment, the antagonir comprises a 2'-O methyl modification. In a highly preferred embodiment, the antagonir comprises a 2',5' locked nucleic acid (LNA) modification.

[00132] Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs may be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. It will further be understood that combinations of modifications (e.g., modifications to backbone linkages and 2'O modifications) may be made to the same nucleic acid molecule. Stabilizing alterations may include the use of nonionic DNA analogs, such as alkyl- and aryl-phosphonates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated.

[00133] A number of studies have looked at the base-pairing requirement between miRNA and its mRNA target for achieving efficient inhibition of translation (reviewed by Bartel 2004, Cell 116-281). In mammalian cells, the first 8 nucleotides of the miRNA may be important (Doench & Sharp 2004 GenesDev 2004-504). However, other parts of the microRNA may also participate in mRNA binding. Moreover, sufficient base pairing at the 3' can compensate for insufficient pairing at the 5' (Brennecke et al., 2005 PLoS 3-e85). Computation studies, analyzing miRNA binding on whole genomes have suggested a specific role for bases 2-7 at the 5' of the miRNA in target binding but the role of the first nucleotide, found usually to be "A" was also recognized (Lewis et al. 2005 Cell 120-15). Similarly, nucleotides 1-7 or 2-8 were used to identify and validate targets by Krek et al. (2005, Nat Genet. 37-495).

[00134] Nucleic acid inhibitors of an miRNA have complementarity to the miRNA molecule whose level is to be inhibited. In one embodiment, the inhibitor and the miRNA are 100% complementary over their full length (i.e., are complementary at 100% of the nucleotides of the miRNA molecule). In another embodiment, the inhibitor and the miRNA molecule are 95%, 90%, 85% or 80% complementary over their full length. In embodiments where the molecules are less than 100% complementary, preferably, the 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases at the 5' end of the miRNA molecule are complementary to the nucleotides present in the inhibitor at the corresponding position; mismatching may occur at other positions and the desired level of complementarity achieved.

[00135] Kits

[00136] In another embodiment, kits are provided which contain the necessary reagents to carry out the assays of the present invention. In one embodiment, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises a means of detecting a change in the level of one, two, three, four, five, six, seven or more microRNA correlated with a diagnosis of IPF in a blood sample from the subject. In some embodiments, the kit comprises a sample collection component with specific tubes and buffers, a miRNA extraction component, miRNA quantitative RT-PCR components with deliberate enzymes and primers and one or more containers comprising primers capable of specifically and quantitatively amplifying any of the IPF-associated miRNAs described herein. The term “specifically amplify” as used herein means that the primers in the kit amplify the IPF-associated miRNA but do not substantially amplify other miRNAs of non-homologous sequence. Quantitative RT-PCR kits may be in single, multiple (multiplex), or in a panel of parallel assays.

[00137] In another embodiment, kits are provided which contain the necessary reagents to carry out the assays of the present invention. In one embodiment, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises a means of detecting a change in the level of one, two, three, four, five, six, seven or more microRNA correlated with a diagnosis of IPF in a blood sample from the subject. In some embodiments, the kit comprises a sample collection component with specific tubes and buffers, a miRNA extraction component, miRNA reverse transcription and/or labeling components (as appropriate), and a component with appropriate primers or customized specific miRNA hybridization components. One or more containers comprising probes or arrays of probes capable of specifically hybridizing to any of the IPF-associated miRNAs described herein. In other embodiments, the kit comprises one or more microarrays comprising probes capable of specifically detecting any of the IPF-associated miRNAs described herein, and includes the additional components for detection that may include chemical, electrical, and/or optical detection methods. The term “specifically hybridize” as used herein means that the probes in the kit hybridize under stringent conditions to the IPF-associated miRNA but not substantially to other miRNAs of non-homologous sequence. In other embodiments, the kit comprises one or more microarrays comprising probes capable of specifically detecting any of the IPF-associated miRNAs described herein.

[00138] In some embodiments, the kit comprises a means for sample collection (e.g., collection tubes and buffers for maintaining microRNA integrity in the sample); instructions and materials for the extraction of microRNA from the sample; instructions and appropriate buffers, substrates and enzymes for microRNA reverse transcription; and instructions and materials (e.g., DNA polymerase, nucleotide substrates, PCR buffer, detection components and PCR primers universal or microRNA specific PCR primers) for microRNA amplification and quantification.

[00139] In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibody or antibodies used in the assay, containers which contain wash reagents (such as phosphate-buffered saline, Tris buffers, and the like), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include nucleic acid probes or primers, either of which may be labeled,.

[00140] Diagnostic Systems

[00141] A “diagnostic system” is any system capable of carrying out the methods of the invention, including computing systems, environments, and/or configurations that may be suitable for use with the methods or system of the claims include, but are not limited to, personal computers, server computers, hand-held or laptop devices, multiprocessor systems, microprocessor-based systems, set top boxes, programmable consumer electronics, network PCs, minicomputers, mainframe computers, distributed computing environments that include any of the above systems or devices, and the like. Specifically contemplated herein are a system adapted to perform the steps of any of the methods described herein, and a computer program product comprising computer-executable instructions embodied in a computer-readable medium for performing the steps of any of the methods described herein.

[00142] Tests to measure and compare levels of one, two, three, four, five, six, seven or more microRNA can be implemented on a wide variety of diagnostic test systems. Diagnostic test systems are apparatuses that typically include means for obtaining test results

from biological samples. Examples of such means include modules that automate the testing (e.g., biochemical, immunological, nucleic acid detection assays). Some diagnostic test systems are designed to handle multiple biological samples and can be programmed to run the same or different tests on each sample. Diagnostic test systems typically include means for collecting, storing and/or tracking test results for each sample, usually in a data structure or database. Examples include well-known physical and electronic data storage devices (e.g., hard drives, flash memory, magnetic tape, paper print-outs). It is also typical for diagnostic test systems to include means for reporting test results. Examples of reporting means include visible display, a link to a data structure or database, or a printer. The reporting means can be nothing more than a data link to send test results to an external device, such as a data structure, data base, visual display, or printer.

[00143] Still another embodiment of the invention is a computer readable medium having computer executable instructions for diagnosing IPF, the computer readable medium comprising: a routine, stored on the computer readable medium and adapted to be executed by a processor, to store one or more predetermined criteria or ranges; and a routine stored on the computer readable medium and adapted to be executed by a processor to compare the level of one, two, three, four, five, six, seven or more microRNA in a test sample data to its respective predetermined criterion or predetermined range to diagnose IPF.

[00144] A computer-readable storage medium can comprise a data storage material encoded with computer readable data or data arrays which, when using a machine programmed with instructions for using said data, is capable of use for a variety of purposes, such as, without limitation, subject information relating to diagnosing IPF. Measurements of microRNA in a sample can be implemented in computer programs executing on programmable computers, comprising, *inter alia*, a processor, a data storage system (including volatile and non-volatile memory and/or storage elements), at least one input device, and at least one output device. Program code can be applied to input data to perform the functions described above and generate output information. The output information can be applied to one or more output devices, according to methods known in the art. The computer may be, for example, a personal computer, microcomputer, or workstation of conventional design. The output may include (a) the level of one, two, three, four, five, six, seven or more microRNAs and (b) the respective one or more predetermined criteria or predetermined ranges. Preferably the levels of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 different microRNAs are detected, such that the output includes at

least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 different levels and predetermined criteria or ranges. Analogously, levels of at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40 or more different microRNAs may be detected.

[00145] Each program can be implemented in a high level procedural or object oriented programming language to communicate with a computer system. However, the programs can be implemented in assembly or machine language, if desired. The language can be a compiled or interpreted language. Each such computer program can be stored on a storage media or device (e.g., ROM or magnetic diskette or others as defined elsewhere in this disclosure) readable by a general or special purpose programmable computer, for configuring and operating the computer when the storage media or device is read by the computer to perform the procedures described herein. The data comparison system of the invention may also be considered to be implemented as a computer-readable storage medium, configured with a computer program, where the storage medium so configured causes a computer to operate in a specific and predefined manner to perform various functions described herein. Levels of microRNA in a sample can then be determined and compared to a predetermined criterion or range as described herein.

[00146] The invention is further described in the following additional embodiments:

[00147] 1A. A method of diagnosing idiopathic pulmonary fibrosis (IPF) in a human subject comprising detecting in a blood sample of from the subject the level of one or more microRNAs, wherein an increase or decrease in the level of the one or more microRNA relative to a predetermined criterion is indicative of a diagnosis of IPF.

[00148] 2A. The method of embodiment 1A, further comprising the step of comparing the level of the microRNA to a predetermined criterion or range.

[00149] 3A. The method of embodiment 1A or embodiment 2A, wherein the one or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23),

miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130)

NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), and combinations thereof.

[00150] 4A. The method of embodiment 1A or embodiment 2A, wherein the one or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85).

NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), and combinations thereof.

[00151] 5A. The method of claim 1A or claim 2A, wherein the one or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), and combinations thereof.

[00152] 6A. The method of embodiment 1A or embodiment 2A, wherein the one or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

[00153] 7A. The method of any one of embodiments 1A-6A, wherein the level or expression pattern of at least 2 different microRNAs is detected.

[00154] 8A. The method of any one of embodiments 1A-6A, wherein the level or expression pattern of at least 10 different microRNA is detected.

[00155] 9A. The method of any one of embodiments 1A-6A, wherein the level or expression pattern of at least 20 different microRNA is detected.

[00156] 10A. The method of any one of embodiments 1A-4A, wherein the presence or an increased level of one or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), and combinations thereof.

[00157] 11A. The method of any one of embodiments 1A-4A, wherein the presence or an increased level of one or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11); miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21) and combinations thereof.

[00158] 12A. The method of any one of embodiments 1A-4A, wherein the presence or an increased level of one or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9),

miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) ; miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14) and combinations thereof.

[00159] 13A. The method of any one of c embodiments 1A-4A, wherein the presence or an increased level of one or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) and combinations thereof.

[00160] 14A. The method of any one of embodiments 1A-13A, wherein the absence or a decreased level of one or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-

3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), and combinations thereof.

[00161] 15A. The method of any one of embodiments 1A-11A, wherein the absence or a decreased level of one or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72),

miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88),) and combinations thereof.

[00162] 16A. The method of any one of embodiments 1A-11A, wherein the absence or a decreased level of one or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61) and combinations thereof.

[00163] 17A. The method of any one of embodiments 1A-11A, wherein the absence or a decreased level of one or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

[00164] 18A. The method of any of embodiments 1A-17A, wherein the sample is selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles.

[00165] 19A. The method of any one of embodiments 1A-17A, wherein the method further comprises administering a therapeutic agent to the subject.

[00166] 20A. A method of treating a human subject diagnosed with idiopathic pulmonary fibrosis (IPF) according to any of embodiments 1A-18A comprising administering a therapeutic agent to the subject to treat IPF.

[00167] 21A. A method of treating a human subject identified as having idiopathic pulmonary fibrosis (IPF) or at risk of IPF based on an abnormal level of one or more IPF-associated microRNAs in a blood sample of the subject, comprising administering a therapeutic agent to the subject to treat IPF.

[00168] 22A. The method of embodiment 20A or embodiment 21A, wherein the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2#

(SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), or combinations thereof.

[00169] 23A. The method of embodiment 20A or embodiment 21A, wherein the level or expression pattern of at least 2 different microRNAs is detected.

[00170] 24A. The method of embodiment 20A or embodiment 21A, wherein the level or expression pattern of at least 10 different microRNA is detected.

[00171] 25A. The method of embodiment 20A or embodiment 21A, wherein the level or expression pattern of at least 20 different microRNA is detected.

[00172] 26A. The method of embodiment 21A, wherein the sample is selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles.

[00173] 27A. The method of any of embodiments 19A-26A, wherein the therapeutic agent is an oligonucleotide that decreases the activity or level of expression of one or more of the microRNA in the subject.

[00174] 28A. The method of any of embodiments 19A-26A, wherein the therapeutic agent is an oligonucleotide that increases the activity or level of expression of one or more of the microRNA in the subject.

[00175] 29A. The method of any of embodiments 19A-26A, wherein the therapeutic agent is an anti-fibrotic agent.

[00176] 30A. The method of embodiment 29A, wherein the anti-fibrotic agent is pirfenidone.

[00177] 31A. The method of any of embodiments 19A-26A, wherein the therapeutic agent is selected from the group consisting of steroids (including but not limited to prednisolone), cytotoxic agents (including but not limited to azathioprine and cyclophosphamide), bardoxolone, LPA agonists (including but not limited to AM152); Torisel (temsirolimus); PI3K inhibitors; pentraxin or serum amyloid P (including but not limited to Pentraxin-2 (PTX-2 or PRM-151)); MEK inhibitors (including but not limited to ARRY-162 and ARRY-300); p38 inhibitors; PAI-1 inhibitors (including but not limited to Tiplaxtinin); agents that reduce the activity of transforming growth factor-beta (TGF- β) (including but not limited to GC-1008 (Genzyme/MedImmune); lerdelimumab (CAT-152; Trabio, Cambridge Antibody); metelimumab(CAT-192,Cambridge Antibody,); LY-2157299 (Eli Lilly); ACU-HTR-028 (Opko Health)) including antibodies that target one or more TGF- β isoforms, inhibitors of TGF- β receptor kinases TGFBR1 (ALK5) and TGFBR2, and modulators of post-receptor signaling pathways; chemokine receptor signaling; endothelin receptor antagonists including inhibitors that target both endothelin receptor A and B and those that selectively target endothelin receptor A (including but not limited to ambrisentan; avosentan; bosentan; clazosentan; darusentan; BQ-153; FR-139317, L-744453; macitentan; PD-145065; PD-156252; PD163610;PS-433540; S-0139; sitaxentan sodium; TBC-3711; zibotentan); agents that reduce the activity of connective tissue growth factor (CTGF) (including but not limited to FG-3019, FibroGen), and including other CTGF-neutralizing antibodies; matrix metalloproteinase (MMP) inhibitors (including but not limited to MMPI-

12, PUP-1 and tigapotide triflutate); agents that reduce the activity of epidermal growth factor receptor (EGFR) including but not limited to erlotinib, gefitinib, BMS-690514, cetuximab,, antibodies targeting EGF receptor, inhibitors of EGF receptor kinase, and modulators of post-receptor signaling pathways; agents that reduce the activity of platelet derived growth factor (PDGF) (including but not limited to Imatinib mesylate (Novartis)) and also including PDGF neutralizing antibodies, antibodies targeting PDGF receptor (PDGFR), inhibitors of PDGFR kinase activity, and post-receptor signaling pathways; agents that reduce the activity of vascular endothelial growth factor (VEGF) (including but not limited to axitinib, bevacizumab, BIBF-1120, CDP-791, CT-322, IMC-18F1, PTC-299, and ramucirumab) and also including VEGF-neutralizing antibodies, antibodies targeting the VEGF receptor 1 (VEGFR1, Flt-1) and VEGF receptor 2 (VEGFR2, KDR), the soluble form of VEGFR1 (sFlt) and derivatives thereof which neutralize VEGF, and inhibitors of VEGF receptor kinase activity; inhibitors of multiple receptor kinases such as BIBF-1120 which inhibits receptor kinases for vascular endothelial growth factor, fibroblast growth factor, and platelet derived growth factor; agents that interfere with integrin function (including but not limited to STX-100 and IMGN-388) and also including integrin targeted antibodies; agents that interfere with the pro-fibrotic activities of IL-4 (including but not limited to AER-001, AMG-317, APG-201, and sIL-4R α) and IL-13 (including but not limited to AER-001, AMG-317, anrukinzumab, CAT-354, cintredekin besudotox, MK-6105, QAX-576, SB-313, SL-102, and TNX-650) and also including neutralizing anti-bodies to either cytokine, antibodies that target IL-4 receptor or IL-13 receptor, the soluble form of IL-4 receptor or derivatives thereof that is reported to bind and neutralize both IL-4 and IL-13, chimeric proteins including all or part of IL-13 and a toxin particularly pseudomonas endotoxin, signaling through the JAK-STAT kinase pathway; agents that interfere with epithelial mesenchymal transition including inhibitors of mTor (including but not limited to AP-23573 or rapamycin); agents that reduce levels of copper such as tetrathiomolybdate; agents that reduce oxidative stress including N-acetyl cysteine and tetrathiomolybdate; and interferon gamma, inhibitors of phosphodiesterase 4 (PDE4) (including but not limited to Roflumilast); inhibitors of phosphodiesterase 5 (PDE5) (including but not limited to mirodenafil, PF-4480682, sildenafil citrate, SLx-2101, tadalafil, udenafil, UK-369003, vardenafil, and zaprinast); or modifiers of the arachidonic acid pathway including cyclooxygenase and 5-lipoxygenase inhibitors (including but not limited to Zileuton), compounds that reduce tissue remodeling or fibrosis including prolyl hydrolase inhibitors (including but not limited to 1016548, CG-0089, FG-2216, FG-4497, FG-5615, FG-6513, fibrostatin A (Takeda), lufironil, P-1894B, and safironil)

and peroxisome proliferator-activated receptor (PPAR)-gamma agonists (including but not limited to pioglitazone and rosiglitazone), and combinations thereof.

[00178] 32A. A kit to be used in the diagnosis of subjects having idiopathic pulmonary fibrosis (IPF) comprising one or more probes that specifically hybridize to, or primers that specifically amplify, one or more microRNAs selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a

(SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), and combinations thereof.

[00179] 33A. A diagnostic test system adapted for performing any of the methods of embodiments 1A-18A.

[00180] 34A. The diagnostic test system of embodiment 32A or embodiment 33A comprising means for obtaining test results comprising the activity or level of one or more microRNA correlated with a diagnosis of idiopathic pulmonary fibrosis (IPF) in a blood sample of the subject; means for collecting and tracking test results for one or more individual blood sample; means for comparing the activity or level of one or more microRNA to a predetermined criterion; and means for reporting whether the activity or level of the one or more microRNA meets or exceeds the predetermined criterion

[00181] 35A. A computer program product comprising computer-executable instructions embodied in a computer-readable medium for performing the steps of any of the methods of embodiments 1A-18A.

[00182] 1B. A method of diagnosing idiopathic pulmonary fibrosis (IPF) in a human subject comprising detecting in a blood sample of from the subject the level of one, two, three, four, five six, seven or more microRNAs, wherein an increase or decrease in the level of the one or more microRNA relative to a predetermined criterion is indicative of a diagnosis of IPF.

[00183] 2B. The method of embodiment 1B further comprising the step of comparing the level of the microRNA to a predetermined criterion or range.

[00184] 3B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a

(SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO:155), miR-106a (SEQ ID NO:156), miR-1227 (SEQ ID NO:157), miR-128 (SEQ ID NO:158), miR-132 (SEQ ID NO:159), miR-140-5p (SEQ ID NO:160), miR-141 (SEQ ID NO:161), miR-17 (SEQ ID NO:162), miR-185 (SEQ ID NO:163), miR-30a-5p (SEQ ID NO:164), miR-30d (SEQ ID NO:165), miR-34a (SEQ ID NO:166), miR-378 (SEQ ID NO:167), miR-425 (SEQ ID NO:168), miR-429 (SEQ ID NO:169), miR-579 (SEQ ID NO:

170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), and combinations thereof.

[00185] 4B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-32 (SEQ ID NO:60), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), and combinations thereof.

NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), let-7e (SEQ ID NO:93), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-324-3p (SEQ ID NO:107), miR-598 (SEQ ID NO:110), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), let-7a# (SEQ ID NO:155), miR-106a (SEQ ID NO:156), miR-1227 (SEQ ID NO:157), miR-128 (SEQ ID NO:158), miR-132 (SEQ ID NO:159), miR-140-5p (SEQ ID NO:160), miR-141 (SEQ ID NO:161), miR-17 (SEQ ID NO:162), miR-185 (SEQ ID NO:163), miR-30a-5p (SEQ ID NO:164), miR-30d (SEQ ID NO:165), miR-34a (SEQ ID NO:166), miR-378 (SEQ ID NO:167), miR-425 (SEQ ID NO:168), miR-429 (SEQ ID NO:169), miR-579 (SEQ ID NO:170), miR-523 (SEQ ID NO:171), miR-551b# (SEQ ID NO:172), let-7a (SEQ ID NO:173), let-7f (SEQ ID NO:174), miR-107 (SEQ ID NO:175), miR-125a-5p (SEQ ID NO:176), miR-181a-2# (SEQ ID NO:177), miR-19b-1# (SEQ ID NO:178), miR-200c (SEQ ID NO:179), miR-27b# (SEQ ID NO:180), miR-331-3p (SEQ ID NO:181), miR-339-5p (SEQ ID NO:182), miR-362-5p (SEQ ID NO:183), miR-370 (SEQ ID NO:184), miR-374b (SEQ ID NO:185), miR-379 (SEQ ID NO:186), miR-454 (SEQ ID NO:187), miR-520a-3p (SEQ ID NO:188), miR-539 (SEQ ID NO:189), miR-758 (SEQ ID NO:190), miR-766 (SEQ ID NO:191), miR-9 (SEQ ID NO:192), miR-98 (SEQ ID NO:193), miR-668 (SEQ ID NO:194), miR-1256 (SEQ ID NO:195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

[00186] 5B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of

miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-26b (SEQ ID NO:40), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-148b (SEQ ID NO:53), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), let-7e (SEQ ID NO:93), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-590-5p (SEQ ID NO:104), miR-598 (SEQ ID NO:110), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO:

156), miR-1227 (SEQ ID NO: 157), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), and combinations thereof.

[00187] 6B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), let-7d (SEQ ID NO: 45), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72), miR-128 (SEQ ID NO: 158), miR-103 (SEQ ID NO: 105), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO: 175), miR-132 (SEQ ID NO: 159), miR-1244 (SEQ ID NO: 20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO: 195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-142-3p (SEQ ID NO: 38), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-150 (SEQ ID NO: 27), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO: 162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO: 163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-21 (SEQ ID NO: 51), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-26a (SEQ ID NO: 70), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-324-3p (SEQ ID NO: 107), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-29b (SEQ ID NO: 125), miR-345

(SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-30b (SEQ ID NO: 42), miR-362-3p (SEQ ID NO: 96), miR-30c (SEQ ID NO: 52), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[00188] 7B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO: 195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO: 162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO: 163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b#

(SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[00189] 8B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), miR-132 (SEQ ID NO: 159), let-7d (SEQ ID NO: 45), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-103 (SEQ ID NO: 105), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-21 (SEQ ID NO: 51), miR-142-3p (SEQ ID NO: 38), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO: 18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof.

[00190] 9B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO: 18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO:

NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof

[00191] 10B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), and combinations thereof.

[00192] 11B The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of

miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), and combinations thereof.

[00193] 12B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

[00194] 13B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-1256 (SEQ ID NO: 195), miR-127-3p (SEQ ID NO: 101), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-301a (SEQ ID NO: 67), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ

ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[00195] 14B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7d (SEQ ID NO: 45), miR-103 (SEQ ID NO: 105), miR-125a-5p (SEQ ID NO: 176), miR-142-3p (SEQ ID NO: 38), miR-26a (SEQ ID NO: 70), miR-29b (SEQ ID NO: 125), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-379 (SEQ ID NO: 186) and combinations thereof.

[00196] 15B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-18a (SEQ ID NO: 39), miR-26b (SEQ ID NO: 40), miR-106b (SEQ ID NO: 41), miR-29c (SEQ ID NO: 44), miR-144 (SEQ ID NO: 46), miR-1260 (SEQ ID NO: 47), miR-361-5p (SEQ ID NO: 48), miR-520e (SEQ ID NO: 49), miR-660 (SEQ ID NO: 50), miR-148b (SEQ ID NO: 53), miR-27b (SEQ ID NO: 54), miR-15b# (SEQ ID NO: 55), miR-16-1# (SEQ ID NO: 57), miR-17# (SEQ ID NO: 58), miR-22 (SEQ ID NO: 59), miR-32 (SEQ ID NO: 60), miR-532-5p (SEQ ID NO: 61), miR-101 (SEQ ID NO: 62), miR-27a (SEQ ID NO: 65), miR-181a (SEQ ID NO: 66), miR-320B (SEQ ID NO: 71), miR-324-5p (SEQ ID NO: 73), let-7b (SEQ ID NO: 76), miR-422a (SEQ ID NO: 77), let-7f-2# (SEQ ID NO: 78), let-7g# (SEQ ID NO: 79), miR-128a (SEQ ID NO: 80), miR-199a-5p (SEQ ID NO: 81), miR-29a# (SEQ ID NO: 83), miR-329 (SEQ ID NO: 84), miR-337-5p (SEQ ID NO: 85), miR-369-3p (SEQ ID NO: 86), miR-376a# (SEQ ID NO: 87), miR-486-3p (SEQ ID NO: 88), miR-20a (SEQ ID NO: 89), miR-106b# (SEQ ID NO: 92), miR-25 (SEQ ID NO: 94), miR-656 (SEQ ID NO: 95), miR-340 (SEQ ID NO: 97), miR-451 (SEQ ID NO: 98), miR-423-5p (SEQ ID NO: 99), miR-652 (SEQ ID NO: 100), miR-495 (SEQ ID NO: 102), miR-328 (SEQ ID NO: 103), miR-19b (SEQ ID NO: 106), miR-145# (SEQ ID NO: 108), miR-199a-3p (SEQ ID NO: 109), miR-151-5P (SEQ ID NO: 111), miR-502-3p (SEQ ID NO: 113), miR-136# (SEQ ID NO: 114), miR-194 (SEQ ID NO: 115), miR-221 (SEQ ID NO: 116), miR-22# (SEQ ID NO: 117), miR-93 (SEQ ID NO: 118), miR-130b (SEQ ID NO: 121), miR-195 (SEQ ID NO:

123), miR-576-3p (SEQ ID NO: 126), miR-212 (SEQ ID NO: 129), miR-143 (SEQ ID NO: 131), dme-miR-7 (SEQ ID NO: 132), miR-30d# (SEQ ID NO: 134), miR-213 (SEQ ID NO: 135), miR-126# (SEQ ID NO: 136), miR-1197 (SEQ ID NO: 137), miR-1255B (SEQ ID NO: 138), miR-335# (SEQ ID NO: 142), miR-33a# (SEQ ID NO: 143), miR-374a# (SEQ ID NO: 144), miR-381 (SEQ ID NO: 145), miR-409-5p (SEQ ID NO: 146), miR-551b (SEQ ID NO: 149), miR-616 (SEQ ID NO: 150), miR-638 (SEQ ID NO: 151), miR-889 (SEQ ID NO: 153), rno-miR-29c# (SEQ ID NO: 154) and combinations thereof.

[00197] 16B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103 (SEQ ID NO: 105), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-758 (SEQ ID NO: 190), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-668 (SEQ ID NO: 194), and combinations thereof.

[00198] 17B. The method of embodiment 1B or embodiment 2B, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-339-5p (SEQ ID NO: 182), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

[00199] 18B. The method of any one of embodiments 1B-17B, wherein the level or expression pattern of at least 2 different microRNAs is detected.

[00200] 19B. The method of any one of embodiments 1B-17B, wherein the level or expression pattern of at least 10 different microRNA is detected.

[00201] 20B. The method of any one of embodiments 1B-17B, wherein the level or expression pattern of at least 20 different microRNA is detected.

[00202] 21B. The method of any one of embodiments 1B-4B, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96, miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), and combinations thereof.

[00203] 22B. The method of any one of embodiments 1B-4B, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more

microRNAs is selected from the group consisting of miR-222 (SEQ ID NO:16), miR-345 (SEQ ID NO:18), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-150 (SEQ ID NO:27), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96, miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), and combinations thereof.

[00204] 23B. The method of any one of embodiments 1B-4B, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) ; miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21) and combinations thereof.

[00205] 24B. The method of any one of embodiments 1B-4B, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) ; miR-

193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14) and combinations thereof.

[00206] 25B. The method of any one of embodiments 1B-4B, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) and combinations thereof.

[00207] 26B. The method of any one of embodiments 1B-25B, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652

(SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

[00208] 27B. The method of any one of embodiments 1B-25B, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-1244 (SEQ ID NO:20), miR-142-3p (SEQ ID NO:38), miR-30b (SEQ ID NO:42), let-7d (SEQ ID NO:45), miR-30c (SEQ ID NO:52), miR-15b (SEQ ID NO:56), miR-190 (SEQ ID NO:63), miR-301a (SEQ ID NO:67),

miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), let-7g (SEQ ID NO:72), miR-20a# (SEQ ID NO:75), miR-28-5p (SEQ ID NO:90), let-7e (SEQ ID NO:93), miR-127-3p (SEQ ID NO:101), miR-103 (SEQ ID NO:105), miR-24-2# (SEQ ID NO:120), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-543 (SEQ ID NO:133), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-664 (SEQ ID NO:152), let-7a (SEQ ID NO:173), let-7f (SEQ ID NO:174), miR-107 (SEQ ID NO:175), miR-125a-5p (SEQ ID NO:176), miR-181a-2# (SEQ ID NO:177), miR-19b-1# (SEQ ID NO:178), miR-200c (SEQ ID NO:179), miR-27b# (SEQ ID NO:180), miR-331-3p (SEQ ID NO:181), miR-339-5p (SEQ ID NO:182), miR-362-5p (SEQ ID NO:183), miR-370 (SEQ ID NO:184), miR-374b (SEQ ID NO:185), miR-379 (SEQ ID NO:186), miR-454 (SEQ ID NO:187), miR-520a-3p (SEQ ID NO:188), miR-539 (SEQ ID NO:189), miR-758 (SEQ ID NO:190), miR-766 (SEQ ID NO:191), miR-9 (SEQ ID NO:192), miR-98 (SEQ ID NO:193), miR-668 (SEQ ID NO:194), miR-1256 (SEQ ID NO:195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

[00209] 28B. The method of any one of embodiments 1B-25B, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ

ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88,) and combinations thereof.

[00210] 29B. The method of any one of embodiments 1B-25B, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61) and combinations thereof.

[00211] 30B. The method of any one of embodiments 1B-25B, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

[00212] 31B. The method of any of embodiments 1B-30B wherein the sample is selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles.

[00213] 32B. The method of any one of embodiments 1B-31B, wherein the method further comprises administering a therapeutic agent to the subject.

[00214] 33B. A method of treating a human subject diagnosed with idiopathic pulmonary fibrosis (IPF) according to any of methods 1B-30B comprising administering a therapeutic agent to the subject to treat IPF.

[00215] 34B. A method of treating a human subject identified as having idiopathic pulmonary fibrosis (IPF) or at risk of IPF based on an abnormal level of one, two, three, four, five, six, seven or more IPF-associated microRNAs in a blood sample of the subject, comprising administering a therapeutic agent to the subject to treat IPF.

[00216] 35B. The method of embodiment 33B or embodiment 34B, wherein the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p

(SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO:155), miR-106a (SEQ ID NO:156), miR-1227 (SEQ ID NO:157), miR-128 (SEQ ID NO:158), miR-132 (SEQ ID NO:159), miR-140-5p (SEQ ID NO:160), miR-141 (SEQ ID NO:161), miR-17 (SEQ ID NO:162), miR-185 (SEQ ID NO:163), miR-30a-5p (SEQ ID NO:164), miR-30d (SEQ ID NO:165), miR-34a (SEQ ID NO:166), miR-378 (SEQ ID NO:167), miR-425 (SEQ ID NO:168), miR-429 (SEQ ID NO:169), miR-579 (SEQ ID NO:170), miR-523 (SEQ ID NO:171), miR-551b# (SEQ ID NO:172), let-7a (SEQ ID NO:173), let-7f (SEQ ID NO:174), miR-107 (SEQ ID NO:175), miR-125a-5p (SEQ ID NO:176), miR-181a-2# (SEQ ID NO:177), miR-19b-1# (SEQ ID NO:178), miR-200c (SEQ ID NO:179), miR-27b# (SEQ ID NO:180), miR-331-3p (SEQ ID NO:181), miR-339-5p (SEQ ID NO:182), miR-362-5p (SEQ ID NO:183), miR-370 (SEQ ID NO:184), miR-374b (SEQ ID NO:185), miR-379 (SEQ ID NO:186), miR-454 (SEQ ID NO:187), miR-520a-3p (SEQ ID NO:188)

NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), or combinations thereof.

[00217] 36B. The method of embodiment 33B or embodiment 34B, wherein the level or expression pattern of at least 2 different microRNAs is detected.

[00218] 37B. The method of embodiment 33B or embodiment 34B, wherein the level or expression pattern of at least 10 different microRNA is detected.

[00219] 38B. The method of embodiment 33B or embodiment 34B, wherein the level or expression pattern of at least 20 different microRNA is detected.

[00220] 39. The method of embodiment 34B, wherein the sample is selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles.

[00221] 40B. The method of any of embodiments 32B-39B, wherein the therapeutic agent is an oligonucleotide that decreases the activity or level of expression of one, two, three, four, five, six, seven or more of the microRNA in the subject.

[00222] 41B. The method of any of embodiments 32B-39B, wherein the therapeutic agent is an oligonucleotide that increases the activity or level of expression of one, two, three, four, five, six, seven or more of the microRNA in the subject.

[00223] 42B. The method of any of embodiments 32B-39B, wherein the therapeutic agent is an anti-fibrotic agent.

[00224] 43B. The method of embodiment 42B, wherein the anti-fibrotic agent is pirfenidone.

[00225] 44B. The method of any of embodiments 32B-39B, wherein the therapeutic agent is selected from the group consisting of steroids (including but not limited to prednisolone), cytotoxic agents (including but not limited to azathioprine and cyclophosphamide), bardoxolone, LPA agonists (including but not limited to AM152); Torisel (temsirolimus); PI3K inhibitors; pentraxin or serum amyloid P (including but not limited to Pentraxin-2 (PTX-2 or PRM-151)); MEK inhibitors (including but not limited to ARRY-162 and ARRY-300); p38 inhibitors; PAI-1 inhibitors (including but not limited to Tiplaxtinin); agents that reduce the activity of transforming growth factor-beta (TGF- β) (including but not limited to GC-1008 (Genzyme/MedImmune); lerdelimumab (CAT-152; Trabio, Cambridge Antibody); metelimumab(CAT-192,Cambridge Antibody,); LY-2157299

(Eli Lilly); ACU-HTR-028 (Opko Health)) including antibodies that target one or more TGF- β isoforms, inhibitors of TGF- β receptor kinases TGFBR1 (ALK5) and TGFBR2, and modulators of post-receptor signaling pathways; chemokine receptor signaling; endothelin receptor antagonists including inhibitors that target both endothelin receptor A and B and those that selectively target endothelin receptor A (including but not limited to ambrisentan; avosentan; bosentan; clazosentan; darusentan; BQ-153; FR-139317, L-744453; macitentan; PD-145065; PD-156252; PD163610;PS-433540; S-0139; sitaxentan sodium; TBC-3711; zibotentan); agents that reduce the activity of connective tissue growth factor (CTGF) (including but not limited to FG-3019, FibroGen), and including other CTGF-neutralizing antibodies; matrix metalloproteinase (MMP) inhibitors (including but not limited to MMPI-12, PUP-1 and tigapotide triflutate); agents that reduce the activity of epidermal growth factor receptor (EGFR) including but not limited to erlotinib, gefitinib, BMS-690514, cetuximab,, antibodies targeting EGF receptor, inhibitors of EGF receptor kinase, and modulators of post-receptor signaling pathways; agents that reduce the activity of platelet derived growth factor (PDGF) (including but not limited to Imatinib mesylate (Novartis)) and also including PDGF neutralizing antibodies, antibodies targeting PDGF receptor (PDGFR), inhibitors of PDGFR kinase activity, and post-receptor signaling pathways; agents that reduce the activity of vascular endothelial growth factor (VEGF) (including but not limited to axitinib, bevacizumab, BIBF-1120, CDP-791, CT-322, IMC-18F1, PTC-299, and ramucirumab) and also including VEGF-neutralizing antibodies, antibodies targeting the VEGF receptor 1 (VEGFR1, Flt-1) and VEGF receptor 2 (VEGFR2, KDR), the soluble form of VEGFR1 (sFlt) and derivatives thereof which neutralize VEGF, and inhibitors of VEGF receptor kinase activity; inhibitors of multiple receptor kinases such as BIBF-1120 which inhibits receptor kinases for vascular endothelial growth factor, fibroblast growth factor, and platelet derived growth factor; agents that interfere with integrin function (including but not limited to STX-100 and IMGN-388) and also including integrin targeted antibodies; agents that interfere with the pro-fibrotic activities of IL-4 (including but not limited to AER-001, AMG-317, APG-201, and sIL-4Ra) and IL-13 (including but not limited to AER-001, AMG-317, anrukinzumab, CAT-354, cintredekin besudotox, MK-6105, QAX-576, SB-313, SL-102, and TNX-650) and also including neutralizing anti-bodies to either cytokine, antibodies that target IL-4 receptor or IL-13 receptor, the soluble form of IL-4 receptor or derivatives thereof that is reported to bind and neutralize both IL-4 and IL-13, chimeric proteins including all or part of IL-13 and a toxin particularly pseudomonas endotoxin, signaling through the JAK-STAT kinase pathway; agents that interfere with epithelial mesenchymal transition including

inhibitors of mTor (including but not limited to AP-23573 or rapamycin); agents that reduce levels of copper such as tetrathiomolybdate; agents that reduce oxidative stress including N-acetyl cysteine and tetrathiomolybdate; and interferon gamma, inhibitors of phosphodiesterase 4 (PDE4) (including but not limited to Roflumilast); inhibitors of phosphodiesterase 5 (PDE5) (including but not limited to mirodenafil, PF-4480682, sildenafil citrate, SLx-2101, tadalafil, udenafil, UK-369003, vardenafil, and zaprinast); or modifiers of the arachidonic acid pathway including cyclooxygenase and 5-lipoxygenase inhibitors (including but not limited to Zileuton), compounds that reduce tissue remodeling or fibrosis including prolyl hydrolase inhibitors (including but not limited to 1016548, CG-0089, FG-2216, FG-4497, FG-5615, FG-6513, fibrostatin A (Takeda), lufironil, P-1894B, and safironil) and peroxisome proliferator-activated receptor (PPAR)-gamma agonists (including but not limited to pioglitazone and rosiglitazone), and combinations thereof.

[00226] 45B. A kit to be used in the diagnosis of subjects having idiopathic pulmonary fibrosis (IPF) comprising one, two, three, four, five, six, seven or more probes that specifically hybridize to, or primers that specifically amplify, one or more microRNAs selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56).

NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO:155), miR-106a (SEQ ID NO:156), miR-1227 (SEQ ID NO:157), miR-128 (SEQ ID NO:158), miR-132 (SEQ ID NO:159), miR-140-5p (SEQ ID NO:160), miR-141 (SEQ ID NO:

161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), and combinations thereof.

[00227] 46B. A diagnostic test system adapted for performing any of the methods of embodiments 1B-31B.

[00228] 47B. The diagnostic test system of embodiment 46B comprising means for obtaining test results comprising the activity or level of one, two, three, four, five, six, seven or more microRNA correlated with a diagnosis of idiopathic pulmonary fibrosis (IPF) in a blood sample of the subject; means for collecting and tracking test results for one or more individual blood sample; means for comparing the activity or level of one or more microRNA to a predetermined criterion; and means for reporting whether the activity or level of the one or more microRNA meets or exceeds the predetermined criterion

[00229] 48B. A computer program product comprising computer-executable instructions embodied in a computer-readable medium for performing the steps of any of the methods of embodiments 1B-31B.

[00230] The invention is further described in the following Examples. The following Examples serve only to illustrate the invention and are not intended to limit the scope of the invention in any way.

EXAMPLES

Example 1 – IPF patients were determined to have a unique miRNA profile compared to healthy controls.

[00231] Materials and Methods:

[00232] Plasma samples were obtained from placebo-treated Caucasian male IPF patients. The design of this trial including patient inclusion/exclusion criteria and treatment have been previously published (King et al 2009). Plasma samples for demographically matched healthy control subjects with associated medical histories and medication use were obtained commercially. Plasma samples from IPF patients were collected in vials containing heparin as the anticoagulant, while sample from control subjects were collected in vials containing EDTA. All samples were obtained under appropriate written Informed Consent. Histories were reviewed for the following additional criteria: not a current smoker (both groups), lack of pulmonary or other significant disease (healthy control group), no recent use of prednisolone or other drugs used off label in the treatment of IPF (healthy control group), no use of prednisolone or other drugs for the treatment of IPF within 28 days prior to sample collection (IPF group). Summary demographics for IPF patients and healthy controls are shown in Table 1.

[00233] Table 1.

	Healthy	IPF	INSPIRE Placebo
Total #	12	24	275
Ethnic origin White	100%	100%	95%
Caucasian male	100%	100%	68%
Age (year)^a	58.2(5.9)	67.1(8.0)	65.9(7.9)
Weight (kg)^b	84.3(11.8)	90.5(17.4)	86.6(18.1)
Smoking status			
Never smoked	17%	17%	31%
Previous smoker	83%	83%	64%
Current smoker	0	0	5%
FVC		78.2(11.3)	73.1(13.4)
DLco		47.0(6.7)	47.3(9.3)
Dyspnea (total score of shortness of breath questionnaires)		32.8(24.5)	35.0(22.7)
Quality of life (total score of St George's respiratory questionnaire)		41.5(20.0)	42.4(18.2)
Distance of 6-minute walk		404.6(90.6)	392.8(112.9)
Use of supplemental oxygen		4%	15%
^a p-value of t-test between controls and IPF patient is 0.003			
^b p-value of t-test between controls and IPF patient is 0.1			

[00234] Samples from IPF patients (n=24), healthy controls (n=12), and appropriate technical replicates (n=8 from IPF patients and n=4 from healthy controls) were deheparanized and grouped into two batches each for RNA isolation by standard methods.

Total RNA was extracted by standard methods. Isolated RNA was reverse transcribed and preamplified using the Applied Biosystems Megaplex RT and Preamplification Human Primer Pools according to manufacturer's protocols.

[00235] miRNAs were profiled by real-time PCR using the TaqMan Human miRNA Array set v3.0 (Cards A+B) according to manufacturer's protocols.

[00236] microRNAs with Ct values less than 35 were selected for data analysis. microRNAs for normalization were selected by a mean centering method (Wylie et al, BMC Research Notes, 4:555, 2011). Normalization and all subsequent analyses were performed in Partek Genomics Suite (Partek, St. Louis, Missouri). Differentially expressed miRNAs were identified by ANOVA with correction for multiple comparisons. Sequences detected in <50% of samples in both the IPF and control groups were excluded. miRNAs present in <50% of samples from one or the other group were evaluated as potentially disease-status specific sequences.

[00237] miRNAs identified as having increased presentation in IPF patient plasma relative to a predetermined criterion are set forth below in Table 2.

[00238] Table 2.

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-miR-155	UUAAUGCUAAUCGUGAUAGGGGU	IPF UP vs Control	1
hsa-miR-767-3p	UCUGCUCAUACCCAUAGGUUUCU	IPF UP vs Control	2
hsa-miR-1303	UUUAGAGACGGGGCUUUGCUCU	IPF UP vs Control	3
hsa-miR-574-3p	CACGCUCAUGCACACACCCACA	IPF UP vs Control	4
hsa-miR-10b#	ACAGAUUCGAUUCUAGGGGAAU	IPF UP vs Control	5
hsa-miR-875-5p	UAUACCUCAGUUUUAUCAGGUG	IPF UP vs Control	6
hsa-miR-29a	UAGCACCAUCUGAAAUCGGUUA	IPF UP vs Control	7
hsa-miR-375	UUUGUUUCGUUCGGCUCGCGUGA	IPF UP vs Control	8
hsa-miR-342-3p	UCUCACACAGAAAUCGCACCCGU	IPF UP vs Control	9
hsa-miR-197	UUCACCACCUUCUCCACCCAGC	IPF UP vs Control	10
hsa-miR-663B	GGUGGCCCGGCCUGCCUGAGG	IPF UP vs Control	11
hsa-miR-193b	AACUGGCCCUCAAAGUCCCGCU	IPF UP vs Control	12
hsa-miR-34a#	CAAUCAGCAAGUAUACUGCCU	IPF UP vs Control	13
hsa-miR-548a-3p	CAAAACUGGCAAUUACUUUJGC	IPF UP vs Control	14
hsa-miR-338-5P	AACAAUAUCCUGGUGCUGAGUG	IPF UP vs Control	15
hsa-miR-222	AGCUACAUUGGCUCACUGGGU	IPF UP vs Control	16
hsa-miR-520D-3P	AAAGUGCUUCUCUUUGGUGGGU	IPF UP vs Control	17
hsa-miR-345	GCUGACUCCUAGUCCAGGGCUC	IPF UP vs Control	18
hsa-miR-99b#	CAAGCUCGUGUCUGUGGGUCCG	IPF UP vs Control	19
hsa-miR-1244	AAGUAGUUGGUUGUUAUGAGAUGGUU	IPF UP vs Control	20
hsa-miR-146a	UGAGAACUGAAUUCCAUGGGUU	IPF UP vs Control	21
hsa-miR-122	UGGAGUGUGACAUGGUGUUJUG	IPF UP vs Control	22
hsa-miR-206	UGGAAUGUAAGGAAGUGUGUGG	IPF UP vs Control	23

hsa-miR-146b-5p	UGAGAACUGAAUUCAUAGGCU	IPF UP vs Control	24
hsa-miR-1300	UUGAGAAGGGAGGCUGCUG	IPF UP vs Control	25
hsa-miR-28-3p	CACUAGAUUGUGAGCUCCUGGA	IPF UP vs Control	26
hsa-miR-150	UCUCCCCAACCCUUGUACCAGUG	IPF UP vs Control	27
hsa-miR-202	AGAGGUUAAGGGCAUGGGAA	IPF UP vs Control	28
hsa-miR-636	UGUGCUUGCUCGUCCCCGCCGA	IPF UP vs Control	29
hsa-miR-27a#	AGGGCUUAGCUGCUUGUGAGCA	IPF UP vs Control	30
hsa-miR-323-3p	CACAUUACACGGUCGACCUCU	IPF UP vs Control	31
hsa-miR-520c-3p	AAAGUGCUUCCUUUAGAGGGU	IPF UP vs Control	32
hsa-miR-191	CAACGGAAUCCCCAAAAGCAGCUG	IPF UP vs Control	33
hsa-miR-1290	UGGAUUUUUGGAUCAGGGA	IPF UP vs Control	34
hsa-miR-572	GUCCGCUCGGCGUGGCCA	IPF UP vs Control	35
hsa-miR-886-3p	CGCGGGUGCUUACUGACCCUU	IPF UP vs Control	36
hsa-miR-320	AAAAGCUGGGUUGAGAGGGCGA	IPF UP vs Control	37

[00239] miRNAs identified as having decreased presentation in IPF patient plasma relative to a predetermined criterion are set forth below in Table 3.

[00240] Table 3.

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-miR-142-3p	UGUAGUGUUUCCUACUUUAUGGA	IPF DOWN vs Control	38
hsa-miR-18a	UAAGGUGCAUCUAGUGCAGAUAG	IPF DOWN vs Control	39
hsa-miR-26b	UUCAAGUAUUCAGGAUAGGU	IPF DOWN vs Control	40
hsa-miR-106b	UAAAGUGCUGACAGUGCAGAU	IPF DOWN vs Control	41
hsa-miR-30b	UGUAAACAUCCUACACUCAGCU	IPF DOWN vs Control	42
hsa-miR-142-5p	CAUAAAGUAGAAAGCACUACU	IPF DOWN vs Control	43
hsa-miR-29c	UAGCACCAUUUGAAAUCGGUUA	IPF DOWN vs Control	44
hsa-let-7d	AGAGGUAGUAGGUUGCAUAGUU	IPF DOWN vs Control	45
hsa-miR-144	UACAGUAUAGAUGAUGUACU	IPF DOWN vs Control	46
hsa-miR-1260	AUCCCACCUCUGGCCACCA	IPF DOWN vs Control	47
hsa-miR-361-5p	UUAUCAGAAUCUCCAGGGUAC	IPF DOWN vs Control	48
hsa-miR-520e	AAAGUGCUUCCUUUUGAGGG	IPF DOWN vs Control	49
hsa-miR-660	UACCCAUUGCAUAUCGGAGUUG	IPF DOWN vs Control	50
hsa-miR-21	UAGCUUAUCAGACUGAUGUUGA	IPF DOWN vs Control	51
hsa-miR-30c	UGUAAACAUCCUACACUCUCAGC	IPF DOWN vs Control	52
hsa-miR-148b	UCAGUGCAUCACAGAACUUUGU	IPF DOWN vs Control	53
hsa-miR-27b	UUCACAGUGGCUAAGUUCUGC	IPF DOWN vs Control	54
hsa-miR-15b#	CGAAUCAUUUUUGCUGCUCUA	IPF DOWN vs Control	55
hsa-miR-15b	UAGCAGCACAUCAUGGUUUACA	IPF DOWN vs Control	56
hsa-miR-16-1#	CCAGUAUUAACUGUGCUGCUGA	IPF DOWN vs Control	57
hsa-miR-17#	ACUGCAGUGAAGGCACUUGUAG	IPF DOWN vs Control	58

hsa-miR-22	AAGCUGGCCAGUUGAAGAACUGU	IPF DOWN vs Control	59
hsa-miR-32	UAUUGCACAUUACUAAGUUGCA	IPF DOWN vs Control	60
hsa-miR-532-5p	CAUGCCUUGAGUGUAGGACCGU	IPF DOWN vs Control	61
hsa-miR-101	UACAGUACUGUGAUACUGAA	IPF DOWN vs Control	62
hsa-miR-190	UGAUUAUGUUUGAUUAUUAGGU	IPF DOWN vs Control	63
hsa-miR-15a#	CAGGCCAUUUGUGCUGCCUCA	IPF DOWN vs Control	64
hsa-miR-27a	UUCACAGUGGCUAAGUUCGC	IPF DOWN vs Control	65
hsa-miR-181a	AACAUUCAACGCUGUCGGUGAGU	IPF DOWN vs Control	66
hsa-miR-301a	CAGUGCAAUAGUAUUGUCAAAGC	IPF DOWN vs Control	67
hsa-miR-374a	UUUAUAAUACAACCUGAUAGUG	IPF DOWN vs Control	68
hsa-miR-144#	GGAUUAUCAUCAUACUGUAAG	IPF DOWN vs Control	69
hsa-miR-26a	UUCAAGUAAUCCAGGAUAGGCU	IPF DOWN vs Control	70
hsa-miR-320B	AAAAGCUGGGUUGAGAGGGCAA	IPF DOWN vs Control	71
hsa-let-7g	UGAGGUAGUAGUUUGUACAGUU	IPF DOWN vs Control	72
hsa-miR-324-5p	CGCAUCCCCUAGGGCAUUGGUGU	IPF DOWN vs Control	73
hsa-miR-19a	UGUGCAAACUAUGCAAAACUGA	IPF DOWN vs Control	74
hsa-miR-20a#	ACUGCAUUAUGAGCACUAAAAG	IPF DOWN vs Control	75
hsa-let-7b	UGAGGUAGUAGGUUGUGUGGUU	IPF DOWN vs Control	76
hsa-miR-422a	ACUGGACUUAGGGUCAGAACGGC	IPF DOWN vs Control	77
hsa-let-7f-2#	CUAUACAGCUACUGUCUUUCC	IPF DOWN vs Control	78
hsa-let-7g#	CUGUACAGGCCACUGCCUUGC	IPF DOWN vs Control	79
hsa-miR-128a	UCACAGUGAACCGGUCUCUUU	IPF DOWN vs Control	80
hsa-miR-199a-5p	CCCAGUGUUCAGACUACCUGUUC	IPF DOWN vs Control	81
hsa-miR-26a-2#	CCUAAUCUUGAUUACUUGUUUC	IPF DOWN vs Control	82
hsa-miR-29a#	ACUGAUUUUUUGGUGUUCAG	IPF DOWN vs Control	83
hsa-miR-329	AACACACCUGGUUAACCUCUUU	IPF DOWN vs Control	84
hsa-miR-337-5p	GAACGGCUUCAUACAGGAGUU	IPF DOWN vs Control	85
hsa-miR-369-3p	AAUAAUACAUGGUUGAUCUUU	IPF DOWN vs Control	86
hsa-miR-376a#	GUAGAUUCUCCUUCUAUGAGUA	IPF DOWN vs Control	87
hsa-miR-486-3p	CGGGGCAGCUCAGUACAGGAU	IPF DOWN vs Control	88
hsa-miR-20a	UAAAGUGCUUAUAGUGCGAGGUAG	IPF DOWN vs Control	89
hsa-miR-28-5p	AAGGAGCUCACAGUCUAUUGAG	IPF DOWN vs Control	90
hsa-miR-148a	UCAGUGCACUACAGAACUUUGU	IPF DOWN vs Control	91
hsa-miR-106b#	CCGCACUGUGGGUACUUGCUGC	IPF DOWN vs Control	92
hsa-let-7e	UGAGGUAGGAGGUUGUAUAGUU	IPF DOWN vs Control	93
hsa-miR-25	CAUUGCACUUGUCUCGGUCUGA	IPF DOWN vs Control	94
hsa-miR-656	AAUAAAUAACAGUCAACCUCU	IPF DOWN vs	95

		Control	
hsa-miR-362-3p	AACACACCUCUUCAAGGAUUC	IPF DOWN vs Control	96
hsa-miR-340	UUUAAGCAAUGAGACUGAUU	IPF DOWN vs Control	97
hsa-miR-451	AAACCGUUACCAUACUGAGUU	IPF DOWN vs Control	98
hsa-miR-423-5p	UGAGGGCAGAGAGCGAGACUUU	IPF DOWN vs Control	99
hsa-miR-652	AAUGGCGCCACUAGGGUUGUG	IPF DOWN vs Control	100
hsa-miR-127-3p	UCGGAUCCGUCUGAGCUUGGU	IPF DOWN vs Control	101
hsa-miR-495	AAACAAACAUGGUGCACUUCUU	IPF DOWN vs Control	102
hsa-miR-328	CUGGCCUCUCUGCCCCUCCGU	IPF DOWN vs Control	103
hsa-miR-590-5p	GAGCUUAUCAUAAAAGUGCAG	IPF DOWN vs Control	104
hsa-miR-103	AGCAGCAUUGUACAGGGCUAUGA	IPF DOWN vs Control	105
hsa-miR-19b	UGUGCAAAUCCAUGCAAAACUGA	IPF DOWN vs Control	106
hsa-miR-324-3p	ACUGCCCCAGGUGCUGCUGG	IPF DOWN vs Control	107
hsa-miR-145#	GGAUUCCUGGAAAUACUGUUCU	IPF DOWN vs Control	108
hsa-miR-199a-3p	ACAGUAGUCUGCACAUUGGUUA	IPF DOWN vs Control	109
hsa-miR-598	UACGUCAUCGUUGUCAUCGUCA	IPF DOWN vs Control	110
hsa-miR-151-5P	UCGAGGAGCUCACAGUCUAGU	IPF DOWN vs Control	111
hsa-miR-130a	CAGUGCAAUGUAAAAGGGCAU	IPF DOWN vs Control	112
hsa-miR-502-3p	AAUGCACCUGGGCAAGGAUUC	IPF DOWN vs Control	113
hsa-miR-136#	CAUCAUCGUCAAAUGAGUCU	IPF DOWN vs Control	114
hsa-miR-194	UGUAACAGCAACUCCAUGUGGA	IPF DOWN vs Control	115
hsa-miR-221	AGCUACAUUGUCUGCUGGGUUUC	IPF DOWN vs Control	116
hsa-miR-22#	AGUUCULCAGUGGCAAGCUUUA	IPF DOWN vs Control	117
hsa-miR-93	CAAAGUGCUGUUCGUGCAGGUAG	IPF DOWN vs Control	118
hsa-miR-335	UCAAGAGCAAUAACGAAAAAUGU	IPF DOWN vs Control	119
hsa-miR-24-2#	UGCCUACUGAGCUGAACACAG	IPF DOWN vs Control	120
hsa-miR-130b	CAGUGCAAUGAUGAAAGGGCAU	IPF DOWN vs Control	121
hsa-miR-99b	CACCCGUAGAACCGACCUUGCG	IPF DOWN vs Control	122
hsa-miR-195	UAGCAGCACAGAAAUUUGGC	IPF DOWN vs Control	123
hsa-miR-411	UAGUAGACCGUAUAGCGUACG	IPF DOWN vs Control	124
hsa-miR-29b	UAGCACCAUUUGAAAUCAGUGUU	IPF DOWN vs Control	125
hsa-miR-576-3p	AAGAUGUGGAAAAAUUGGAAUC	IPF DOWN vs Control	126
hsa-miR-340#	UCCGUCUCAGUUACUUUAUAGC	IPF DOWN vs Control	127
hsa-miR-148b#	AAGUUCUGUUACACUCAGGC	IPF DOWN vs Control	128
hsa-miR-212	UAACAGUCUCCAGUCACGGCC	IPF DOWN vs Control	129
hsa-miR-152	UCAGUGCAUGACAGAACUUGG	IPF DOWN vs Control	130
hsa-miR-143	UGAGAUGAAGCACUGUAGCUC	IPF DOWN vs Control	131

dme-miR-7	UGGAAGACUAGUGAUUUUGUUGU	IPF DOWN vs Control	132
hsa-miR-543	AAACAUUCGCGGUGGCACUUCUU	IPF DOWN vs Control	133
hsa-miR-30d#	CUUUCAGUCAGAUGUUUGCUGC	IPF DOWN vs Control	134
hsa-miR-213	ACCAUCGACCGUUGAUUGUACC	IPF DOWN vs Control	135
hsa-miR-126#	CAUUAUUACUUUUGGUACGCG	IPF DOWN vs Control	136
hsa-miR-1197	UAGGACACACAUGGUCUACUUCU	IPF DOWN vs Control	137
hsa-miR-1255B	CGGAUGAGCAAAGAAAGUGGUU	IPF DOWN vs Control	138
hsa-miR-154#	AAUCAUACACGGUUGACCUAUU	IPF DOWN vs Control	139
hsa-miR-196b	UAGGUAGUUUCCUGUUGUUGGG	IPF DOWN vs Control	140
hsa-miR-21#	CAACACCAGUCGAUGGGCUGU	IPF DOWN vs Control	141
hsa-miR-335#	UUUUUCAUUUAUUGCUCUGACC	IPF DOWN vs Control	142
hsa-miR-33a#	CAAUGUUUCCACAGUGCAUCAC	IPF DOWN vs Control	143
hsa-miR-374a#	CUUAUCAGAUUGUAUUGUAUU	IPF DOWN vs Control	144
hsa-miR-381	UAUACAAGGGCAAGCUCUCUGU	IPF DOWN vs Control	145
hsa-miR-409-5p	AGGUUACCCGAGCAACUUUGCAU	IPF DOWN vs Control	146
hsa-miR-411#	UAUGUAACACGGGUCCACUAACC	IPF DOWN vs Control	147
hsa-miR-548J	AAAAGUAAUUGCGGUCUUUGGU	IPF DOWN vs Control	148
hsa-miR-551b	GCGACCCAUCUUGGUUUCAG	IPF DOWN vs Control	149
hsa-miR-616	AGUCAUUGGAGGGUUUGAGCAG	IPF DOWN vs Control	150
hsa-miR-638	AGGGAUCGCGGGCGGGUGGGCGGCCU	IPF DOWN vs Control	151
hsa-miR-664	UAUCAUUUAUCCCCAGCCUACA	IPF DOWN vs Control	152
hsa-miR-889	UUAAUAUCGGACAACCAUUGU	IPF DOWN vs Control	153
rno-miR-29c#	UGACCGAUUUCUCCUGGUGUUC	IPF DOWN vs Control	154

Example 2 – IPF patients were determined to have a unique miRNA profile compared to healthy controls.

[00241] Materials and Methods:

[00242] Plasma samples were obtained from placebo-treated white male IPF patients. Plasma samples for demographically matched healthy control subjects with associated medical histories and medication use were obtained commercially. All plasma samples were collected in vials containing EDTA as the anticoagulant. All samples were obtained under appropriate written Informed Consent. Histories were reviewed for the following additional criteria: not a current smoker (both groups), lack of pulmonary or other significant disease (healthy control group), no recent use of prednisolone or other drugs used off label in the treatment of IPF (healthy control group), no use of prednisolone or other drugs for the

treatment of IPF within 28 days prior to sample collection (IPF group). Summary demographics for IPF patients and healthy controls are shown in Table 4.

[00243] Table 4.

	Healthy	IPF
Total #	13	15
Ethnic origin White	100%	100%
Male	100%	100%
Age (year)^a	60.8	64.7
Weight (kg)^b	87.1	89.4
Smoking status		
Never smoked	46%	33%
Previous smoker	54%	67%
Current smoker	0	0
FVC % predicted	-	70.7
DLco % predicted (Hgb- corrected)	-	46.7
6 minute walk distance (m)	-	440.1
Death	-	7%
ΔFVC% predicted (Baseline to Week 72)	-	-9.2
Δ 6 minute walk distance (m) (Baseline to Week 72)	-	-46.9

[00244] Samples from IPF patients (n=15), healthy controls (n=15), and appropriate technical replicates (n=3 from IPF patients and n=3 from healthy controls) were grouped into two batches each for RNA isolation by standard methods. Total RNA was extracted by standard methods. Isolated RNA was reverse transcribed and preamplified using the Applied Biosystems Megaplex RT and Preamplification Human Primer Pools according to manufacturer's protocols.

[00245] miRNAs were profiled by real-time PCR using the TaqMan Human miRNA Array set v3.0 (Cards A+B) according to manufacturer's protocols.

[00246] Two control samples were excluded due to poor data quality. For all remaining samples microRNAs with Ct values less than 35 were selected for data analysis. microRNAs for normalization were selected by a mean centering method (Wylie et al, BMC Research Notes, 4:555, 2011). Normalization and all subsequent analyses were performed in Partek Genomics Suite (Partek, St. Louis, Missouri). Differentially expressed miRNAs were identified by ANOVA with correction for multiple comparisons. Sequences detected in <50% of samples in both the IPF and control groups were excluded. miRNAs present in

<50% of samples from one or the other group were evaluated as potentially disease-status specific sequences.

[00247] miRNAs identified as having increased presentation in IPF patient plasma relative to a predetermined criterion are set forth below in Table 5.

[00248] Table 5.

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-miR-130a	CAGUGCAAUGUUAAAAGGGCAU	IPF UP vs Control	112
hsa-miR-142-5p	CAUAAAGUAGAAAGCACUACU	IPF UP vs Control	43
hsa-miR-148a	UCAGUGCACUACAGAACUUUGU	IPF UP vs Control	91
hsa-miR-152	UCAGUGCAUGACAGAACUUGG	IPF UP vs Control	130
hsa-miR-15a#	CAGGCCAUUUGUGCUGCUCUA	IPF UP vs Control	64
hsa-miR-19a	UGUGCAAAUCUAUGCAAAACUGA	IPF UP vs Control	74
hsa-miR-21	UAGCUUAUCAGACUGAUGUUGA	IPF UP vs Control	51
hsa-miR-21#	CAACACCAGUCGAUGGGCUGU	IPF UP vs Control	141
hsa-miR-26a-2#	CCUAAUCUUGAUUACUUGUUUC	IPF UP vs Control	82
hsa-miR-324-3p	ACUGCCCCAGGUGCUGCUGG	IPF UP vs Control	107
hsa-miR-335	UCAAGAGCAAAACGAAAAAUGU	IPF UP vs Control	119
hsa-miR-362-3p	AACACACCUAUUCAAGGAUUC	IPF UP vs Control	96
hsa-miR-590-5p	GAGCUUAUCAUAAAAGUGGCAG	IPF UP vs Control	104
hsa-miR-598	UACGUCAUCGUUGUCAUCGUCA	IPF UP vs Control	110
hsa-miR-122	UGGAGUGUGACAAUGGUGUUUG	IPF UP vs Control	22
hsa-miR-146a	UGAGAACUGAAUUCCAUGGGUU	IPF UP vs Control	21
hsa-miR-146b-5p	UGAGAACUGAAUUCCAUAGGCU	IPF UP vs Control	24
hsa-miR-150	UCUCCCCACCCUUGUACCAGUG	IPF UP vs Control	27
hsa-miR-222	AGCUACAUCUGGCUACUGGGU	IPF UP vs Control	16
hsa-miR-345	GCUGACUCCUAGUCCAGGGCUC	IPF UP vs Control	18
hsa-let-7a#	CUAUACAAUCUACUGUCUUUC	IPF UP vs Control	155
hsa-miR-106a	AAAAGUGCUUACAGUGCAGGUAG	IPF UP vs Control	156
hsa-miR-1227	CGUGCCACCCUUUUCCCCAG	IPF UP vs Control	157
hsa-miR-128	UCACAGUGAACCGGUUCUUU	IPF UP vs Control	158
hsa-miR-132	UAACAGUCUACAGCCAUGGUUG	IPF UP vs Control	159
hsa-miR-140-5p	CAGUGGUUUUACCCUAUGGUAG	IPF UP vs Control	160
hsa-miR-141	UAACACUGUCUGGUAAAGAUGG	IPF UP vs Control	161
hsa-miR-17	CAAAGUGCUUACAGUGCAGGUAG	IPF UP vs Control	162
hsa-miR-185	UGGAGAGAAAGGCAGUUCUGA	IPF UP vs Control	163
hsa-miR-30a-5p	UGUAAACAUCCUCGACUGGAAG	IPF UP vs Control	164
hsa-miR-30d	UGUAAACAUCCCCGACUGGAAG	IPF UP vs Control	165
hsa-miR-34a	UGGCAGUGCUUAGCUGGUUGU	IPF UP vs Control	166
hsa-miR-378	ACUGGACUUGGAGUCAGAAGG	IPF UP vs Control	167
hsa-miR-425	AAUGACACGAUCACUCCCCGUUGA	IPF UP vs Control	168
hsa-miR-429	UAUUACUGUCUGGUAAAACCGU	IPF UP vs Control	169

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-miR-579	UUCAUUUGGUUAUAAACCGCGAUU	IPF UP vs Control	170
hsa-miR-523	GAACGCGCUUCCCUAUAGAGGGU	IPF UP vs Control	171
hsa-miR-551b#	GAAAUCAGCGUGGGUGAGACC	IPF UP vs Control	172

[00249] miRNAs identified as having decreased presentation in IPF patient plasma relative to a predetermined criterion are set forth below in Table 6.

[00250] Table 6.

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-let-7d	AGAGGUAGUAGGUJUGCAUAGUU	IPF DOWN vs Control	45
hsa-let-7e	UGAGGUAGGAGGUUGUAUAGUU	IPF DOWN vs Control	93
hsa-let-7g	UGAGGUAGUAGUUUGUACAGUU	IPF DOWN vs Control	72
hsa-miR-103	AGCAGCAUUGUACAGGGCUAUGA	IPF DOWN vs Control	105
hsa-miR-127-3p	UCGGAUCCGUCUGAGCUUGGCU	IPF DOWN vs Control	101
hsa-miR-142-3p	UGUAGUGUUUCCUACUUUAUGGA	IPF DOWN vs Control	38
hsa-miR-144#	GGAUUAUCAUCAUAUACUGUAAG	IPF DOWN vs Control	69
hsa-miR-148b#	AAGUUCUGUUUAACACUCAGGC	IPF DOWN vs Control	128
hsa-miR-154#	AAUCAUACACGGUUGACCUAUU	IPF DOWN vs Control	139
hsa-miR-15b	UAGCAGCACAUCAUGGUUUACA	IPF DOWN vs Control	56
hsa-miR-190	UGAUUAUGUUUGAUUAUAGGU	IPF DOWN vs Control	63
hsa-miR-196b	UAGGUAGUUUCCUGUUGUUGGG	IPF DOWN vs Control	140
hsa-miR-20a#	ACUGCAUUAUGAGCACUUAAAG	IPF DOWN vs Control	75
hsa-miR-24-2#	UGCCUACUGAGCUGAAACACAG	IPF DOWN vs Control	120
hsa-miR-26a	UUCAAGUAUACCAGGAUAGGCU	IPF DOWN vs Control	70
hsa-miR-28-5p	AAGGAGCUCACAGUCUAUUGAG	IPF DOWN vs Control	90
hsa-miR-29b	UAGCACCAUUGAAAUCAGUGUU	IPF DOWN vs Control	125
hsa-miR-301a	CAGUGCAAUAGUAUUGUCAAAGC	IPF DOWN vs Control	67
hsa-miR-30b	UGUAAACAUCCUACACUCAGCU	IPF DOWN vs Control	42
hsa-miR-30c	UGUAAACAUCCUACACUCAGC	IPF DOWN vs Control	52
hsa-miR-340#	UCCGUCUCAGUUACUUUAUAGC	IPF DOWN vs Control	127
hsa-miR-374a	UUUAUAAUACAACCUGAUAGUG	IPF DOWN vs Control	68
hsa-miR-411	UAGUAGACCGUAUAGCGUACG	IPF DOWN vs Control	124
hsa-miR-411#	UAUGUAACACGGUCCACUAACC	IPF DOWN vs Control	147
hsa-miR-543	AAACAUUCGGUGGCACUUCUU	IPF DOWN vs Control	133
hsa-miR-548J	AAAAGUAUUUGCAGGUUUUGGU	IPF DOWN vs Control	148
hsa-miR-664	UAUUCAUUUAUCCCCAGCCUACA	IPF DOWN vs Control	152
hsa-miR-99b	CACCCGUAGAACCGACCUUGCG	IPF DOWN vs Control	122
hsa-miR-1244	AAGUAGUJUGGUUUGUAUGAGAUGGU U	IPF DOWN vs Control	20
hsa-let-7a	UGAGGUAGUAGGUUGUAUAGUU	IPF DOWN vs Control	173
hsa-let-7f	UGAGGUAGUAGAUUGUAUAGUU	IPF DOWN vs Control	174
hsa-miR-107	AGCAGCAUUGUACAGGGCUAUC	IPF DOWN vs Control	175
hsa-miR-125a-5p	UCCCUGAGACCCUUUAACCUGUGA	IPF DOWN vs Control	176
hsa-miR-181a-2#	ACCACUGACCGUUGACGUACC	IPF DOWN vs Control	177
hsa-miR-19b-1#	AGUUUUGCAGGUUGCAUCCAGC	IPF DOWN vs Control	178
hsa-miR-200c	UAAUACUGCCGGUAAUGAUGGA	IPF DOWN vs Control	179

hsa-miR-27b#	AGAGCUUAGCUGAUUGGUGAAC	IPF DOWN vs Control	180
hsa-miR-331-3p	GCCCCUGGGCCUAUCCUAGAA	IPF DOWN vs Control	181
hsa-miR-339-5p	UCCCUGUCCUCGCCAGGAGCUCACG	IPF DOWN vs Control	182
hsa-miR-362-5p	AAUCCUUGGAACCUAGGUGUGAGU	IPF DOWN vs Control	183
hsa-miR-370	GCCUGCUGGGUGGAACCUGGU	IPF DOWN vs Control	184
hsa-miR-374b	AUAUAUAACCAACUGCUAAGUG	IPF DOWN vs Control	185
hsa-miR-379	UGGUAGACUAUGGAACGUAGG	IPF DOWN vs Control	186
hsa-miR-454	UAGUGCAAAUAUUGCUCUUAAGGGU	IPF DOWN vs Control	187
hsa-miR-520a-3p	AAAGUGCUUCCUUUGGACUGU	IPF DOWN vs Control	188
hsa-miR-539	GGAGAAAUUAUCCUUGGUGUGU	IPF DOWN vs Control	189
hsa-miR-758	UUUGUGACCUGGUCCACUAACC	IPF DOWN vs Control	190
hsa-miR-766	ACUCCAGCCCCACAGCCUCAGC	IPF DOWN vs Control	191
hsa-miR-9	UCUUUGGUUAUCUAGCUGUAUGA	IPF DOWN vs Control	192
hsa-miR-98	UGAGGUAGUAAGUUGUAUUGUU	IPF DOWN vs Control	193
hsa-miR-668	UGUCACUCGGCUCGGCCCACUAC	IPF DOWN vs Control	194
hsa-miR-1256	AGGCAUUGACUUCUCACUAGCU	IPF DOWN vs Control	195
hsa-miR-299-5p	UGGUUUACCGUCCCACAUACAU	IPF DOWN vs Control	196

[00251] The data provided in Tables 5 and 6 above, shows that unique miRNA profiles are present in IPF patients compared to healthy controls subjects and that these unique profiles are detectable in a blood sample of the patient. The data presented herein demonstrate that the levels of one or more miRNA detected in the blood sample of a human subject are useful tools for the diagnosis of IPF.

Example 3 – IPF patients were determined to have a unique miRNA profile compared to healthy controls in a further study.

[00252] *Materials and Methods:* Plasma samples were obtained from placebo-treated white male IPF patients. Plasma samples for demographically matched healthy control subjects with associated medical histories and medication use were obtained commercially. All samples were collected in vials containing EDTA as the anticoagulant. All samples were obtained under appropriate written Informed Consent. Histories were reviewed for the following additional criteria: not a current smoker (both groups), lack of pulmonary or other significant disease (healthy control group), no recent use of prednisolone or other drugs used off label in the treatment of IPF (healthy control group), no use of prednisolone or other drugs for the treatment of IPF within 28 days prior to sample collection (IPF group).

Summary demographics for IPF patients and healthy controls are shown in Table 7.

Table 7.

	Healthy controls (n = 15)	Progressive (n = 15)	Stable (n = 15)
Ethnic origin white	100%	100%	100%

Male	100%	100%	100%
Age (year)	64.8	66.4	66.3
BMI	27.7	28.7	28.6
Weight (kg)	84.5	87.5	87.2
Current/previous/never smoker	13 / 27 / 60%	0 / 60 / 40%	0 / 67 / 33%
Baseline			
• FVC % predicted	70.6	70.1	
• DL_{CO} % predicted (Hgb-corrected)	45.2	48.0	
• 6-minute walk distance (m)	453.2	417.9	
Outcomes			
• Death	7%	0%	
• ΔFVC % predicted (Baseline to Week 72)	-11.4%	-2.6%	
• Δ6MW (Baseline to Week 72; m)	-52.1	23.07	
• ΔFVC % predicted (24 week change)	-10.6	0.6	
• ΔFVC % predicted (48 week change)	-12.4	-1.0	

[00253] Samples from IPF patients (n=30, including 15 progressive IPF and 15 stable IPF), healthy controls (n=15) were grouped into two batches each for RNA isolation by standard methods. Total RNA was extracted by standard methods. Isolated RNA was reverse transcribed and preamplified using the Applied Biosystems Megaplex RT and Preamplification Human Primer Pools according to manufacturer's protocols.

[00254] miRNAs were profiled by real-time PCR using the TaqMan Human miRNA Array set v3.0 (Cards A+B) according to manufacturer's protocols.

[00255] microRNAs with Ct values less than 35 were selected for data analysis. microRNAs for normalization were selected by a mean centering method (Wylie et al, BMC Research Notes, 4:555, 2011). Normalization and all subsequent analyses were performed in Partek Genomics Suite (Partek, St. Louis, Missouri). Differentially expressed miRNAs were identified by ANOVA with correction for multiple comparisons. Sequences detected in <50% of samples in both the IPF and control groups were excluded. miRNAs present in <50% of samples from one or the other group were evaluated as potentially disease-status specific sequences. Differentially expressed miRNAs between progressive IPF and stable IPF patients were identified in a similar manner.

[00256] miRNAs identified as having increased presentation in IPF patient plasma relative to a predetermined criterion are set forth below in Table 8.

Table 8.

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-let-7b	UGAGGUAGUAGGUUGUGUGGUU	IPF UP vs Control	76
hsa-miR-106a	AAAAGUGCUUACAGUGCAGGUAG	IPF UP vs Control	156
hsa-miR-10b#	ACAGAUUCGAUUUCUAGGGGAAU	IPF UP vs Control	5
hsa-miR-1183	CACUGUAGGUGAUGGUGAGAGUGGGCA	IPF UP vs control	197
hsa-miR-122	UGGAGUGUGACAUUGGUGUUUG	IPF UP vs Control	22
hsa-miR-1227	CGUGCCACCCUUUUCCCCAG	IPF UP vs Control	157
hsa-miR-1233	UGAGCCCUGUCCUCCCGCAG	IPF UP vs control	198
hsa-miR-1247	ACCCGUCCGUUCGUCCCCGGA	IPF UP vs control	199
hsa-miR-1270	CUGGAGAUUAUGGAAGAGCUGUGU	IPF UP vs control	201
hsa-miR-1274A	GUCCCCUGUUCAGGCGCCA	IPF UP vs control	202
hsa-miR-1275	GUGGGGGAGAGGCUGUC	IPF UP vs control	203
hsa-miR-1290	UGGAUUUUUUGGAUCAGGGGA	IPF UP vs Control	34
hsa-miR-1298	UUCAUUCGGCUGUCCAGAUGUA	IPF UP vs control	204
hsa-miR-1303	UUUAGAGACGGGUCUUGCUCU	IPF UP vs Control	3
hsa-miR-132	UAACAGUCUACAGCCAUGGUCG	IPF UP vs Control	159
hsa-miR-135b	UAUGGCCUUUCAUUCUAUGUGA	IPF UP vs control	205
hsa-miR-138	AGCUGGUGUUGUGAAUCAGGCCG	IPF UP vs control	206
hsa-miR-146a	UGAGAACUGAAUUCCAUGGGUU	IPF UP vs Control	21
hsa-miR-17	CAAAGUGCUUACAGUGCAGGUAG	IPF UP vs Control	162
hsa-miR-186	CAAAGAAUUCUCCUUUUGGGCU	IPF UP vs control	210
hsa-miR-193a-3p	AACUGGCCUACAAAGUCCAGU	IPF UP vs control	212
hsa-miR-193b	AACUGGCCUCAAAAGUCCCGCU	IPF UP vs Control	12
hsa-miR-197	UUCACCACCUUCUCCACCCAGC	IPF UP vs Control	10
hsa-miR-200a	UAACACUGUCUGGUACGAUGU	IPF UP vs control	214
hsa-miR-205	UCCUCAUUCACCCGGAGUCUG	IPF UP vs control	215
hsa-miR-206	UGGA AUGUAAGGAAGUGUGUGG	IPF UP vs Control	23
hsa-miR-20b	CAAAGUGCUCAUAGUGCAGGUAG	IPF UP vs control	216
hsa-miR-214	ACAGCAGGCACAGACAGGCAGU	IPF UP vs control	217
hsa-miR-214#	UGCCUGUCUACACUUGCUGUGC	IPF UP vs control	218
hsa-miR-218	UUGUGCUGUAUCUAACCAUGU	IPF UP vs control	219
hsa-miR-220b	CCACCACCGUGUCUGACACUU	IPF UP vs control	220
hsa-miR-222	AGCUACAUCUGGUACUGGGU	IPF UP vs Control	16
hsa-miR-223	UGUCAGUUUGUCAAAUACCCA	IPF UP vs control	221
hsa-miR-26a-2#	CCUAAUCUUGAUUACUUGUUUC	IPF UP vs Control	82
hsa-miR-30a-3p	CUUUCAGUCGGAUGUUUGCAGC	IPF UP vs control	223
hsa-miR-320	AAAAGCUGGGUUGAGAGGGCGA	IPF UP vs Control	37
hsa-miR-326	CCUCUGGGCCCUUCCUCCAG	IPF UP vs control	225
hsa-miR-338-5P	AACAAUAUCCUGGUGCUGAGUG	IPF UP vs Control	15
hsa-miR-345	GCUGACUCCUAGUCCAGGGCUC	IPF UP vs Control	18
hsa-miR-346	UGUCUGCCGCAUGCCUGCCUCU	IPF UP vs control	226
hsa-miR-34a	UGGCAGUGUCUUAGCUGGUUGU	IPF UP vs Control	166
hsa-miR-34a#	CAAUCAGCAAGUAUACUGCCU	IPF UP vs Control	13
hsa-miR-375	UUUGUUUCGUUCGGCUCGCGUGA	IPF UP vs Control	8
hsa-miR-429	UAAAUCUGUCUGGUAAAACCGU	IPF UP vs Control	169

hsa-miR-450a	UUUUGCGAUGUGUUCCUAUAU	IPF UP vs control	228
hsa-miR-450b-5p	UUUUGCAUAUGUUCCUGAAUA	IPF UP vs control	229
hsa-miR-455-5p	UAUGUGCCUUUGGACUACUCG	IPF UP vs control	230
hsa-miR-501-5p	AAUCCUUUGUCCUGGGUGAGA	IPF UP vs control	234
hsa-miR-511	GUGUCUUUGCUCUGCAGCUA	IPF UP vs control	236
hsa-miR-518d-3p	CAAAGCGCUUCCCUCUUGGAGC	IPF UP vs control	237
hsa-miR-518e	AAAGCGCUUCCCUCUAGAGUG	IPF UP vs control	238
hsa-miR-518f	GAAAGCGCUUCUCUUUAGAGG	IPF UP vs control	239
hsa-miR-548a-3p	CAAAACUGGCAAUUACUUUUGC	IPF UP vs Control	14
hsa-miR-548c-3p	CAAAAUCUCAUUACUUUUGC	IPF UP vs control	240
hsa-miR-570	CGAAAACAGCAAUUACUUUUGC	IPF UP vs control	241
hsa-miR-571	UGAGUUGGCCAUCUGAGUGAG	IPF UP vs control	242
hsa-miR-574-3p	CACGCUCUAGCACACACCCACA	IPF UP vs Control	4
hsa-miR-577	UAGAUAAAAAUUUGGUACCUG	IPF UP vs control	243
hsa-miR-590-5p	GAGCUUAUUCAUAAAAGUGCAG	IPF UP vs Control	104
hsa-miR-598	UACGUCAUCGUUGUCAUCGUCA	IPF UP vs Control	110
hsa-miR-618	AAACUCUACUUGUCCUUCUGAGU	IPF UP vs control	244
hsa-miR-885-5p	UCCAUUACACUACCCUGCCUCU	IPF UP vs control	247
hsa-miR-9#	AUAAAGCUAGAUAAACCGAAAGU	IPF UP vs control	249
hsa-miR-95	UUCAACGGGUAUUUAUUGAGCA	IPF UP vs control	250

[00257] miRNAs identified as having decreased presentation in IPF patient plasma relative to a control are set forth below in Table 9.

Table 9.

microRNA ID	Sequence Data	Differential Regulation	SEQ ID NO.
hsa-let-7a	UGAGGUAGUAGGUUGUUAUAGUU	IPF DOWN vs Control	173
hsa-let-7d	AGAGGUAGUAGGUUGCAUAGUU	IPF DOWN vs Control	45
hsa-let-7e	UGAGGUAGGAGGUUGUUAUAGUU	IPF DOWN vs Control	93
hsa-let-7f	UGAGGUAGUAGAUUGUUAUAGUU	IPF DOWN vs Control	174
hsa-let-7g	UGAGGUAGUAGUUUGUACAGUU	IPF DOWN vs Control	72
hsa-miR-103	AGCAGCAUUGUACAGGGCUAUGA	IPF DOWN vs Control	105
hsa-miR-106b#	CCGCACUGUGGGUACUUGCUGC	IPF DOWN vs Control	92
hsa-miR-107	AGCAGCAUUGUACAGGGCUAUCA	IPF DOWN vs Control	175
hsa-miR-1244	AAGUAGUUGGUUUGUAUGAGAUGGUU	IPF DOWN vs Control	20
hsa-miR-1249	ACGCCUUCCCCCCCCUUUCUCA	IPF DOWN vs control	200
hsa-miR-125a-5p	UCCCGAGACCCUUUAACCUGUGA	IPF DOWN vs Control	176
hsa-miR-1260	AUCCCAACCUCUGCCACCA	IPF DOWN vs Control	47
hsa-miR-127-3p	UCGGAUCCGUCUGAGCUUGGU	IPF DOWN vs Control	101
hsa-miR-142-3p	UGUAGUGUUUCCUACUUUAUGGA	IPF DOWN vs Control	38
hsa-miR-144#	GGAAUCAUCAUAACUGUAAG	IPF DOWN vs Control	69
hsa-miR-145	GUCCAGUUUCCAGGAAUCCU	IPF DOWN vs control	207
hsa-miR-148b#	AAGUUCUGUUUAACACUCAGGC	IPF DOWN vs Control	128
hsa-miR-151-5P	UCGAGGAGCUCACAGUCUAGU	IPF DOWN vs Control	111
hsa-miR-15a	UAGCAGCACAUAAUGGUUJUGUG	IPF DOWN vs control	208

hsa-miR-15b	UAGCAGCACAUCAUGGUUUACA	IPF DOWN vs Control	56
hsa-miR-181a	AACAUUCAACGCUGUCGGUGAGU	IPF DOWN vs Control	66
hsa-miR-181a-2#	ACCACUGACCGUUGACUGUACC	IPF DOWN vs Control	177
hsa-miR-181c	AACAUUCAACCUGUCGGUGAGU	IPF DOWN vs control	209
hsa-miR-18a#	ACUGCCUAAGUGCUCCUUCUGG	IPF DOWN vs control	211
hsa-miR-190	UGAUAUGUUUGAUUAUUAGGU	IPF DOWN vs Control	63
hsa-miR-194	UGUAACAGCAACUCCAUGUGGA	IPF DOWN vs Control	115
hsa-miR-196b	UAGGUAGUUUCCUGUUGUUGGG	IPF DOWN vs Control	140
hsa-miR-199a-5p	CCCAGUGUUUCAGACUACCUGUUC	IPF DOWN vs Control	81
hsa-miR-199b-5p	CCCAGUGUUUAGACUAUCUGUUC	IPF DOWN vs control	213
hsa-miR-19b-1#	AGUUUUGCAGGUUUGCAUCCAGC	IPF DOWN vs Control	178
hsa-miR-200c	UAAUACUGCCGGUAAUGAUGGA	IPF DOWN vs Control	179
hsa-miR-20a	UAAAGUGCUUAUAGUGCAGGUAG	IPF DOWN vs Control	89
hsa-miR-20a#	ACUGCAUUAUGAGCACUUAAG	IPF DOWN vs Control	75
hsa-miR-23b	AUCACAUUGCCAGGGAUUACC	IPF DOWN vs control	222
hsa-miR-24-2#	UGCCUACUGAGCUGAACACAG	IPF DOWN vs Control	120
hsa-miR-26a	UUCAAGUAUCCAGGAUAGGCU	IPF DOWN vs Control	70
hsa-miR-27b#	AGAGCUUAGCUGAUUGGUGAAC	IPF DOWN vs Control	180
hsa-miR-28-5p	AAGGAGCUCACAGUCUAUUGAG	IPF DOWN vs Control	90
hsa-miR-29b	UAGCACCAUUUGAAAUCAGUGUU	IPF DOWN vs Control	125
hsa-miR-301a	CAGUGCAAUAGUAUUGUCAAAGC	IPF DOWN vs Control	67
hsa-miR-30b	UGUAAAACAUCCUACACUCAGCU	IPF DOWN vs Control	42
hsa-miR-30c	UGUAAAACAUCCUACACUCUCAGC	IPF DOWN vs Control	52
hsa-miR-30e-3p	CUUUCAGUCGGAUGUUUACAGC	IPF DOWN vs control	224
hsa-miR-324-5p	CGCAUCCCCUAGGGCAUUGGUGU	IPF DOWN vs Control	73
hsa-miR-331-3p	GCCCCUGGGCCUAUCCUAGAA	IPF DOWN vs Control	181
hsa-miR-339-5p	UCCCUGGUCCUCCAGGAGCUCACG	IPF DOWN vs Control	182
hsa-miR-340#	UCCGUCUCAGUUACUUUAUAGC	IPF DOWN vs Control	127
hsa-miR-362-5p	AAUCCUUGGAACCUAGGUGUGAGU	IPF DOWN vs Control	183
hsa-miR-370	GCCUGCUGGGUGGAACCUGGU	IPF DOWN vs Control	184
hsa-miR-374a	UUUAUAAUACAACCUGUAAGUG	IPF DOWN vs Control	68
hsa-miR-374b	AUAAUAAUACAACCUGCUAAGUG	IPF DOWN vs Control	185
hsa-miR-379	UGGUAGACUAUGGAACGUAGG	IPF DOWN vs Control	186
hsa-miR-411	UAGUAGACCGUUAUAGCGUACG	IPF DOWN vs Control	124
hsa-miR-431	UGUCUUGCAGGCCGUCAUGCA	IPF DOWN vs control	227
hsa-miR-454	UAGUGCAAUUAUGCUCUUAUAGGGU	IPF DOWN vs Control	187
hsa-miR-487a	AAUCAUACAGGGACAUCCAGUU	IPF DOWN vs control	231
hsa-miR-493	UGAAGGUCUACUGUGUGCCAGG	IPF DOWN vs control	232
hsa-miR-494	UGAAACAUACACGGGAAACCUC	IPF DOWN vs control	233
hsa-miR-495	AAACAAACAUGGUGGCACUUCUU	IPF DOWN vs Control	102
hsa-miR-505#	GGGAGCCAGGAAGUAUUGAUGU	IPF DOWN vs control	235
hsa-miR-539	GGAGAAAUUAUCCUUGGUGUGU	IPF DOWN vs Control	189
hsa-miR-543	AAACAUUCGCGGUGCACUUCUU	IPF DOWN vs Control	133
hsa-miR-548J	AAAAGUAUUUGCGGUCUUUGGU	IPF DOWN vs Control	148
hsa-miR-664	UAUUCAUUUAUCCCCAGCCUACA	IPF DOWN vs Control	152
hsa-miR-744#	CUGUUGGCCACUAACCUAACC	IPF DOWN vs control	245

hsa-miR-758	UUUGUGACCUGGUCCACUAACC	IPF DOWN vs Control	190
hsa-miR-766	ACUCCAGCCCCACAGCCUCAGC	IPF DOWN vs Control	191
hsa-miR-769-5p	UGAGACCUCUGGGUUCUGAGCU	IPF DOWN vs control	246
hsa-miR-9	UCUUUGGUUAUCUAGCUGUAUGA	IPF DOWN vs Control	192
hsa-miR-98	UGAGGUAGUAAGUUGUAUUGUU	IPF DOWN vs Control	193
hsa-miR-99b	CACCGUAGAACCGACCUUGCG	IPF DOWN vs Control	122

[00258] The data provided in Tables 8 and 9 above, shows that unique miRNA profiles are present in IPF patients compared to healthy controls subjects and that these unique profiles are detectable in a blood sample of the patient. In addition, analysis of the miRNAs in the samples indicated that two miRNAs (i.e., miR-1183 (SEQ ID NO: 197) and miR-892b (SEQ ID NO: 248)) have decreased presentation in progressive IPF compared to stable IPF patients. The data presented herein demonstrate that the levels of one or more miRNA detected in the blood sample of a human subject are useful tools for the diagnosis of IPF.

[00259] All of the references cited herein, including patents, patent applications, literature publications, and the like, are hereby incorporated in their entireties by reference.

[00260] While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred compounds and methods may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

What is claimed is:

1. A method of diagnosing idiopathic pulmonary fibrosis (IPF) in a human subject comprising detecting in a blood sample of from the subject the level of one, two, three, four, five six, seven or more microRNAs, wherein an increase or decrease in the level of the one or more microRNA relative to a predetermined criterion is indicative of a diagnosis of IPF.
2. The method of claim 1 further comprising the step of comparing the level of the microRNA to a predetermined criterion or range.
3. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74),

miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178),

miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1249 (SEQ ID NO: 200), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1298 (SEQ ID NO: 204), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-186 (SEQ ID NO: 210), miR-18a# (SEQ ID NO: 211), miR-193a-3p (SEQ ID NO: 212), miR-199b-5p (SEQ ID NO: 213), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-23b (SEQ ID NO: 222), miR-30a-3p (SEQ ID NO: 223), miR-30e-3p (SEQ ID NO: 224), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-431 (SEQ ID NO: 227), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-501-5p (SEQ ID NO: 234), miR-505# (SEQ ID NO: 235), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), miR-885-5p (SEQ ID NO: 247), miR-892b (SEQ ID NO: 248), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), and combinations thereof.

4. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ

NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), and combinations thereof.

5. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-26b (SEQ ID NO:40), miR-142-5p (SEQ ID NO:43), let-7d (SEQ ID NO:45), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-148b (SEQ ID NO:53), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-17# (SEQ ID NO:58), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p

(SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), let-7e (SEQ ID NO:93), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-590-5p (SEQ ID NO:104), miR-598 (SEQ ID NO:110), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

6. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), let-7d (SEQ ID NO: 45), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID

NO: 157), let-7g (SEQ ID NO: 72), miR-128 (SEQ ID NO: 158), miR-103 (SEQ ID NO: 105), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO: 175), miR-132 (SEQ ID NO: 159), miR-1244 (SEQ ID NO: 20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO: 195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-142-3p (SEQ ID NO: 38), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-150 (SEQ ID NO: 27), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO: 162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO: 163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-21 (SEQ ID NO: 51), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-26a (SEQ ID NO: 70), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-324-3p (SEQ ID NO: 107), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-29b (SEQ ID NO: 125), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-30b (SEQ ID NO: 42), miR-362-3p (SEQ ID NO: 96), miR-30c (SEQ ID NO: 52), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

7. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), let-7e (SEQ ID NO: 93), miR-122 (SEQ ID NO: 22), let-7f (SEQ ID NO: 174), miR-1227 (SEQ ID NO: 157), let-7g (SEQ ID NO: 72), miR-130a (SEQ ID NO: 112), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID

NO:20), miR-140-5p (SEQ ID NO: 160), miR-1256 (SEQ ID NO:195), miR-141 (SEQ ID NO: 161), miR-125a-5p (SEQ ID NO: 176), miR-142-5p (SEQ ID NO: 43), miR-127-3p (SEQ ID NO: 101), miR-146a (SEQ ID NO: 21), miR-146b-5p (SEQ ID NO: 24), miR-144# (SEQ ID NO: 69), miR-148a (SEQ ID NO: 91), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-152 (SEQ ID NO: 130), miR-15b (SEQ ID NO: 56), miR-15a# (SEQ ID NO: 64), miR-181a-2# (SEQ ID NO: 177), miR-17 (SEQ ID NO:162), miR-190 (SEQ ID NO: 63), miR-185 (SEQ ID NO:163), miR-196b (SEQ ID NO: 140), miR-19a (SEQ ID NO: 74), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-21# (SEQ ID NO: 141), miR-20a# (SEQ ID NO: 75), miR-222 (SEQ ID NO: 16), miR-24-2# (SEQ ID NO: 120), miR-26a-2# (SEQ ID NO: 82), miR-30a-5p (SEQ ID NO: 164), miR-27b# (SEQ ID NO: 180), miR-30d (SEQ ID NO: 165), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-335 (SEQ ID NO: 119), miR-345 (SEQ ID NO: 18), miR-301a (SEQ ID NO: 67), miR-34a (SEQ ID NO: 166), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-331-3p (SEQ ID NO: 181), miR-425 (SEQ ID NO: 168), miR-339-5p (SEQ ID NO: 182), miR-429 (SEQ ID NO: 169), miR-340# (SEQ ID NO: 127), miR-523 (SEQ ID NO: 171), miR-362-5p (SEQ ID NO: 183), miR-551b# (SEQ ID NO: 172), miR-370 (SEQ ID NO: 184), miR-579 (SEQ ID NO: 170), miR-374a (SEQ ID NO: 68), miR-590-5p (SEQ ID NO: 104), miR-374b (SEQ ID NO: 185), miR-598 (SEQ ID NO: 110), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO:124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

8. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO:173), miR-132 (SEQ ID NO: 159), let-7d (SEQ ID NO: 45), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-103 (SEQ ID NO: 105), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-21 (SEQ ID NO: 51), miR-142-3p (SEQ ID NO: 38), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO:18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID

NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof.

9. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO:173), miR-148a (SEQ ID NO: 91), let-7e (SEQ ID NO: 93), miR-152 (SEQ ID NO: 130), let-7f (SEQ ID NO: 174), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-1256 (SEQ ID NO: 195), miR-222 (SEQ ID NO: 16), miR-144# (SEQ ID NO: 69), miR-345 (SEQ ID NO:18), miR-148b# (SEQ ID NO: 128), miR-34a (SEQ ID NO: 166), miR-154# (SEQ ID NO: 139), miR-523 (SEQ ID NO: 171), miR-15b (SEQ ID NO: 56), miR-551b# (SEQ ID NO: 172), miR-181a-2# (SEQ ID NO: 177), miR-590-5p (SEQ ID NO: 104), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), and combinations thereof

10. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e

(SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), and combinations thereof.

11. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), and combinations thereof.

12. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID

NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

13. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-1256 (SEQ ID NO: 195), miR-127-3p (SEQ ID NO: 101), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-299-5p (SEQ ID NO: 196), miR-301a (SEQ ID NO: 67), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-668 (SEQ ID NO: 194), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

14. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7d (SEQ ID NO: 45), miR-103 (SEQ ID NO: 105), miR-125a-5p (SEQ ID NO: 176), miR-142-3p (SEQ ID NO: 38), miR-26a (SEQ ID NO: 70), miR-29b (SEQ ID NO: 125), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-379 (SEQ ID NO: 186) and combinations thereof.

15. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-18a (SEQ ID NO: 39), miR-26b (SEQ ID NO: 40), miR-106b (SEQ ID NO: 41), miR-29c (SEQ ID NO: 44), miR-144 (SEQ ID NO: 46), miR-1260 (SEQ ID NO: 47), miR-361-5p (SEQ ID NO: 48), miR-520e (SEQ ID NO: 49), miR-660 (SEQ ID NO: 50), miR-148b (SEQ ID NO: 53), miR-27b (SEQ ID NO: 54), miR-15b# (SEQ ID NO: 55), miR-16-1# (SEQ ID NO: 57), miR-17# (SEQ ID NO: 58), miR-22 (SEQ ID NO: 59), miR-32 (SEQ ID NO: 60), miR-532-5p (SEQ

ID NO: 61), miR-101 (SEQ ID NO: 62), miR-27a (SEQ ID NO: 65), miR-181a (SEQ ID NO: 66), miR-320B (SEQ ID NO: 71), miR-324-5p (SEQ ID NO: 73), let-7b (SEQ ID NO: 76), miR-422a (SEQ ID NO: 77), let-7f-2# (SEQ ID NO: 78), let-7g# (SEQ ID NO: 79), miR-128a (SEQ ID NO: 80), miR-199a-5p (SEQ ID NO: 81), miR-29a# (SEQ ID NO: 83), miR-329 (SEQ ID NO: 84), miR-337-5p (SEQ ID NO: 85), miR-369-3p (SEQ ID NO: 86), miR-376a# (SEQ ID NO: 87), miR-486-3p (SEQ ID NO: 88), miR-20a (SEQ ID NO: 89), miR-106b# (SEQ ID NO: 92), miR-25 (SEQ ID NO: 94), miR-656 (SEQ ID NO: 95), miR-340 (SEQ ID NO: 97), miR-451 (SEQ ID NO: 98), miR-423-5p (SEQ ID NO: 99), miR-652 (SEQ ID NO: 100), miR-495 (SEQ ID NO: 102), miR-328 (SEQ ID NO: 103), miR-19b (SEQ ID NO: 106), miR-145# (SEQ ID NO: 108), miR-199a-3p (SEQ ID NO: 109), miR-151-5P (SEQ ID NO: 111), miR-502-3p (SEQ ID NO: 113), miR-136# (SEQ ID NO: 114), miR-194 (SEQ ID NO: 115), miR-221 (SEQ ID NO: 116), miR-22# (SEQ ID NO: 117), miR-93 (SEQ ID NO: 118), miR-130b (SEQ ID NO: 121), miR-195 (SEQ ID NO: 123), miR-576-3p (SEQ ID NO: 126), miR-212 (SEQ ID NO: 129), miR-143 (SEQ ID NO: 131), dme-miR-7 (SEQ ID NO: 132), miR-30d# (SEQ ID NO: 134), miR-213 (SEQ ID NO: 135), miR-126# (SEQ ID NO: 136), miR-1197 (SEQ ID NO: 137), miR-1255B (SEQ ID NO: 138), miR-335# (SEQ ID NO: 142), miR-33a# (SEQ ID NO: 143), miR-374a# (SEQ ID NO: 144), miR-381 (SEQ ID NO: 145), miR-409-5p (SEQ ID NO: 146), miR-551b (SEQ ID NO: 149), miR-616 (SEQ ID NO: 150), miR-638 (SEQ ID NO: 151), miR-889 (SEQ ID NO: 153), rno-miR-29c# (SEQ ID NO: 154) and combinations thereof.

16. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103 (SEQ ID NO: 105), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-154# (SEQ ID NO: 139), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-374a (SEQ ID NO: 68), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-758 (SEQ ID NO: 190), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-668 (SEQ ID NO: 194), and combinations thereof.

17. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7g (SEQ ID NO: 72), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-339-5p (SEQ ID NO: 182), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), and combinations thereof.

18. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103 (SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO:

172), miR-1183 (SEQ ID NO: 197) and miR-892b, (SEQ ID NO: 248) and combinations thereof.

19. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103(SEQ ID NO:105), miR-107 (SEQ ID NO:175), miR-1244(SEQ ID NO:20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO:124), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-26a-2# (SEQ ID NO: 82), miR-34a (SEQ ID NO: 166), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b (SEQ ID NO: 248), and combinations thereof.

20. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of let-7b (SEQ ID NO: 76), miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-151-5P (SEQ ID NO: 111), miR-154# (SEQ ID NO: 139), miR-15a (SEQ ID NO: 208), miR-181a (SEQ ID NO: 66), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-194 (SEQ ID NO: 115), miR-199a-5p (SEQ ID NO: 81), miR-199b-5p (SEQ ID NO: 213), miR-20a (SEQ ID NO: 89), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-324-5p (SEQ ID NO: 73), miR-411# (SEQ ID NO: 147), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO:231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO:233), miR-495 (SEQ ID NO: 102), miR-505# (SEQ ID NO: 235), miR-520a-3p (SEQ ID NO: 188), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), let-7a# (SEQ ID NO: 155), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO:197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-128 (SEQ ID

NO: 158), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-130a (SEQ ID NO: 112), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-142-5p (SEQ ID NO: 43), miR-146b-5p (SEQ ID NO: 24), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-185 (SEQ ID NO: 163), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO.: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-19a (SEQ ID NO: 74), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-20b (SEQ ID NO: 216), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-320 (SEQ ID NO: 37), miR-324-3p (SEQ ID NO: 107), miR-326 (SEQ ID NO: 225), miR-335 (SEQ ID NO: 119), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-362-3p (SEQ ID NO: 96), miR-375 (SEQ ID NO: 8), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234) miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-574-3p (SEQ ID NO: 4), miR-577 (SEQ ID NO: 243), miR-579 (SEQ ID NO: 170), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103(SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244(SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-

539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b, (SEQ ID NO: 248) and combinations thereof.

21. The method of claim 1 or claim 2, wherein the one, two, three, four, five, six, seven or more microRNA are selected from the group consisting of miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-199a-5p (SEQ ID NO: 81), miR-23b (SEQ ID NO: 222), miR-29b (SEQ ID NO: 125), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-744# (SEQ ID NO: 245), miR-154# (SEQ ID NO: 139), miR-27b# (SEQ ID NO: 180), miR-374a (SEQ ID NO: 68), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-548J (SEQ ID NO: 148), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-214# (SEQ ID NO: 218), miR-214 (SEQ ID NO: 217), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-375 (SEQ ID NO: 8), miR-429 (SEQ ID NO: 169), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-95 (SEQ ID NO: 250), let-7a# (SEQ ID NO: 155), miR-130a (SEQ ID NO: 112), miR-132 (SEQ ID NO: 159), miR-141 (SEQ ID NO: 161),

miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-345 (SEQ ID NO: 18), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-579 (SEQ ID NO: 170), miR-598 (SEQ ID NO: 110), let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103 (SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), miR-1183 (SEQ ID NO: 197) and miR-892b, (SEQ ID NO: 248) and combinations thereof.

22. The method of any one of claims 1-21, wherein the level or expression pattern of at least 2 different microRNAs is detected.

23. The method of any one of claims 1-21, wherein the level or expression pattern of at least 10 different microRNA is detected.

24. The method of any one of claims 1-21, wherein the level or expression pattern of at least 20 different microRNA is detected.

25. The method of any one of claims 1-4, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs

is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), let-7b (SEQ ID NO:76), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), and combinations thereof.

26. The method of any one of claims 1-4, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-222 (SEQ ID NO:16), miR-345 (SEQ ID NO:18), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-150 (SEQ ID NO:27), miR-130a (SEQ ID NO: 112), miR-142-5p (SEQ ID NO: 43), miR-148a (SEQ ID NO: 91), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-26a-2# (SEQ ID NO: 82), miR-324-3p (SEQ ID NO: 107),

miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96, miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), and combinations thereof.

27. The method of any one of claims 1-4, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) ; miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21) and combinations thereof.

28. The method of any one of claims 1-4, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) ; miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14) and combinations thereof.

29. The method of any one of claims 1-4, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5),

miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11) and combinations thereof.

30. The method of any one of claims 1-29, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-20a# (SEQ ID NO:75), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-28-5p (SEQ ID NO:90), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-151-5P (SEQ ID NO:111), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134).

NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), and combinations thereof.

31. The method of any one of claims 1-29, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-1244 (SEQ ID NO:20), miR-142-3p (SEQ ID NO:38), miR-30b (SEQ ID NO:42), let-7d (SEQ ID NO:45), miR-30c (SEQ ID NO:52), miR-15b (SEQ ID NO:56), miR-190 (SEQ ID NO:63), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), let-7g (SEQ ID NO:72), miR-20a# (SEQ ID NO:75), miR-28-5p (SEQ ID NO:90), let-7e (SEQ ID NO:93), miR-127-3p (SEQ ID NO:101), miR-103 (SEQ ID NO:105), miR-24-2# (SEQ ID NO:120), miR-99b (SEQ ID NO:122), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-543 (SEQ ID NO:133), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-664 (SEQ ID NO:152), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ

ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), and combinations thereof.

32. The method of any one of claims 1-29, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88) and combinations thereof.

33. The method of any one of claims 1-29, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID

NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61) and combinations thereof.

34. The method of any one of claims 1-29, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), and combinations thereof.

35. The method of any one of claims 18-24, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72), miR-103 (SEQ ID NO: 105), miR-106b# (SEQ ID NO: 92), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-1249 (SEQ ID NO: 200), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-145 (SEQ ID NO: 207), miR-148b# (SEQ ID NO: 128), miR-151-5P (SEQ ID NO: 111), miR-15a (SEQ ID NO: 208), miR-15b (SEQ ID NO: 56), miR-181a (SEQ ID NO: 66), miR-181a-2# (SEQ ID NO: 177), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-190 (SEQ ID NO: 63), miR-194 (SEQ ID NO: 115), miR-196b (SEQ ID NO: 140), miR-199a-5p (SEQ ID NO: 81), miR-199b-5p (SEQ ID NO: 213), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a (SEQ ID NO: 89), miR-20a# (SEQ ID NO: 75), miR-23b (SEQ ID NO: 222), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-30e-3p (SEQ ID NO: 224), miR-324-5p (SEQ ID NO: 73), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-431 (SEQ ID NO: 227), miR-454

(SEQ ID NO: 187), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-505# (SEQ ID NO: 235), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-744# (SEQ ID NO: 245), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-769-5p (SEQ ID NO: 246), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122), miR-148b# (SEQ ID NO: 128), miR-668 (SEQ ID NO: 194), miR-411# (SEQ ID NO: 147), miR-520a-3p (SEQ ID NO. 188), and combinations thereof.

36. The method of any one of claims 18-24, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), miR-103 (SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-28-5p (SEQ ID NO: 90), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), and combinations thereof.

37. The method of any one of claims 18-24, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7a (SEQ ID NO: 173), let-7d (SEQ ID NO: 45), let-7e (SEQ ID NO: 93), let-7f (SEQ ID NO: 174), let-7g (SEQ ID NO: 72); miR-103 (SEQ ID NO: 105), miR-107 (SEQ ID NO: 175), miR-1244 (SEQ ID NO: 20), miR-125a-5p (SEQ ID NO: 176), miR-127-3p (SEQ ID NO: 101), miR-142-3p (SEQ ID NO: 38), miR-144# (SEQ ID NO: 69), miR-148b# (SEQ ID NO: 128), miR-15b (SEQ ID NO: 56), miR-181a-2# (SEQ ID NO: 177), miR-190 (SEQ ID NO: 63), miR-196b (SEQ ID NO: 140), miR-19b-1# (SEQ

ID NO: 178), miR-200c (SEQ ID NO: 179), miR-20a# (SEQ ID NO: 75), miR-24-2# (SEQ ID NO: 120), miR-26a (SEQ ID NO: 70), miR-27b# (SEQ ID NO: 180), miR-28-5p (SEQ ID NO: 90), miR-29b (SEQ ID NO: 125), miR-301a (SEQ ID NO: 67), miR-30b (SEQ ID NO: 42), miR-30c (SEQ ID NO: 52), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-340# (SEQ ID NO: 127), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374a (SEQ ID NO: 68), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-411 (SEQ ID NO: 124), miR-454 (SEQ ID NO: 187), miR-539 (SEQ ID NO: 189), miR-543 (SEQ ID NO: 133), miR-548J (SEQ ID NO: 148), miR-664 (SEQ ID NO: 152), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-99b (SEQ ID NO: 122); miR-668 (SEQ ID NO: 194), and combinations thereof.

38. The method of any one of claims 18-24, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-199a-5p (SEQ ID NO: 81), miR-23b (SEQ ID NO: 222), miR-29b (SEQ ID NO: 125), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-744# (SEQ ID NO: 245), miR-154# (SEQ ID NO: 139), miR-27b# (SEQ ID NO: 180), miR-374a (SEQ ID NO: 68), miR-411# (SEQ ID NO: 147), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-548J (SEQ ID NO: 148), and combinations thereof.

39. The method of any one of claims 18-24, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-106b# (SEQ ID NO: 92), miR-1249 (SEQ ID NO: 200), miR-145 (SEQ ID NO: 207), miR-151-5P (SEQ ID NO: 111), miR-154# (SEQ ID NO: 139), miR-15a (SEQ ID NO: 208), miR-181a (SEQ ID NO: 66), miR-181c (SEQ ID NO: 209), miR-18a# (SEQ ID NO: 211), miR-194 (SEQ ID NO: 115), miR-199a-5p (SEQ ID NO: 81), miR-199b-5p (SEQ ID NO: 213), miR-20a (SEQ ID NO: 89), miR-23b (SEQ ID NO: 222), miR-30e-3p (SEQ ID NO: 224), miR-324-5p (SEQ ID NO: 73), miR-411# (SEQ ID NO: 147), miR-431 (SEQ ID NO: 227), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-495 (SEQ ID NO: 102), miR-505#

(SEQ ID NO: 235), miR-520a-3p (SEQ ID NO: 188), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), and combinations thereof.

40. The method of any one of claims 18-24, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7b (SEQ ID NO: 76), miR-106a (SEQ ID NO: 156), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-132 (SEQ ID NO: 159), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-222 (SEQ ID NO: 16), miR-223 (SEQ ID NO: 221), miR-26a-2# (SEQ ID NO: 82), miR-30a-3p (SEQ ID NO: 223), miR-320 (SEQ ID NO: 37), miR-326 (SEQ ID NO: 225), miR-338-5P (SEQ ID NO: 15), miR-345 (SEQ ID NO: 18), miR-346 (SEQ ID NO: 226), miR-34a (SEQ ID NO: 166), miR-34a# (SEQ ID NO: 13), miR-375 (SEQ ID NO: 8), miR-429 (SEQ ID NO: 169), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-574-3p (SEQ ID NO: 4), miR-577 (SEQ ID NO: 243), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), miR-26a-2# (SEQ ID NO: 82), miR-551b# (SEQ ID NO: 172), let-7a# (SEQ ID NO: 155), miR-1260 (SEQ ID NO: 47), miR-128 (SEQ ID NO: 158), miR-130a (SEQ ID NO: 112), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-142-5p (SEQ ID NO: 43), miR-146b-5p (SEQ ID NO: 24), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-185 (SEQ ID NO: 163), miR-19a (SEQ ID NO: 74), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165).

NO: 165), miR-324-3p (SEQ ID NO: 107), miR-335 (SEQ ID NO: 119), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-579 (SEQ ID NO: 170), and combinations thereof.

41. The method of any one of claims 18-24, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-26a-2# (SEQ ID NO: 82), miR-34a (SEQ ID NO: 166), miR-551b# (SEQ ID NO: 172), and combinations thereof.

42. The method of any one of claims 18-24, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-106a (SEQ ID NO: 156), miR-122 (SEQ ID NO: 22), miR-1227 (SEQ ID NO: 157), miR-132 (SEQ ID NO: 159), miR-146a (SEQ ID NO: 21), miR-17 (SEQ ID NO: 162), miR-222 (SEQ ID NO: 16), miR-26a-2# (SEQ ID NO: 82), miR-345 (SEQ ID NO: 18), miR-34a (SEQ ID NO: 166), miR-429 (SEQ ID NO: 169), miR-590-5p (SEQ ID NO: 104), miR-598 (SEQ ID NO: 110), miR-551b# (SEQ ID NO: 172), and combinations thereof.

43. The method of any one of claims 18-24, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-214# (SEQ ID NO: 218), miR-214 (SEQ ID NO: 217), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-375 (SEQ ID NO: 8), miR-429 (SEQ ID NO: 169), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238),

miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-95 (SEQ ID NO: 250), let-7a# (SEQ ID NO: 155), miR-130a (SEQ ID NO: 112), miR-132 (SEQ ID NO: 159), miR-141 (SEQ ID NO: 161), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-345 (SEQ ID NO: 18), miR-362-3p (SEQ ID NO: 96), miR-378 (SEQ ID NO: 167), miR-579 (SEQ ID NO: 170), miR-598 (SEQ ID NO: 110), and combinations thereof.

44. The method of any one of claims 18-24, wherein the presence or an increased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of IPF, and the one or more microRNAs is selected from the group consisting of let-7b (SEQ ID NO: 76), let-7a# (SEQ ID NO: 155), miR-10b# (SEQ ID NO: 5), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1260 (SEQ ID NO: 47), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-128 (SEQ ID NO: 158), miR-1290 (SEQ ID NO: 34), miR-1298 (SEQ ID NO: 204), miR-1303 (SEQ ID NO: 3), miR-130a (SEQ ID NO: 112), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-142-5p (SEQ ID NO: 43), miR-146b-5p (SEQ ID NO: 24), miR-148a (SEQ ID NO: 91), miR-150 (SEQ ID NO: 27), miR-152 (SEQ ID NO: 130), miR-15a# (SEQ ID NO: 64), miR-185 (SEQ ID NO: 163), miR-186 (SEQ ID NO: 210), miR-193a-3p (SEQ ID NO: 212), miR-193b (SEQ ID NO: 12), miR-197 (SEQ ID NO: 10), miR-19a (SEQ ID NO: 74), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-206 (SEQ ID NO: 23), miR-20b (SEQ ID NO: 216), miR-21 (SEQ ID NO: 51), miR-21# (SEQ ID NO: 141), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-30a-3p (SEQ ID NO: 223), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-320 (SEQ ID NO: 37), miR-324-3p (SEQ ID NO: 107), miR-326 (SEQ ID NO: 225), miR-335 (SEQ ID NO: 119), miR-338-5P (SEQ ID NO: 15), miR-346 (SEQ ID NO: 226), miR-34a# (SEQ ID NO: 13), miR-362-3p (SEQ ID NO: 96), miR-375 (SEQ ID NO: 8), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-501-5p (SEQ ID NO: 234) miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548a-3p (SEQ ID NO: 14), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-574-

3p (SEQ ID NO: 4), miR-577 (SEQ ID NO: 243), miR-579 (SEQ ID NO: 170), miR-618 (SEQ ID NO: 244), miR-885-5p (SEQ ID NO: 247), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250) and combinations thereof.

45. The method of any one of claims 18-24, wherein the absence or a decreased level of one, two, three, four, five, six, seven or more microRNA is detected, relative to a predetermined criterion, is indicative of a diagnosis of progressive IPF, and the one or more microRNAs is selected from the group consisting of miR-1183 (SEQ ID NO: 197) and miR-892b (SEQ ID NO: 248).

46. The method of any of claims 1-45, wherein the sample is selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles.

47. The method of any one of claims 1-46, wherein the method further comprises administering a therapeutic agent to the subject.

48. A method of treating a human subject diagnosed with idiopathic pulmonary fibrosis (IPF) according to any of methods 1-46 comprising administering a therapeutic agent to the subject to treat IPF.

49. A method of treating a human subject identified as having idiopathic pulmonary fibrosis (IPF) or at risk of IPF based on an abnormal level of one, two, three, four, five, six, seven or more IPF-associated microRNAs in a blood sample of the subject, comprising administering a therapeutic agent to the subject to treat IPF.

50. The method of claim 48 or claim 49, wherein the one, two, three, four, five, six, seven or more microRNAs is selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-

886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59), miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142)

NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO: 155), miR-106a (SEQ ID NO: 156), miR-1227 (SEQ ID NO: 157), miR-128 (SEQ ID NO: 158), miR-132 (SEQ ID NO: 159), miR-140-5p (SEQ ID NO: 160), miR-141 (SEQ ID NO: 161), miR-17 (SEQ ID NO: 162), miR-185 (SEQ ID NO: 163), miR-30a-5p (SEQ ID NO: 164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO:196), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1249 (SEQ ID NO: 200), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1298 (SEQ ID NO: 204), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-186 (SEQ ID NO: 210), miR-18a# (SEQ ID NO: 211), miR-193a-3p (SEQ ID NO: 212), miR-199b-5p (SEQ ID NO: 213), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-23b (SEQ ID NO: 222), miR-30a-3p (SEQ ID NO: 223), miR-30e-3p (SEQ ID NO: 224), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-431 (SEQ ID NO: 227), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-501-5p (SEQ ID NO: 234), miR-505# (SEQ ID NO: 235), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO:

243), miR-618 (SEQ ID NO: 244), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), miR-885-5p (SEQ ID NO: 247), miR-892b (SEQ ID NO: 248), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), or combinations thereof.

51. The method of claim 48 or claim 49, wherein the level or expression pattern of at least 2 different microRNAs is detected.

52. The method of claim 48 or claim 49, wherein the level or expression pattern of at least 10 different microRNA is detected.

53. The method of claim 48 or claim 49, wherein the level or expression pattern of at least 20 different microRNA is detected.

54. The method of claim 49, wherein the sample is selected from the group consisting of whole blood, serum, plasma, exosomes and isolated microvesicles.

55. The method of any of claims 47-54, wherein the therapeutic agent is an oligonucleotide that decreases the activity or level of expression of one, two, three, four, five, six, seven or more of the microRNA in the subject.

56. The method of any of claims 47-54, wherein the therapeutic agent is an oligonucleotide that increases the activity or level of expression of one, two, three, four, five, six, seven or more of the microRNA in the subject.

57. The method of any of claims 47-54, wherein the therapeutic agent is an anti-fibrotic agent.

58. The method of claim 57, wherein the anti-fibrotic agent is pirfenidone.

59. The method of any of claims 47-54, wherein the therapeutic agent is selected from the group consisting of steroids (including but not limited to prednisolone), cytotoxic agents (including but not limited to azathioprine and cyclophosphamide), bardoxolone, LPA agonists (including but not limited to AM152); Torisel (temsirolimus); PI3K inhibitors; pentraxin or serum amyloid P (including but not limited to Pentraxin-2 (PTX-2 or PRM-151)); MEK inhibitors (including but not limited to ARRY-162 and ARRY-300); p38 inhibitors; PAI-1 inhibitors (including but not limited to Tiplaxtinin); agents that reduce the activity of transforming growth factor-beta (TGF- β) (including but not limited to GC-1008 (Genzyme/MedImmune); lerdelimumab (CAT-152; Trabio, Cambridge Antibody); metelimumab(CAT-192,Cambridge Antibody,); LY-2157299 (Eli Lilly); ACU-HTR-028 (Opko Health)) including antibodies that target one or more TGF- β isoforms, inhibitors of

TGF- β receptor kinases TGFBR1 (ALK5) and TGFBR2, and modulators of post-receptor signaling pathways; chemokine receptor signaling; endothelin receptor antagonists including inhibitors that target both endothelin receptor A and B and those that selectively target endothelin receptor A (including but not limited to ambrisentan; avosentan; bosentan; clazosentan; darusentan; BQ-153; FR-139317, L-744453; macitentan; PD-145065; PD-156252; PD163610; PS-433540; S-0139; sitaxentan sodium; TBC-3711; zibotentan); agents that reduce the activity of connective tissue growth factor (CTGF) (including but not limited to FG-3019, FibroGen), and including other CTGF-neutralizing antibodies; matrix metalloproteinase (MMP) inhibitors (including but not limited to MMPI-12, PUP-1 and tigapotide trifluate); agents that reduce the activity of epidermal growth factor receptor (EGFR) including but not limited to erlotinib, gefitinib, BMS-690514, cetuximab, antibodies targeting EGF receptor, inhibitors of EGF receptor kinase, and modulators of post-receptor signaling pathways; agents that reduce the activity of platelet derived growth factor (PDGF) (including but not limited to Imatinib mesylate (Novartis)) and also including PDGF neutralizing antibodies, antibodies targeting PDGF receptor (PDGFR), inhibitors of PDGFR kinase activity, and post-receptor signaling pathways; agents that reduce the activity of vascular endothelial growth factor (VEGF) (including but not limited to axitinib, bevacizumab, BIBF-1120, CDP-791, CT-322, IMC-18F1, PTC-299, and ramucirumab) and also including VEGF-neutralizing antibodies, antibodies targeting the VEGF receptor 1 (VEGFR1, Flt-1) and VEGF receptor 2 (VEGFR2, KDR), the soluble form of VEGFR1 (sFlt) and derivatives thereof which neutralize VEGF, and inhibitors of VEGF receptor kinase activity; inhibitors of multiple receptor kinases such as BIBF-1120 which inhibits receptor kinases for vascular endothelial growth factor, fibroblast growth factor, and platelet derived growth factor; agents that interfere with integrin function (including but not limited to STX-100 and IMGN-388) and also including integrin targeted antibodies; agents that interfere with the pro-fibrotic activities of IL-4 (including but not limited to AER-001, AMG-317, APG-201, and sIL-4Ra) and IL-13 (including but not limited to AER-001, AMG-317, anrukizumab, CAT-354, cintredekin besudotox, MK-6105, QAX-576, SB-313, SL-102, and TNX-650) and also including neutralizing anti-bodies to either cytokine, antibodies that target IL-4 receptor or IL-13 receptor, the soluble form of IL-4 receptor or derivatives thereof that is reported to bind and neutralize both IL-4 and IL-13, chimeric proteins including all or part of IL-13 and a toxin particularly pseudomonas endotoxin, signaling through the JAK-STAT kinase pathway; agents that interfere with epithelial mesenchymal transition including inhibitors of mTor (including but not limited to AP-23573 or rapamycin); agents that reduce

levels of copper such as tetrathiomolybdate; agents that reduce oxidative stress including N-acetyl cysteine and tetrathiomolybdate; and interferon gamma, inhibitors of phosphodiesterase 4 (PDE4) (including but not limited to Roflumilast); inhibitors of phosphodiesterase 5 (PDE5) (including but not limited to mirodenafil, PF-4480682, sildenafil citrate, SLx-2101, tadalafil, udenafil, UK-369003, vardenafil, and zaprinast); or modifiers of the arachidonic acid pathway including cyclooxygenase and 5-lipoxygenase inhibitors (including but not limited to Zileuton), compounds that reduce tissue remodeling or fibrosis including prolyl hydrolase inhibitors (including but not limited to 1016548, CG-0089, FG-2216, FG-4497, FG-5615, FG-6513, fibrostatin A (Takeda), lufironil,P-1894B, and safironil) and peroxisome proliferator-activated receptor (PPAR)-gamma agonists (including but not limited to pioglitazone and rosiglitazone), and combinations thereof.

60. A kit to be used in the diagnosis of subjects having idiopathic pulmonary fibrosis (IPF) comprising one, two, three, four, five, six, seven or more probes that specifically hybridize to, or primers that specifically amplify, one or more microRNAs selected from the group consisting of miR-155 (SEQ ID NO:1), miR-767-3p (SEQ ID NO:2), miR-1303 (SEQ ID NO:3), miR-574-3p (SEQ ID NO:4), miR-10b# (SEQ ID NO:5), miR-875-5p (SEQ ID NO:6), miR-29a (SEQ ID NO:7), miR-375 (SEQ ID NO:8), miR-342-3p (SEQ ID NO:9), miR-197 (SEQ ID NO:10), miR-663B (SEQ ID NO:11), miR-193b (SEQ ID NO:12), miR-34a# (SEQ ID NO:13), miR-548a-3p (SEQ ID NO:14), miR-338-5P (SEQ ID NO:15), miR-222 (SEQ ID NO:16), miR-520D-3P (SEQ ID NO:17), miR-345 (SEQ ID NO:18), miR-99b# (SEQ ID NO:19), miR-1244 (SEQ ID NO:20), miR-146a (SEQ ID NO:21), miR-122 (SEQ ID NO:22), miR-206 (SEQ ID NO:23), miR-146b-5p (SEQ ID NO:24), miR-1300 (SEQ ID NO:25), miR-28-3p (SEQ ID NO:26), miR-150 (SEQ ID NO:27), miR-202 (SEQ ID NO:28), miR-636 (SEQ ID NO:29), miR-27a# (SEQ ID NO:30), miR-323-3p (SEQ ID NO:31), miR-520c-3p (SEQ ID NO:32), miR-191 (SEQ ID NO:33), miR-1290 (SEQ ID NO:34), miR-572 (SEQ ID NO:35), miR-886-3p (SEQ ID NO:36), miR-320 (SEQ ID NO:37), miR-142-3p (SEQ ID NO:38), miR-18a (SEQ ID NO:39), miR-26b (SEQ ID NO:40), miR-106b (SEQ ID NO:41), miR-30b (SEQ ID NO:42), miR-142-5p (SEQ ID NO:43), miR-29c (SEQ ID NO:44), let-7d (SEQ ID NO:45), miR-144 (SEQ ID NO:46), miR-1260 (SEQ ID NO:47), miR-361-5p (SEQ ID NO:48), miR-520e (SEQ ID NO:49), miR-660 (SEQ ID NO:50), miR-21 (SEQ ID NO:51), miR-30c (SEQ ID NO:52), miR-148b (SEQ ID NO:53), miR-27b (SEQ ID NO:54), miR-15b# (SEQ ID NO:55), miR-15b (SEQ ID NO:56), miR-16-1# (SEQ ID NO:57), miR-17# (SEQ ID NO:58), miR-22 (SEQ ID NO:59),

miR-32 (SEQ ID NO:60), miR-532-5p (SEQ ID NO:61), miR-101 (SEQ ID NO:62), miR-190 (SEQ ID NO:63), miR-15a# (SEQ ID NO:64), miR-27a (SEQ ID NO:65), miR-181a (SEQ ID NO:66), miR-301a (SEQ ID NO:67), miR-374a (SEQ ID NO:68), miR-144# (SEQ ID NO:69), miR-26a (SEQ ID NO:70), miR-320B (SEQ ID NO:71), let-7g (SEQ ID NO:72), miR-324-5p (SEQ ID NO:73), miR-19a (SEQ ID NO:74), miR-20a# (SEQ ID NO:75), let-7b (SEQ ID NO:76), miR-422a (SEQ ID NO:77), let-7f-2# (SEQ ID NO:78), let-7g# (SEQ ID NO:79), miR-128a (SEQ ID NO:80), miR-199a-5p (SEQ ID NO:81), miR-26a-2# (SEQ ID NO:82), miR-29a# (SEQ ID NO:83), miR-329 (SEQ ID NO:84), miR-337-5p (SEQ ID NO:85), miR-369-3p (SEQ ID NO:86), miR-376a# (SEQ ID NO:87), miR-486-3p (SEQ ID NO:88), miR-20a (SEQ ID NO:89), miR-28-5p (SEQ ID NO:90), miR-148a (SEQ ID NO:91), miR-106b# (SEQ ID NO:92), let-7e (SEQ ID NO:93), miR-25 (SEQ ID NO:94), miR-656 (SEQ ID NO:95), miR-362-3p (SEQ ID NO:96), miR-340 (SEQ ID NO:97), miR-451 (SEQ ID NO:98), miR-423-5p (SEQ ID NO:99), miR-652 (SEQ ID NO:100), miR-127-3p (SEQ ID NO:101), miR-495 (SEQ ID NO:102), miR-328 (SEQ ID NO:103), miR-590-5p (SEQ ID NO:104), miR-103 (SEQ ID NO:105), miR-19b (SEQ ID NO:106), miR-324-3p (SEQ ID NO:107), miR-145# (SEQ ID NO:108), miR-199a-3p (SEQ ID NO:109), miR-598 (SEQ ID NO:110), miR-151-5P (SEQ ID NO:111), miR-130a (SEQ ID NO:112), miR-502-3p (SEQ ID NO:113), miR-136# (SEQ ID NO:114), miR-194 (SEQ ID NO:115), miR-221 (SEQ ID NO:116), miR-22# (SEQ ID NO:117), miR-93 (SEQ ID NO:118), miR-335 (SEQ ID NO:119), miR-24-2# (SEQ ID NO:120), miR-130b (SEQ ID NO:121), miR-99b (SEQ ID NO:122), miR-195 (SEQ ID NO:123), miR-411 (SEQ ID NO:124), miR-29b (SEQ ID NO:125), miR-576-3p (SEQ ID NO:126), miR-340# (SEQ ID NO:127), miR-148b# (SEQ ID NO:128), miR-212 (SEQ ID NO:129), miR-152 (SEQ ID NO:130), miR-143 (SEQ ID NO:131), miR-7 (SEQ ID NO:132), miR-543 (SEQ ID NO:133), miR-30d# (SEQ ID NO:134), miR-213 (SEQ ID NO:135), miR-126# (SEQ ID NO:136), miR-1197 (SEQ ID NO:137), miR-1255B (SEQ ID NO:138), miR-154# (SEQ ID NO:139), miR-196b (SEQ ID NO:140), miR-21# (SEQ ID NO:141), miR-335# (SEQ ID NO:142), miR-33a# (SEQ ID NO:143), miR-374a# (SEQ ID NO:144), miR-381 (SEQ ID NO:145), miR-409-5p (SEQ ID NO:146), miR-411# (SEQ ID NO:147), miR-548J (SEQ ID NO:148), miR-551b (SEQ ID NO:149), miR-616 (SEQ ID NO:150), miR-638 (SEQ ID NO:151), miR-664 (SEQ ID NO:152), miR-889 (SEQ ID NO:153), miR-29c# (SEQ ID NO:154), let-7a# (SEQ ID NO:155), miR-106a (SEQ ID NO:156), miR-1227 (SEQ ID NO:157), miR-128 (SEQ ID NO:158), miR-132 (SEQ ID NO:159), miR-140-5p (SEQ ID NO:160), miR-141 (SEQ ID NO:161), miR-17 (SEQ ID NO:162), miR-185 (SEQ ID NO:163), miR-30a-5p (SEQ ID NO:

164), miR-30d (SEQ ID NO: 165), miR-34a (SEQ ID NO: 166), miR-378 (SEQ ID NO: 167), miR-425 (SEQ ID NO: 168), miR-429 (SEQ ID NO: 169), miR-579 (SEQ ID NO: 170), miR-523 (SEQ ID NO: 171), miR-551b# (SEQ ID NO: 172), let-7a (SEQ ID NO: 173), let-7f (SEQ ID NO: 174), miR-107 (SEQ ID NO: 175), miR-125a-5p (SEQ ID NO: 176), miR-181a-2# (SEQ ID NO: 177), miR-19b-1# (SEQ ID NO: 178), miR-200c (SEQ ID NO: 179), miR-27b# (SEQ ID NO: 180), miR-331-3p (SEQ ID NO: 181), miR-339-5p (SEQ ID NO: 182), miR-362-5p (SEQ ID NO: 183), miR-370 (SEQ ID NO: 184), miR-374b (SEQ ID NO: 185), miR-379 (SEQ ID NO: 186), miR-454 (SEQ ID NO: 187), miR-520a-3p (SEQ ID NO: 188), miR-539 (SEQ ID NO: 189), miR-758 (SEQ ID NO: 190), miR-766 (SEQ ID NO: 191), miR-9 (SEQ ID NO: 192), miR-98 (SEQ ID NO: 193), miR-668 (SEQ ID NO: 194), miR-1256 (SEQ ID NO: 195), miR-299-5p (SEQ ID NO: 196), miR-1183 (SEQ ID NO: 197), miR-1233 (SEQ ID NO: 198), miR-1247 (SEQ ID NO: 199), miR-1249 (SEQ ID NO: 200), miR-1270 (SEQ ID NO: 201), miR-1274A (SEQ ID NO: 202), miR-1275 (SEQ ID NO: 203), miR-1298 (SEQ ID NO: 204), miR-135b (SEQ ID NO: 205), miR-138 (SEQ ID NO: 206), miR-145 (SEQ ID NO: 207), miR-15a (SEQ ID NO: 208), miR-181c (SEQ ID NO: 209), miR-186 (SEQ ID NO: 210), miR-18a# (SEQ ID NO: 211), miR-193a-3p (SEQ ID NO: 212), miR-199b-5p (SEQ ID NO: 213), miR-200a (SEQ ID NO: 214), miR-205 (SEQ ID NO: 215), miR-20b (SEQ ID NO: 216), miR-214 (SEQ ID NO: 217), miR-214# (SEQ ID NO: 218), miR-218 (SEQ ID NO: 219), miR-220b (SEQ ID NO: 220), miR-223 (SEQ ID NO: 221), miR-23b (SEQ ID NO: 222), miR-30a-3p (SEQ ID NO: 223), miR-30e-3p (SEQ ID NO: 224), miR-326 (SEQ ID NO: 225), miR-346 (SEQ ID NO: 226), miR-431 (SEQ ID NO: 227), miR-450a (SEQ ID NO: 228), miR-450b-5p (SEQ ID NO: 229), miR-455-5p (SEQ ID NO: 230), miR-487a (SEQ ID NO: 231), miR-493 (SEQ ID NO: 232), miR-494 (SEQ ID NO: 233), miR-501-5p (SEQ ID NO: 234), miR-505# (SEQ ID NO: 235), miR-511 (SEQ ID NO: 236), miR-518d-3p (SEQ ID NO: 237), miR-518e (SEQ ID NO: 238), miR-518f (SEQ ID NO: 239), miR-548c-3p (SEQ ID NO: 240), miR-570 (SEQ ID NO: 241), miR-571 (SEQ ID NO: 242), miR-577 (SEQ ID NO: 243), miR-618 (SEQ ID NO: 244), miR-744# (SEQ ID NO: 245), miR-769-5p (SEQ ID NO: 246), miR-885-5p (SEQ ID NO: 247), miR-892b (SEQ ID NO: 248), miR-9# (SEQ ID NO: 249), miR-95 (SEQ ID NO: 250), and combinations thereof.

61. A diagnostic test system adapted for performing any of the methods of claims 1-46.

62. The diagnostic test system of claim 61 comprising means for obtaining test results comprising the activity or level of one, two, three, four, five, six, seven or more microRNA correlated with a diagnosis of idiopathic pulmonary fibrosis (IPF) in a blood sample of the subject; means for collecting and tracking test results for one or more individual blood sample; means for comparing the activity or level of one or more microRNA to a predetermined criterion; and means for reporting whether the activity or level of the one or more microRNA meets or exceeds the predetermined criterion.

63. A computer program product comprising computer-executable instructions embodied in a computer-readable medium for performing the steps of any of the methods of claims 1-46.

PCA Mapping (84.4%)




FIGURE 1




FIGURE 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2012/066221

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12Q1/68
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, Sequence Search, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>K. V. PANDIT ET AL: "Inhibition and Role of let-7d in Idiopathic Pulmonary Fibrosis", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 182, no. 2, 15 July 2010 (2010-07-15), pages 220-229, XP55031319, ISSN: 1073-449X, DOI: 10.1164/rccm.200911-1698OC the whole document</p> <p>-----</p> <p>-/-</p>	1-3, 48-50, 60,61

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

5 February 2013

Date of mailing of the international search report

18/02/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Mueller, Frank

INTERNATIONAL SEARCH REPORT

International application No PCT/US2012/066221

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAMEER R. OAK ET AL: "A Micro RNA Processing Defect in Rapidly Progressing Idiopathic Pulmonary Fibrosis", PLOS ONE, vol. 6, no. 6, 21 June 2011 (2011-06-21), page e21253, XP55031325, DOI: 10.1371/journal.pone.0021253 the whole document -----	1-3, 48-50, 60,61
X	WO 2010/039502 A2 (UNIV PITTSBURGH [US]; YOUSEF HANADIE [US]; KAMINSKI NAFTALI [US]; BENO) 8 April 2010 (2010-04-08) the whole document -----	1-3, 48-50, 60,61
X	OGLESBY IRENE K ET AL: "MicroRNAs in inflammatory lung disease - master regulators or target practice?", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 11, no. 1, 28 October 2010 (2010-10-28), page 148, XP021071367, ISSN: 1465-9921, DOI: 10.1186/1465-9921-11-148 the whole document -----	1,2,48, 49,60,61
X	KUSUM V PANDIT ET AL: "MicroRNAs in idiopathic pulmonary fibrosis", TRANSLATIONAL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 157, no. 4, 18 January 2011 (2011-01-18), pages 191-199, XP028368080, ISSN: 1931-5244, DOI: 10.1016/J.TRSL.2011.01.012 [retrieved on 2011-01-25] the whole document -----	1,2,48, 49,60,61

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2012/066221

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010039502 A2	08-04-2010 US WO	2012045395 A1 2010039502 A2	23-02-2012 08-04-2010